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SUMMARY  
Mesenchymal stem cells (MSCs) display pleiotropic functions, which include secretion of 
soluble factors with immunosuppressive activity implicated in cancer progression. We compared 
the immunomodulatory effects of paired intra-tumor (T-) and adjacent non-tumor tissue (N-)-
derived MSCs from patients with squamous cell lung carcinoma (SCC) on circulating natural 
killer (NK) cells from healthy donors. We observed that T-MSCs were more strongly 
immunosuppressive than N-MSCs and affected both NK function and phenotype, as defined by 
CD56 expression. T-MSCs shifted NK cells toward the CD56dim phenotype and differentially 
modulated CD56bright/dim subset functions. Whereas MSCs affected both degranulation and 
expression of activating receptors in the CD56dim subset, they primarily inhibited interferon-γ 
production in the CD56bright subset. Pharmacological inhibition of prostaglandin E2 (PGE2) 
synthesis, and in some MSCs, IL-6 activity, restored NK function, whereas NK cell stimulation 
by PGE2 alone mimicked T-MSC-mediated immunosuppression. Our observations provide 
insight into how stromal responses to cancer dampen NK cell activity in human lung SCC.  
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RÉSUMÉ 
Les cellules mésenchymateuses souches (CMS) sont des cellules du stroma (tissu de soutien), 
avec des fonctions multiples, dont des propriétés immunosuppressives impliquées dans la 
progression tumorale et nécessitant la sécrétion de facteurs solubles. Dans ce travail, nous avons 
comparé les effets immunomodulatoires de CMS humaines isolées de pièces de résection de 
cancer pulmonaire épidermoïde (T-CMS), avec ceux de CMS issues du tissu pulmonaire non 
tumoral adjacent (N-CMS), prélevé chez les mêmes patients. Nous nous sommes intéressés à 
l’effet des CMS sur l’immunité innée, en particulier sur les cellules tueuses naturelles (NK). 
Nous avons observé que les T-CMS sont plus immunosuppressives que les N-CMS et affectent 
aussi bien la fonction que le phénotype des NK, y compris leur expression du CD56. Les T-CMS 
induisent préférentiellement des NK CD56dim, et ont des effets différents sur les fonctions des 
sous-populations CD56dim et CD56bright. Les CMS affectent à la fois la degranulation et 
l’expression des récepteurs activateurs des CD56dim, alors qu’elles inhibent principalement la 
sécrétion d’IFN-γ dans la sous-population CD56bright. L’inhibition pharmacologique de la 
synthèse de la prostaglandine E2 (PGE2), et pour certaines CMS, de l’activité de l’IL-6, est 
capable de restaurer la fonction des NK, alors que la stimulation par la PGE2 seule reproduit 
l’effet suppresseur des T-CMS. Nos observations permettent une meilleure compréhension de la 
réponse stromale et de son caractère immunosuppresseur sur les NK dans le cancer pulmonaire 
chez l’homme.  
 
  
8 
 
ABBREVIATIONS 
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1. INTRODUCTION 
1.1 General introduction 
Cancer progression requires interactions between tumor cells and the host microenvironment, 
which includes, among others, a variety of stromal and immune cells. The immune system’s 
natural capacity to detect and destroy abnormal cells may prevent the development of many 
cancers. However, cancer cells are sometimes able to avoid detection and destruction by the 
immune system. These dual effects of the immune system on developing tumors are referred to 
as “cancer immunoediting”, a process comprised of three phases that are collectively denoted as 
the three “Es” of cancer immunoediting: Elimination (1), Equilibrium (2), and Escape (3). (1) 
Native immune effector cells, such as natural killer (NK) cells, can eliminate nascent 
transformed cells in an initial innate immune response. (2) During tumor growth, tumor cell 
variants weakly immunogenic and resistant to immune attack are generated. These cells proceed 
to the equilibrium phase even though the elimination phase continues through immune selection 
pressure. (3) Tumor progression leads to the release of tumor-derived soluble factors that 
underlie several mechanisms of immune evasion in the escape phase (Kim et al., 2007). 
The tumor microenvironment is composed of a network of diverse cellular and structural 
constituents whose functions are interdependent and recapitulate a wound healing response: 
inflammatory and immune cells, vascular cells, and a variety of stromal cells, among which are 
MSCs and numerous components of the extracellular matrix (ECM) along with their biologically 
active degradation products. The relative abundance of the different constituents may vary 
widely among different tumor types and among specimens of the same tumor type in different 
individuals. Such variation may be important in determining the anti-tumor immune response. 
However, the resemblance between tumor-associated tissue remodeling and physiologic tissue 
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repair suggests that the wound healing response that they generate may be a shared feature 
among divergent solid tumors. Despite variable intensity among individual tumors, it may 
provide an array of common therapeutic targets. MSCs may provide a particularly relevant 
therapeutic target within the tumor stroma based on their pleiotropic effects on tumor growth and 
the immune response. MSCs may both promote and constrain tumor growth, although their net 
effect appears to be predominantly protumorigenic (Berger et al., 2016; Djouad et al., 2007; 
Karnoub et al., 2007; Khakoo et al., 2006; Lazennec and Jorgensen, 2008). In addition, they have 
opposite effects on immune cell modulation, promoting inflammation on the one hand and 
exhibiting an immunosuppressive profile, which favors tumor progression, on the other. Thus, 
harnessing MSC plasticity toward the expression of anti-tumorigenic, anti-inflammatory and pro-
immunogenic properties may be an attractive therapeutic option. However, it requires in-depth 
understanding of the functional relationship between tumor cells, MSCs and immune cells and 
particularly how tumor cells subvert MSCs to function in their favor.  
1.2 Lung cancers 
Lung cancer is the second most common malignancy and the leading cancer in terms of lethality 
worldwide (Siegel et al., 2015). The two major forms of lung cancer are non–small-cell lung 
cancer (NSCLC) and small-cell lung cancer. More than 85% of cases fall into the NSCLC class, 
which is associated with a predicted 5-year survival of 17.8% (Chen et al., 2014). Non–small-cell 
lung cancer can be divided into three major histological subtypes: squamous-cell carcinoma 
(SCC, ~40%), adenocarcinoma (50%), and large-cell lung cancer. Smoking causes all types of 
lung cancer but is most strongly linked with small-cell lung cancer and squamous-cell 
carcinoma, whereas adenocarcinoma is the most common type in patients who have never 
smoked (Herbst et al., 2008). Despite advances in early detection, NSCLC is often diagnosed at 
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an advanced stage and has a poor prognosis. Treatment depends on the stage of the tumor and 
includes surgery, radiation therapy, chemotherapy, a variety of targeted therapies (e.g. receptor 
tyrosine kinase enzyme inhibitors) and immunotherapy — alone or in combination (Peters et al., 
2017). However, the 5-year survival for advanced non-surgical stages is poor (about 5-10%). 
NSCLC that has spread to other parts of the body is often refractory to any currently available 
form of treatment. Metastatic, or stage IV NSCLC, has a 5-year survival of about 1%. Whereas 
other cancers such as breast cancer and melanoma have benefited from advances in targeted 
therapies, such as checkpoint inhibitors, most types of lung cancer have not shown similarly 
promising results. Nevertheless, other forms of immunotherapy need to be explored as an adjunct 
to standard therapy, in an effort to reverse immunologic tolerance in the tumor 
microenvironment (Bremnes et al., 2011).  
The tumor microenvironment provides a wide range of resources that support NSCLC 
progression (Chen et al., 2014; Wood et al., 2014) among which are diverse stromal cells, 
including activated MSCs (Bussard et al., 2016; Raffaghello and Dazzi, 2015; Shi et al., 2017).  
In this work, we used MSCs isolated from human lung squamous cell carcinoma samples and 
from non-tumor adjacent lung tissue to explore and compare their immunomodulatory potential. 
1.3 Mesenchymal Stem Cells 
Although they were initially described in the bone marrow (BM), MSCs display a broad tissue 
distribution and are found in adipose, synovial and lung tissue as well as in umbilical cord and 
peripheral blood (Williams and Hare, 2011). They are a heterogeneous stromal cell population 
and characterization of their sub-populations has been hampered by the lack of specific markers. 
Their defining properties include: the capacity to differentiate into mesodermal- and non-
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mesodermal-derived tissues (multilineage differentiation into osteocytes, adipocytes and 
chondrocytes) (Dominici et al., 2006), but also into endodermal and neuroectodermal lineages 
(Williams and Hare, 2011); recurrent surface marker expression patterns, expressing CD105, 
CD73 and CD90 and lacking CD45, CD34, CD14, CD11b, CD79a, CD19 and HLA-DR (Ma et 
al., 2014a); low expression levels of MHC class I molecules, and minimal or no MHC class II 
molecules nor co-stimulatory molecules, such as CD40, CD80, CD86, precluding antigen 
presenting activity (Fibbe and Noort, 2003); and the capacity to adhere to cell culture plates 
(Dominici et al., 2006). MSCs can take the morphological appearance of fibroblasts and they are 
in fact considered to be fibroblast progenitors. 
MSCs are believed to play a critical role in tissue repair. Mediators of inflammation and immune 
cells, together with endothelial cells and fibroblasts, orchestrate changes in the 
microenvironment that result in the mobilization and differentiation of MSCs into diverse 
stromal components that replace damaged tissue cells. These MSCs can be tissue-resident or 
recruited from the bone marrow. However, the mechanisms by which MSCs are mobilized and 
recruited to damaged sites are not fully understood. In addition, how they survive and 
differentiate into distinct cell types in vivo is still not clear (Shi et al., 2012a). Once MSCs have 
entered the microenvironment of injured tissues, many factors, including cytokines such as tumor 
necrosis factor-α (TNF-α), interleukin-1 (IL-1), interferon-γ (IFN-γ), toxins of infectious agents 
and hypoxia can stimulate the release of an array of growth factors by MSCs, including 
epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor 
(PDGF), transforming growth factor β (TGFβ), vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF),  insulin-like growth factor-1 (IGF-1), angiopoietin-1 (Ang-1), 
keratinocyte growth factor (KGF) and stromal cell-derived factor-1 (SDF-1). These growth 
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factors, in turn, promote the activation of fibroblasts, endothelial cells and tissue progenitor cells, 
which ensure tissue regeneration and repair (Lee et al., 2011; Ma et al., 2014b; Shi et al., 2012a).  
In addition to tissue regeneration, MSCs have been reported to exhibit various functions, such as 
enhancement of angiogenesis, prevention of apoptosis and fibrosis through the secretion of 
paracrine mediators, and many others summarized in Figure 1. 
 
Figure 1: Summary of MSC functions (Bergfeld and DeClerck, 2010; Maumus et al., 2011; Pittenger et al., 1999; 
Shi et al., 2012b). 
Among this plethora of effector functions, MSCs have been reported to exert different 
immunomodulatory activities after priming by cytokines from a pro-inflammatory 
microenvironment (inflammation, cancer or infection, e.g.), particularly IFN-γ, TNFα and IL-1β 
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or through toll-like receptor (TLR) stimulation (Bernardo and Fibbe, 2013; Dumitru et al., 2014; 
Krampera, 2011).  
MSCs express TLR1-6 at mRNA levels, and 2-4 and 7 and 9 also at the protein level. MSC 
activation through TLR3 and 4 leads to the secretion of IL-1, IL-6, IL-8, TRAIL and CCL5 
(Romieu-Mourez et al., 2009). Experimentally, the duration of TLR stimulation on MSCs seems 
to play a role in the subsequent activation profile developed by MSCs. Short term stimulation 
with ligands for TLR can induce MSC polarization to MSC1 or MSC2 types. TLR4 stimulation 
promotes IL-6, IL-8 and TGFβ1 secretion, whereas TLR3 stimulation increases IL-4, IL-1RA, 
indoleamine 2,3-dioxygenase 1 (IDO), and prostaglandin E2 (PGE2) (Giuliani et al., 2014; 
Krampera, 2011; Waterman et al., 2010). Thus, TLR4-primed MSCs are polarized into pro-
inflammatory MSC1 phenotype (tumor-growth inhibition), whereas TLR3-primed MSCs are 
polarized into the classical immunosuppressive MSC2 phenotype (Waterman et al., 2010, 2012). 
The level of inflammation is also critical in the polarization of MSCs. MSCs become 
immunosuppressive only when exposed to sufficiently high levels of pro-inflammatory cytokines 
(TNFα, IFN-γ) (Li et al., 2012; Ren et al., 2010) and this immune-suppressive phenotype of 
MSCs (MSC2) is influenced by TLR3 stimulation and late stages of inflammation (Li et al., 
2012). In the presence of low levels of TNFα and IFN-γ (early phase of inflammation), MSCs 
may adopt a pro-inflammatory phenotype (MSC1) and enhance immune responses, in part 
through TLR4 expressed on their surface (Waterman et al., 2010). IFN-γ, TNFα and/or TLR3 are 
able to increase MSC production of PGE2 and IDO. Some studies showed that both TLR3 and 4 
enhance immunosuppression through IDO (Opitz et al., 2009); and others showed increase of 
proinflammatory cytokines in both (Romieu-Mourez et al., 2009).  
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Thus, MSC licensing to become activated cells depends on activation by proinflammatory 
cytokines, on priming stimuli such as TLR, and on timing of MSC engagement in the activation 
process of immune effector cells (Krampera, 2011).  
The immunosuppressive effects of MSCs require proximity to their target cells, which include T 
and B lymphocytes as well as NK cells, and are mediated by secretion of soluble factors and cell-
to-cell contact (Figure 2). Activated/primed MSCs upregulate MHC class I molecules, ICAM-1 
and VCAM-1 adhesion molecules, and the immunosuppressive molecule PD-L1. These latter 
three molecules recognize ligands on immune cells, promote cell-to-cell adhesion and then 
expose immune cells to secreted immunosuppressive molecules (Ren et al., 2010).  
 
Figure 2: Possible interaction mechanisms between MSCs and cells of the innate and adaptive immune systems 
(Uccelli et al., 2008).  
Following activation, the spectrum of MSC immunosuppressive activity in humans includes 
secretion of human leukocyte antigen (HLA-G), TGFβ, PGE2, tumor necrosis factor-inducible 
protein 6 (TSG-6), heme oxygenase 1 (HO-1), IL-10, IL-6, IDO1, HGF and leukemia inhibitory 
factor (LIF) as well as programmed death ligand (PD-L1/2) and Fas Ligand (FasL) signaling 
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(Kansy et al., 2014; Krampera et al., 2013; Ma et al., 2014; Poggi and Giuliani, 2016; Poggi et 
al., 2014; Spaggiari and Moretta, 2013; Stagg and Galipeau, 2013; Turley et al., 2015; Uccelli et 
al., 2006; Wang et al., 2014; Le Blanc and Davies, 2015).  
 
Moreover, thanks to their immunomodulatory properties and their role in tissue repair, MSCs 
have held promise, from animal models to clinical trials, in the treatment of numerous connective 
tissue and immune disorders (Figure 3). Indeed, from a therapeutic perspective, and facilitated by 
the ease of preparation and immunologic privilege (HLA-I and II negative), MSCs are emerging 
as a promising therapeutic agent for tissue regeneration (Williams and Hare, 2011).  
 
Figure 3: Percentages of the common diseases now treated with mesenchymal stem cells (Wei et al., 2013). 
1.4  Mesenchymal Stem Cells and Cancer 
Accumulating evidence suggests that MSCs have the ability to migrate and engraft into tumor 
sites (Kidd et al., 2009) and MSC mobilization has been observed with almost all tested types of 
solid cancer, including lung cancer (Loebinger et al., 2009).  
MSC modulation of tumor growth and immune cells: In the tumor, MSCs can exert stimulatory 
(Beckermann et al., 2008) or inhibitory (Nomoto-Kojima et al., 2011) effects on cancer cell 
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growth, invasion, and metastasis through direct or indirect interactions with tumor cells 
(Karnoub et al., 2007; Liu et al., 2011). Thus, although MSCs can have opposing effects on 
tumor growth, their net effect seems to be protumorigenic and reflects the imbalance between 
pro- and antitumorigenic activities that can vary depending on tumor type (and regionally within 
the tumors), the ecology of the host milieu and the stage in the evolution of a particular tumor. 
Moreover, MSCs could contribute to tumor development through the modulation of immune 
surveillance. 
 
MSCs deposit ECM, which constitutes a physical barrier to immune cell infiltration but also 
provides an essential substratum to immune cell migration (Puré and Lo, 2016). MSCs also 
secrete IL-1β and IL-6 that regulate the desmoplastic response in tumors, which may limit 
infiltration and regulate the function of infiltrating leukocytes, and affect T cell proliferation 
(Hong et al., 2014). Recently, Ridge et al. proposed a comprehensive review of the role of MSCs 
in tumor progression (Ridge et al., 2017). As mentioned above, MSCs modulate the immune 
response through secreted immunomodulatory molecules but also by cell-to-cell contact. 
Moreover, several studies highlight the role of exosomes and other extracellular vesicles (EVs) 
on immune modulation induced by MSCs as they could be potential carriers of PGE2, TGFβ, 
and IDO (Burrello et al., 2016; Di Trapani et al., 2016). Exosomes are EVs of 30–100 nm of 
diameter secreted by different types of living cells, among which MSCs and tumor cells. These 
EVs can carry a plethora of molecules, including a variety of receptors, adhesion molecules, 
cytokines, chemokines, as well as cell-specific antigens. Moreover, they are also enriched in a 
range of nucleic acids (Robbins and Morelli, 2014; Yáñez-Mó et al., 2015). The 
immunomodulatory effects of MSCs can therefore be speculated to be achieved either through 
the release of the above mentioned factors and proteins directly into the extracellular milieu as 
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soluble molecules, or they may be packaged into EVs together with nucleic acids and other post-
transcriptional modulators which could influence the inflammatory response when released 
(Robbins and Morelli, 2014).  
 
Despite these pro-tumorigenic effects, MSCs have also been proposed as an attractive candidate 
for delivery of anti-tumor agents, based on their ability to home to tumor sites and to secrete 
cytokines (Seo et al., 2011). 
Effect of the tumor microenvironment on MSC phenotype: The tumor microenvironment 
exhibits the molecular characteristics of a “wound that never heals” that continuously releases 
various cytokines and other mediators, which establish a persistent stalemate between 
inflammation and repair in the tissue (Dvorak, 1986). Tumor-derived signals have the capacity to 
modulate the phenotype of tissue resident and tumor-attracted MSCs (T-MSCs) that become 
constituents of the tumor niche and harbor distinct features from those of healthy tissue MSCs 
(N-MSCs) or bone marrow MSCs (BM-MSCs) (Sun et al., 2014) (Figure 4). Differences 
between non-tumor associated MSCs and T-MSCs are probably mainly caused by the cytokines 
present in the inflammatory tumor microenvironment. For example, MSCs treated with IFN-γ 
and TNFα have been shown to upregulate TGFβ and VEGF expression (Jing et al., 2012; Liu et 
al., 2011). TGFβ could then promote epithelial–mesenchymal transition (EMT) and metastasis 
(Jing et al., 2012). In addition, IFN-γ or TNFα can also enhance the immunosuppressive effects 
of MSCs (Ren et al., 2012).  
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Figure 4: Different effects of non-tumor associated MSCs (N-MSCs) and Tumor-derived MSCs (T-MSCs) on 
tumors. N-MSCs are “educated” by the tumor inflammatory microenvironment after homing to tumor tissues, and 
their transformation to T-MSCs exerts different effects on tumor development.  Promote Inhibit 
 Controversial. Taken from Sun et al., 2014.  
Another component of the tumor microenvironment that could participate in the modulation of 
MSC phenotype are exosomes. Exosomes derived from breast and ovarian cancer cells can cause 
adipose-derived MSCs to adopt Tumor-associated Fibroblasts (TAF) phenotypes, with 
upregulated α-SMA expression. Additionally, they can promote MSC expression of the tumor-
associated factors SDF-1, VEGF, CCL5, and TGFβ (Cho et al., 2012; Dostert et al., 2017) 
 
The characteristics of T-MSCs: MSCs in tumor tissues are significantly affected by both tumor 
cells and the chronically inflammatory tumor microenvironment. MSCs are non-neoplastic and 
chromosomally normal in solid tumors (Brune et al., 2011; McLean et al., 2011). Moreover, 
MSCs are more prevalent in tumor tissues than in adjacent normal tissues (Hernanda et al., 2013) 
and exhibit a significantly greater proliferative capacity (Ding et al., 2012; Gottschling et al., 
2013; Johann et al., 2010; McLean et al., 2011; Xu et al., 2011). In addition, T-MSCs exhibit 
stronger migratory capabilities than non-tumor MSCs (Xu et al., 2011) and exhibit strong drug 
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resistance. Gottschling et al. performed a comparative molecular and functional analysis of 
MSCs derived from non-small cell lung cancer and corresponding normal lung tissue 
(Gottschling et al., 2013). NSCLC-MSCs showed accelerated growth kinetics and reduced 
sensitivity to cisplatin, as well as an altered gene expression profile (Gottschling et al., 2013). T-
MSCs also exhibit stronger immnosuppressive activity compared to BM-MSCs (Johann et al., 
2010; Razmkhah et al., 2011; Ren et al., 2012). Finally, T-MSCs have been shown to promote 
tumor cell proliferation (McLean et al., 2011) and have the ability to increase the proportion of 
cancer stem cells (Luo et al., 2014; McLean et al., 2011) (Figure 4). 
 
In this work, we focused on the immunomodulatory functions of lung tumor-associated MSCs in 
comparison with paired non-tumor associated MSCs from the same patients, by studying their 
modulation of NK cell function. In particular, we focused on the role of PGE2 and IL-6 secreted 
by lung MSCs in MSC-NK interactions. 
1.5 Natural Killer Cells 
NK cells are involved in both the adaptive and innate immune responses. They have the intrinsic 
ability to kill their cellular targets without prior sensitization and without MHC (Major 
histocompatibility complex) restriction, and to recognize virus-infected cells. They are effector 
lymphocytes of the innate immune system that control several types of tumors and microbial 
infections by limiting their spread and subsequent tissue damage. They were first described in 
mice in the beginning of the 1970s as a new lymphocyte population: large granular lymphocytes 
of innate immunity. Recent evidence highlights a role for NK cells in “memory” adaptive 
immunity (Sun and Lanier, 2009). NK cells represent 5 to 20% of circulating lymphocytes and 
are widely present in tissues, particularly in secondary lymphoid tissues (lymph node, spleen, 
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tonsils) and in inflamed tissues (Grégoire et al., 2007). Natural killer cells are characterized by 
the expression of CD56 and the absence of CD3. According to the level of CD56 expression, 
they are subdivided into two functional subpopulations: CD56bright and CD56dim. CD56bright and 
CD56dim expressions are associated with elevated cytokine production and high degranulation 
potential, respectively (Caligiuri, 2008; Cooper et al., 2001b, 2001a; Lanier et al., 1986). The 
CD56bright population produces immunomodulatory cytokines, including IFN-γ (Cooper et al., 
2001b). They are considered to be a less mature CD56dim precursor. CD56dim is the terminally 
differentiated NK subset and is primarily responsible for exerting cytolytic functions (Chan et 
al., 2007). However, CD56dim NK cells can also produce cytokines, specifically IFN-γ, after 
triggering via NKp46 and NKp30 activating receptors or after stimulation with combinations of 
IL-2, IL-12 and IL-15 (De Maria and Moretta, 2011). CD56 is also expressed by a T cell subtype 
and some cancers cells (Lanier et al., 1989). Its role on NK cell function is still unknown. NK 
cells, in particular the CD56dim subset, also express the low-affinity receptor for the Fc portion of 
IgG CD16 (FcγRIIIA), whose expression is not restricted to these cells, and which is involved in 
antibody dependent cell cytotoxicity (ADCC).  
Distribution of CD56dim and CD56bright subsets is different according to the organ. In the blood, 
the CD56dim subpopulation is dominant and represents 90% of NK cells. NK cells do not 
undergo sustained proliferation in vitro, with differences between CD56 subtypes. CD56bright 
cells express the high affinity IL-2 receptor (IL2Rαβγ) and expand 10-fold more than CD56dim 
subset upon low-doses of IL-2. CD56dim cells express the intermediate affinity IL-2 receptor 
(IL2Rβγ) and do not respond to IL-2 stimulation by increasing their proliferation but rather 
display enhanced cytotoxicity (Caligiuri et al., 1993; Henney et al., 1981). 
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NK cells are able to lyse target cells through two main cell-to-cell contact dependent 
mechanisms: ADCC and the Natural Cytotoxicity. NK cells can also indirectly participate in 
target cell death by secreting pro-inflammatory cytokines (IFN-γ and TNFα).  
NK cells are an important source of cytokines and chemokines, with immunomodulatory 
functions in the immune response and involvement in the control of adaptive immune responses. 
Secretion of cytokines and chemokines is highly regulated in NK cells and is dependent on the 
origin of the stimulation: monokine-dependent (IL-12, IL-15 and IL-18 e.g.) or target-dependent.  
IFN-γ: IFN-γ is the most abundant cytokine produced by NK cells. It plays multiple roles in 
innate and adaptive immune responses against viruses and intracellular bacteria and in tumor 
control (stimulation of immune response toward cancer cells and enhancement of tumor cell 
immunogenicity). In this latter process NK cells provide early and important sources of IFN-γ 
production as they might be the first to recognize developing tumors. IFN-γ secreted at the tumor 
site augments MHC expression on tumor cells increasing their immunogenicity which in turn can 
induce tumor cell elimination. NK cells not only operate in early stages of tumor development 
but also act as helpers in the priming of CD8+ and T helper (Th1) cells by producing IFN-γ 
(Alshaker and Matalka, 2011; Schoenborn and Wilson, 2007). On the other hand, the pro-tumor 
functions of IFN-γ involve proliferative and anti-apoptotic signals, as well as escape of the tumor 
cells from recognition and cytolysis by Cytotoxic T lymphocytes (CTLs) and NK cells. Which 
face is ultimately displayed may depend on the contexts of tumor specificity, micro 
environmental factors, and signaling (Zaidi and Merlino, 2011). Other molecules secreted by NK 
cells include TNFα, TNFβ, GM-CSF, IL-5, IL-8, IL-10, MIP-1α, MIP-1β, and IL-13 (Cooper et 
al., 2001a). 
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Trotta et al. have shown that production of IFN-γ is regulated in vitro and in vivo by the SHIP1 
phosphatase whose expression is higher in CD56bright (Trotta et al., 2005). This subset usually 
requires two signals to produce IFN-γ, and one of them is almost always IL-12. The second 
signal consists of IL-1, IL-2, IL-15 or IL-18, or engagement of NK activating receptors (CD16 or 
NKG2D e.g.) (Bryceson et al., 2006). Chemokine production by CD56bright cells is highly 
dependent on the precise monokine combination used for stimulation. For IFN-γ, optimal stimuli 
are IL-12 and IL-18 together. Thus, the monokine environment determines the NK response 
profile. NK cells are also able to secrete cytokines following target cell recognition. Surprisingly, 
CD56dim NK subtype was reported to be the main producer of IFN-γ following stimulation by 
K562 cells (Fauriat et al., 2010).  
In the present work, we used IL-2 stimulated NK cells and it has been shown that after IL-2 in 
vitro stimulation, CD56bright cells show a higher proliferative potential and cytotoxic activity 
compared to CD56dim cells (Nagler et al., 1989). 
NK cell activation: NK transition from a quiescent state to activation requires the integration of 
different signals from activating and inhibitory NK receptors which determine whether or not the 
NK cell will become cytotoxic. Thus the balance between positive and negative signals derived 
from membrane receptors determines NK activation (Figure 5). The lack of inhibition is not 
sufficient to induce NK activation and a positive signal is always required. Cytotoxicity is 
primarily based on granule exocytosis upon formation of an immunological synapse. Granules 
contain preformed perforin and granzymes. The granule membrane fuses with the plasma 
membrane, externalizes, and releases the cytotoxic contents. Perforin penetrates the target cell 
membrane and granzymes (a family of serine proteases) trigger cell apoptosis (Lieberman, 
2003). Lining the membrane of the lytic granules is the lysosomal-associated-membrane protein-
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1 (LAMP-1, or CD107a). Up-regulation of this molecule on the NK cell membrane is a marker 
of NK cell degranulation and strongly correlates with both cytokine secretion and NK cell-
mediated lysis of target cells (Alter et al., 2004).  
 
Figure 5: Natural-killer-cell recognition of target cells (Fauci et al., 2005). 
Immunological synapse: The immunological synapse was originally defined in the late 1990s 
(Grakoui et al., 1999; Monks et al., 1998) as the crucial junction between a T cell and an antigen-
presenting cell (APC) at which T-cell receptors interact with MHC molecules. Subsequent 
studies extended these observations and identified relevant immunological synapses between 
different types of immune cells, as well as between immune cells and non-immune cells. Thus, 
an immunological synapse can be defined as the intentional arrangement of molecules in an 
immune cell at the interface with another cell (Orange, 2008). The NK-cell lytic synapse (Figure 
6) is formed in a series of stages that are required for cytolytic function. These include 
recognition/initiation, effector and termination stages that together enable the precise delivery of 
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lytic-granule contents onto a susceptible target cell (Orange, 2008). Numerous additional 
functions have been proposed for the immunological synapse: ligand recognition, signal 
amplification and integration, costimulation, precise targeting of cytotoxicity (McCann et al., 
2003), directed secretion (arrangement of molecules at the synapse can create a conduit through 
which cellular components can be secreted) (Davis et al., 1999; Vyas et al., 2001), protein 
transfer, inhibition/prevention of activation and signal termination.  
 
Figure 6: NK cell lytic granules. NK cells contain various related organelles with distinct morphology, including 
mature lytic granules, lytic granule precursors, multivesicular bodies and late endosomes (see figure – red 
arrowheads denote lytic granules and their precursory forms). These can polarize to the immunological synapse 
where their contents can be secreted into a cleft formed between NK and target cell (Orange, 2008). 
 
NK cell activating receptors: Activating receptors induce NK cell activation through 
combinatorial synergy (Long et al., 2013). Only when the resulting signal from activation of 
multiple engaged receptors surpasses the activation threshold, do NK cells trigger cytokine 
secretion or direct cellular cytotoxicity. Activating receptors include NKG2D and the Natural 
Cytotoxicity Receptors (NCR) NKp30, NKp44 and NKp46 (Figure 7, in green). The latter is 
sometimes considered as a co-stimulatory receptor (Figure 7, in yellow). Other molecules, 
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formerly considered as co-receptors (Figure 7, in yellow), participate in the activation of NK cell 
cytotoxicity: the DNAX accessory molecule (DNAM-1, CD226), signaling lymphocytic 
activation molecule (SLAM) family, molecule 2B4 (CD244) and NKp80. CD16 is also an 
activating receptor and exerts a direct cytotoxic function through the binding of appropriate 
ligands on target cells (Mandelboim et al., 1999).  
 
Figure 7: NK cell surface receptors and their ligands. The known ligands are reported in brackets. Other families of 
receptors are not shown, including cytokine receptors, chemotactic, adhesion receptors, and inhibitory co-receptors 
(Handgretinger et al., 2016). 
NKG2D is one of the best characterized activating NK cell receptors that works both as 
activating and co-stimulatory receptor. Ligands of the human NKG2D receptor are the MHC I-
related molecules MICA/MICB, and the UL16-binding proteins (ULBP-1 to ULBP-6). These 
ligands are rarely expressed (except for MICA) in healthy tissues but induced by various cellular 
stresses, such as tumor cell transformation. Although primary tumors frequently express NKG2D 
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ligands, they also develop mechanisms for NK cell evasion, for example systemic release of 
NKG2D ligands by tumors, which causes downregulation of NK cell-expressed NKG2D (Groh 
et al., 2002). Constitutive expression of ligands can also induce the downregulation of NKG2D 
receptor leading to reduced immune surveillance (Oppenheim et al., 2005). NKG2D expression 
can be positively or negatively regulated by cytokines: it can be induced by IL-2, IL-12, IL-15, 
IL-18, TNFα, and IFNα, and diminished by TGFβ (Castriconi et al., 2003).  
NKp30 and NKp46 are constitutively expressed on NK cells, whereas NKp44 is only expressed 
on activated NK cells. NKp46 (NCR1) is involved in tumor eradication but also in the process of 
tumor immunoediting (Elboim et al., 2010). Potential ligands of NKp46 on tumor cells are yet 
unknown, except for the hemagglutinin antigens (HA) expressed on virus-infected cells. NKp44 
(NCR2) binds to viral hemagglutinins for the recognition of infected cells and to tumor cells in a 
heparan sulfate proteoglycan (HSPG)-dependent manner (Hershkovitz et al., 2007). In addition, 
NKp44 receptor recognizes Proliferating Cell Nuclear Antigen (PCNA), which is overexpressed 
in cancer cells. Their interaction paradoxically inhibits NK cell function and PCNA can promote 
cancer survival by immune evasion through inhibition of NKp44-mediated NK cell attack 
(Rosental et al., 2011). NKp30 (NCR3) is involved in NK-mediated recognition and lysis of 
multiple tumor cell lines and primary tumor cells. NKp30 ligands are poorly defined, except for 
B7-H6 restricted to malignant tissues (Brandt et al., 2009). Others ligands are BAT3 (BAG6) and 
pp65. The B7-H6 cell surface molecule can be upregulated upon TLR stimulation of myeloid 
cells in inflammatory conditions (Pesce et al., 2015). This molecule can be secreted as a soluble 
form and binds to the NKp30 receptor. Some tumor cells, like K562 or ovarian carcinoma cells, 
express high levels of surface B7-H6 (Brandt et al., 2009; Pesce et al., 2015). Patients expressing 
low levels of NKp30 display impaired NK-mediated antitumor cytolytic activity and low IFN-γ 
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production in response to B7-H6+ target cells. Interestingly, the soluble and exosomal form of 
the NKp30 ligand BAG6 has been described in leukemias. Thus, the chronic receptor-ligand 
interactions that in the tumor environment induce loss of NKp30 may be due to continuous 
perturbation by soluble or surface-bound B7-H6 molecules. 
DNAM-1 (CD226) is a leukocyte adhesion molecule involved in the induction phase of NK cell 
activation. Its expression is dependent on the surface expression of lymphocyte function 
associated-antigen (LFA-1) (Shibuya et al., 1999). The αLβ2 integrin, LFA-1 (CD11a/CD18), is 
expressed on most leukocytes and mediates cell-cell adhesion upon binding to its ligands, the 
intercellular adhesion molecules ICAM-1 (CD54), ICAM-2 (CD102), or ICAM-3 (CD50) 
(Fawcett et al., 1992; Staunton et al., 1989). Upon target cell recognition, the conformational 
state of LFA-1 changes in educated NK cells and rapid colocalization of active LFA-1 and 
DNAM-1 occurs at the immunological synapse (Enqvist et al., 2015). CD112 (Nectin-2) and 
CD155 (PVR: poliovirus receptor), two nectin family proteins regulated by cellular stress, have 
been identified as the ligands for DNAM-1. They are strongly expressed by tumor cell lines 
(Bottino et al., 2003). In association with NCR or NKG2D receptors, DNAM-1 is involved in the 
recognition and lysis of different types of cancer cells. Its role in anti-tumor immunity is more 
important when ligands for other activating receptors are poorly expressed (Gilfillan et al., 
2008). Decreased DNAM-1 expression on NK cells was described in lung carcinoma patients 
(Platonova et al., 2011a). DNAM-1 is part of an important family of adhesion molecules that 
bind nectins and nectin-like family proteins (Martinet and Smyth, 2015). These molecules 
include DNAM-1, T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), 
CD96, and cytotoxic and regulatory T cell molecule (CRTAM). DNAM-1 has been studied as an 
adhesion molecule that controls NK cell-mediated cytotoxicity. Interestingly, the two other 
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molecules that contain inhibitory motifs — CD96 and TIGIT — also bind to DNAM-1 ligands 
and were recently found to counterbalance the DNAM-1-mediated activation of NK cells 
(Bottino et al., 2003; Chan et al., 2014; Stanietsky et al., 2009).  
NK cell inhibitory receptors: As NK cell activation is regulated by classical MHC class I 
molecules, KIRs (Killer Cell Immunoglobulin-Like Receptors) are the main receptors involved 
in the recognition of specific HLA-I alleles. KIRs bind to the self-MHC class I ligands (HLA-A, 
-B, -C) and upon ligation transmit signals that abrogate the effects of activating receptors 
(Vilches and Parham, 2002) (Figure 5). The KIR superfamily comprises activating (Figure 7, in 
green) and inhibitory receptors (Figure 7, in red). Inhibitory KIRs are characterized by a long 
cytoplasmic tail carrying two ITIMs (Immunoreceptor Tyrosine-based Inhibitory Motifs), 
whereas activating receptors lack ITIMs and have short cytoplasmic tails associated with adaptor 
molecules containing ITAMs (Immunoreceptor Tyrosine-based Activation Motifs). Each 
individual has his own repartition of KIR genes, which are highly polymorph. Most NK cells 
express one or two KIRs with at least one inhibitory receptor specific for self-HLA class I 
molecule.  
Another inhibitory receptor is NKG2A (Figure 7, in red). NKG2A contains two ITIM motifs and 
forms a heterodimer with CD94 molecule. A natural ligand of CD94/NKG2A heterodimer is 
HLA-E, a non-classical HLA class I molecule expressed on the cell surface of most leukocytes 
and on transformed cells. Ligation of CD94/NKG2A by HLA-E transmits inhibitory signaling 
that suppresses NK cell effector functions, resulting in decreased cytotoxicity and cytokine 
secretion. In patients with non-small cell lung cancer, intratumoral NK cells display higher gene 
expression levels of NKG2A relative to non-tumor NK cells (Gillard-Bocquet et al., 2013). Non-
classical HLA-E and HLA-G molecules are often overexpressed by tumor cells, participating in 
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tumor escape through interaction with inhibitory receptors and subsequent inhibition of NK and 
CTLs. Soluble HLA (sHLA) production has been described as another mechanism of tumor 
escape. 
Interestingly, cytokine secretion and cytotoxicity can be uncoupled when NK cells contact their 
target cells. Eric Vivier’s laboratory has studied NK cell activation and response and the 
transformation of quantitative differences (strength of stimulation) into qualitative differences 
(cytotoxicity only versus cytotoxicity and cytokine production) (Vivier et al., 2013). His group 
identified distinct signaling pathways, triggering either cytotoxicity or cytokine and chemokine 
production. Cytotoxicity triggered by the engagement of cell-surface receptors involves the 
sequential activation of PI(3)K, Rac1, PAK, MEK1 and MEK2 and finally MAPKs Erk1 and 
Erk2. The coupling of NKG2D and CD137, or the coupling of several KIR to an intracellular 
cascade (ADAP and the CARD11-BCL10-MALT1 (CBM) signalosome), exclusively triggers 
cytokine and chemokine production by NK cells but not cytotoxicity. There are also ADAP-
CBM–independent mechanisms that lead to cytokine secretion but not cytotoxicity (as the 
stimulation mediated by IL-12 and IL-18). The fraction of NK cells that become cytolytic after 
contact with target cells (cell degranulation) is higher than the fraction of NK cells that produce 
IFN-γ in the same conditions. ADAP might be activated only above a certain threshold of NK 
cell activation, whereas triggering of the cytotoxic module might occur at lower strength of 
stimulation (Vivier et al., 2013).  
Activation of NK cells therefore requires integration of signals from their target cells that may be 
subject to modulation by diverse cell types, including MSCs (Moretta et al., 2001; Spaggiari et 
al., 2008; Vivier et al., 2008).  
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In this thesis, we looked at the phenotype (receptors expressed) and the function (IFN-γ 
production and degranulation) of freshly isolated NK cells from healthy donors subjected to IL-2 
activation and MSC modulation in vitro.  
 
1.6 Natural Killer Cells and Cancer 
Generally, tumor cells downregulate MHC class I molecule expression and upregulate ligands 
for NK cell activating receptors, and thereby overcome the threshold for NK cell activation and 
become potential targets for NK cell lysis (Figure 8).  
 
Figure 8: Recognition of tumor cells by NK cells (Vivier et al., 2012). 
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The major receptors involved in NK-tumor cells recognition are recapitulated in Figure 9. Thus, 
as a first line of defense against tumors and pathogens, NK cells patrol tissues and can exert 
antitumor immunosurveillance by secreting cytokines, including IFN-γ, TNFα, and IL-10, and 
releasing cytotoxic granules whose contents kill tumor cells. However, tumor cells use direct and 
indirect mechanisms to escape NK surveillance. Direct mechanisms consist of shedding soluble 
ligands for NK cell-activating receptors (shed ligands can block tumor cell recognition by NK 
cells by preventing receptor-ligand interaction (Groh et al., 2002)), upregulation of HLA 
molecules, and release of inhibitory cytokines. Indirect mechanisms are activation of Treg, DC 
killing, and phagocyte-derived inhibitory cytokines. 
 
Figure 9: NK receptors and their cellular ligands expressed by tumor cells (Chester et al., 2015). 
An 11-year follow-up epidemiologic survey has shown that a low NK cell activity is associated 
with increased cancer risk in adults (Imai et al., 2000). In lung cancer patients, a low NK 
cytotoxicity in peripheral blood is associated with a poor prognosis (Cremer et al., 2012; 
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Platonova et al., 2011a). In selected human malignancies such as acute myeloid leukemia, 
allogeneic hematopoietic cell transplantations (HSCT) have shown that the development of 
donor NK cells in recipient tumor patients lacking donor KIR ligands (HLA) can lead to 
improved engraftment and post-transplant survival (Ruggeri et al., 2006). NK cells are the first 
lymphocyte population to recover after HSCT and participate in graft-versus-leukemia (GvL) 
effect (donor NK cells mismatched to the host leukemia HLA trigger cytotoxicity due to a lack 
of the self-inhibitory signal) (Ruggeri et al., 2006; Velardi, 2008; Velardi et al., 2009).  
Other evidence for the role of NK cells in tumor control relies on the observation that NK cells 
infiltrate diverse solid tumors, amongst others clear-cell renal cell carcinoma, melanoma, non-
small cell lung cancer, gastrointestinal stromal tumors (GIST) and colorectal carcinoma (CRC) 
(Carrega et al., 2008; Delahaye et al., 2011; Kornstein et al., 1987; Platonova et al., 2011a; 
Schleypen et al., 2003; Villegas et al., 2002; Wittnebel et al., 2007). 
NK cells in lung cancer: NK cells are found in the stroma of human lung tumors, especially in 
squamous cell carcinoma (Jin et al., 2014a) where they primarily display a CD56dim phenotype, 
low expression of multiple activating receptors (Platonova et al., 2011b; Vitale et al., 2014), and 
reduced function (Cremer et al., 2012; Gillard-Bocquet et al., 2013; Hodge et al., 2014; Pross 
and Lotzová, 1993). Platonova et al. showed that intratumoral NK cells displayed a profound 
alteration of their phenotype, with a drastic reduction of receptor expression level (NKp30, 
NKp80, CD16, NKG2D, and DNAM-1, among others) (Platonova et al., 2011b). Another group 
(Esendagli et al., 2008) observed a low expression of CD56, NKG2D, and NKp46 in lung 
cancer. Low NK cell activity in cancer-diagnosed patients is associated with poor prognosis, and 
those with advanced stage cancer often possess minimally cytotoxic NK cells (Pross and 
Lotzová, 1993). In early NSCLC Vitale et al. observed (2014) that the majority of NK cells are 
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CD56dim, with a decrease of NKp30, NKp80, CD16, DNAM-1 and of cytokine production and 
degranulation (Vitale et al., 2014). Several groups also observed an increase of the NK inhibitory 
receptors (Jin et al., 2014b).  
In lung cancer, the number of NK cell has been shown to be associated with the histology (more 
NK cell infiltration in SCC than in ADC), the size of primary tumor, the smoking status and, in 
some cases, with the prognosis (Jin et al., 2014b). Intratumor NK cells are mainly localized at the 
invasive margin. In NSCLC, NK cells represent 1.7-34.4% of tumor-infiltrating lymphocytes 
(TIL) and are mainly CD56dim and NKp46+, with a decrease in NKp30, NKp80, CD16, DNAM-
1, and an increase in CD69 and NKp44. In SCC, 7-10% of TIL are NK cells and 98% are dim. 
Peripheral blood NK cells are associated with prognosis but not intratumor NK cells, and clinical 
outcome is more associated with NK phenotype and function than with NK density (Cremer et 
al., 2012; Platonova et al., 2011b). Others studies have shown an increase in CD56brightCD16-
NKp44+CD69+ NK subset (CD69 is a marker of residency) (Carrega et al., 2014; Marquardt et 
al., 2017a), with decrease in cytotoxicity against cancer cells in vitro, whereas they release 
abundant cytokines (Carrega et al., 2008). IFN-γ, TNFα, IL-4 or IL-10 secreted by NK cells can 
contribute to tumor rejection by modulating tumor stroma and inhibiting tumor-induced 
angiogenesis (Blankenstein, 2005). Thus, a lower cytolytic activity in NSCLC-NK cells does not 
necessarily mean an ineffective anticancer activity. NK cells found in the immune infiltrate of 
NSCLC seem to be different from those associated with the non-tumor lungs. The percentage of 
bright NK cells in lung tumors remains less than half the total NK population. Generally, the 
HLA class I allele specific KIR receptors are expressed on subsets of CD56dimCD16+ cytolytic 
NK cells, whereas the immunomodulatory CD56brightCD16- NK subset uniformly expresses 
CD94/NKG2A and lacks KIRs. Indeed and surprisingly, in NSCLC NK, an evident expression 
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of KIR was detectable in CD56brightCD16- tumor NK cells, possibly as a consequence of tumor 
microenvironment-derived signals. 
1.7 Natural Killer Cells and Mesenchymal Stem Cells 
Recent studies have indicated that activated NK cells, but not freshly isolated resting NK cells, 
were capable of effectively lysing MSCs via their activating receptors (NKp30, NKG2D, and 
DNAM-1) (Casado et al., 2013; Sotiropoulou et al., 2006a; Spaggiari et al., 2006a, 2008) (Figure 
10). Indeed, human BM-MSCs express several ligands for NK cell receptors, such as MICA/B, 
ULBPs, CD112, CD155 (Poggi et al., 2005; Spaggiari et al., 2006b, 2008), and ICAM-1 (CD54). 
Lysis of target cells by NK cells requires a number of steps: target cell binding, calcium entry, 
and release of cytolytic enzymes. Stromal cells are killed by IL-2-activated NK cells upon 
LFA1-ICAM-1 interactions, and NKG2D-MICA/B and ULBP3 are involved in the delivery of 
the lethal hit. Among the surface structures involved in effector-target cell interaction, LFA1 
plays a key role in cell-to-cell adhesion as well as in delivering an activating signal (Poggi et al., 
2005). NK-mediated lysis of MSCs could be inhibited when MSCs are exposed to IFN-γ as a 
consequence of the up-regulation of HLA class I molecules at the surface of MSC target cells 
(Spaggiari et al., 2006a). Licensed MSCs exposed to IFN-γ are protected from NK lysis also 
through the downregulation of ULBP3 ligands and the increase of PGE2 and IDO1 secretion. 
IFN-γ also increases ICAM-1 expression, which increases physical contacts between NK and 
their target cells (Chang et al., 2002).  
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Figure 10: Interplay of NK cells and MSCs in NK cell-mediated lysis and immunomodulatory role on NK cell 
activity (Casado et al., 2013).  
Interaction between MSCs and NK cells are complex and evolve over time. NK cytotoxicity 
rises when the degree of NK cell activation increases and is inversely correlated with activation 
of MSCs (Figure 10). Soluble mediators secreted by the two cell types explain, a least in part, 
this bidirectional exchange. The IFN-γ secreted by activated NK cells may induce the release of 
immunomodulatory factors from MSCs (e.g. IL-10, TGFβ, PGE2 or HGF) which in turn, inhibit 
NK cell-mediated cytotoxicity against MSCs (Casado et al., 2013; Tseng et al., 2014).  
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BM-MSCs can inhibit NK cell proliferation, cytotoxicity and cytokine production by secreting 
IDO1, TGFβ, HLA-G and PGE2 (Casado et al., 2013; Krampera et al., 2006; Rasmusson et al., 
2003; Spaggiari et al., 2008).  
 
Freshly versus previously activated NK cells: BM-MSCs alter the phenotype of circulating NK 
cells and suppress proliferation and cytokine secretion of resting and activated NK cells 
(Aggarwal and Pittenger, 2005; Sotiropoulou et al., 2006a; Spaggiari et al., 2006a, 2008). BM-
MSCs suppress IL-2 and IL-15 induced proliferation and IFN-γ production, but not the 
cytotoxicity of freshly isolated NK cells (Spaggiari et al., 2008). In contrast, when confronted 
with previously activated NK cells, MSCs can interfere with NK mediated cytotoxicity, cytokine 
production, the expression of activating receptors (NKp30, NKp44, NKG2D) and granzyme B 
release. Their inhibitory effects are primarily mediated by cell-cell contact and secretion of IDO, 
PGE2, TGFβ1, HLA-G5 and Activin (Chatterjee et al., 2014; Le Blanc and Mougiakakos, 2012; 
Spaggiari et al., 2008). MSCs cannot be lysed by freshly isolated NK cells, but only by pre 
activated NK cells (MSCs allo and autogenic to NK cells) (Rasmusson et al., 2003). 
 Proliferation: Inhibition of NK-cell proliferation is mostly mediated by soluble factors 
(Sotiropoulou et al., 2006a; Spaggiari and Moretta, 2013) such as IDO and PGE2. Krampera et 
al. have shown that the suppressive activity of MSCs required the presence of IFN-γ produced by 
activated T cells and NK cells, and was related to the ability of IFN-γ to stimulate the production 
of IDO by MSCs, which in turn inhibited the proliferation of activated T or NK cells (Krampera 
et al., 2006). In their model, they used BM-MSCs and did not observe any effect of TGFβ1. 
Similarly, Spaggiari et al. studied the interaction between BM-MSCs and IL-2/IL-15 stimulated 
NK cells. While they did not observe any effect of TGFβ1 or PGE2 alone, they identified a 
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synergistic effect of PGE2 and IDO and showed that IDO alone was sufficient for inhibiting NK 
cell proliferation (Spaggiari et al., 2008). In contrast, using BM-MSCs and IL-15 stimulated NK 
cells, Sotiropoulou et al. observed an inhibition of NK proliferation in direct and indirect co-
cultures mediated by PGE2 and TGFβ1, with an additive effect of both soluble factors 
(Sotiropoulou et al., 2006a). Pradier et al. supported the hypothesis of a combination of 
inhibitory molecules involved in MSC-mediated immunosuppression (Pradier et al., 2011).  
Cytokines: MSCs are able to inhibit NK cell cytokine (IFN-γ and IL-10) production (Pradier et 
al., 2011; Sotiropoulou et al., 2006a; Spaggiari et al., 2008), particularly in the CD56bright NK cell 
subset, but the mechanisms are not fully understood. PGE2 and IDO might be involved but with 
divergent results in vitro (Sotiropoulou et al., 2006b; Spaggiari et al., 2008). Finally, Chatterjee 
has shown the role of Activin-A, a member of the TGFβ family, in cytokine inhibition 
(Chatterjee et al., 2014).  
NK receptors and cytotoxicity: It has been shown that BM-MSCs could induce a down-
regulation of NKp30, NKp44, NKG2D receptors without any changes in CD56, KIR, NKp46, 
CD69, CD16 and NKG2A expression, mediated by PGE2 and IDO in a contact-dependent 
manner and associated with decreased NK cytotoxicity (Pradier et al., 2011; Spaggiari et al., 
2008). In addition, Sotiropoulou et al. observed a downregulation of 2B4, CD132 and DNAM-1 
expression (Sotiropoulou et al., 2006b). Although inhibition of cytotoxicity by MSCs appears to 
rely mostly on cell-to-cell contact (Spaggiari and Moretta, 2013) (through receptors), it also 
involves secreted mediators. NK cells cultured shortly with IL-2 in the presence of MSCs 
showed reduced cytotoxic potential against tumor cells (Krampera et al., 2006), which was more 
pronounced against HLA class I-positive than HLA class I-negative cells (Sotiropoulou et al., 
2006b). The role of PGE2 and IDO is frequently observed in different studies, whereas TGFβ is 
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more rarely involved (Sotiropoulou et al., 2006a; Spaggiari et al., 2008). To exclude that the 
reduced cytotoxicity of co-cultured NK cells was due to their exhaustion after killing of MSCs, 
freshly isolated NK cells were used in the majority of the studies.   
CD56 subsets: The interaction between MSCs and CD56 NK subtypes has been previously 
studied by Sotiropoulou et al. who identified a selective inhibition of the CD56bright subtype 
rather than a selective expansion of the dim subtype (Sotiropoulou et al., 2006b). CD56 
expression was also reduced after co-culture with the tumor stroma (Johann et al., 2010). 
TLRs: As mentioned previously, MSCs from different tissues express several TLR that promote 
their viability, proliferation, and cytokine secretion. TLR ligand stimulation modulates NKG2D 
ligands expressed on MSCs. After TLR priming, the surface expression of MICA protects them 
from NK cells (decrease at the surface and increase of shedding). In addition, others ligands 
expressed by MSCs participate in MSC protection. Inhibition by specific mAbs against DNAM-
1 and ULPB3 significantly modifies NK-induced MSC lysis. Moreover, CD112 and ULPB3 (but 
not CD155) are slightly increased by TLR3 treatment. TLR3-primed adult BM and embryonic 
MSCs are more resistant than unprimed MSCs to IL-2-activated NK-induced killing. After TLR 
priming, Giuliani et al. observed an increased production by MSCs of proinflammatory and 
angiogenic factors, and PGE2. MICA, with DNAM-1 and ULBP3 ligands, is part of a network, 
which contributes to insure immunoprotection of MSCs against NK cytolytic activity in a 
context of proinflammatory microenvironment mediated by TLR ligands (Giuliani et al., 2014). 
It has been shown that MSCs derived from lung cancer tissues have higher expressions of TLR4 
mRNA compared to normal bone marrow-derived MSCs. TLR4+ MSCs have a stronger 
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inhibitory effect on NK cell proliferation and cytotoxicity (Lu et al., 2015a). NKG2D receptor 
expression on NK cells is also inhibited by sorted TLR4+MSCs (Lu et al., 2015b). 
Most of our understanding of the functional MSC-NK cell relationship stems from experiments 
using normal BM-MSCs, peripheral blood NK cells and tumor cell lines. In tumors, however, 
MSCs may become constituents of the tumor niche and display distinct features from those of 
MSCs derived from healthy tissues or the BM (DelaRosa et al., 2012; Di Trapani et al., 2013; 
Gottschling et al., 2013; Johann et al., 2010; Liu et al., 2014). These features remain to be fully 
elucidated.  
 
In this work, we provided insights into the effects of lung tumor-associated MSCs on freshly 
isolated NK cell activity after IL-2 treatment. Indeed, we compared the immunosuppressive 
effects of T-MSCs with those of N-MSCs isolated from the same patient, and with those of BM-
MSCs isolated from healthy donors. We observed marked differences between those three MSC 
samples, concerning their phenotype and immunosuppressive function.  
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Mesenchymal stem cells (MSCs) display pleiotropic
functions, which include secretion of soluble factors
with immunosuppressive activity implicated in can-
cer progression. We compared the immunomodula-
tory effects on natural killer (NK) cells of paired intra-
tumor (T)- and adjacent non-tumor tissue (N)-derived
MSCs from patients with squamous cell lung carci-
noma (SCC). We observed that T-MSCs were more
strongly immunosuppressive than N-MSCs and
affected both NK function and phenotype, as defined
byCD56 expression. T-MSCs shifted NK cells toward
the CD56dim phenotype and differentially modulated
CD56bright/dim subset functions. Whereas MSCs
affected both degranulation and activating receptor
expression in the CD56dim subset, they primarily in-
hibited interferon-g production in the CD56bright sub-
set. Pharmacological inhibition of prostaglandin E2
(PGE2) synthesis and, in some MSCs, interleukin-6
(IL-6) activity restored NK function, whereas NK cell
stimulation by PGE2 alone mimicked T-MSC-medi-
ated immunosuppression. Our observations provide
insight into how stromal responses to cancer
dampen NK cell activity in human lung SCC.
INTRODUCTION
Lung cancer is the second most common malignancy and the
leading cancer in terms of lethality worldwide. More than 85%
of cases fall into the non-small-cell lung cancer (NSCLC) class,
which is associated with a predicted 5-year survival of 17.8%
and whose predominant histological subtypes are adenocarci-
noma (50%) and squamous cell carcinoma (SCC) (40%;
Chen et al., 2014). The tumor microenvironment provides
a wide range of resources that support NSCLC progression
(Wood et al., 2014), among which are diverse stromal cells,
including activated mesenchymal stem cells (MSCs) (Bussard
et al., 2016; Raffaghello and Dazzi, 2015).Cell Report
This is an open access article under the CC BY-NAlthough they were initially described in the bone marrow
(BM), MSCs display a broad tissue distribution and are found
in adipose, synovial, and lung tissue as well as in umbilical
cord and peripheral blood (Williams and Hare, 2011). MSCs
are a heterogeneous stromal cell population defined based on
three functional and phenotypic criteria: adherence to plastic;
expression of selected and lack of lineage-specific cell surface
markers; and the capacity to differentiate toward a variety of
mesenchymal lineages (Dominici et al., 2006). Among a plethora
of effector functions, MSCs have been reported to exert immu-
nosuppressive activity after priming by cytokines from a pro-in-
flammatory microenvironment, particularly interferon-g (IFN-g),
tumor necrosis factor a (TNFa), and interleukin-1b (IL-1b) or
through toll-like receptor (TLR) stimulation (Bernardo and Fibbe,
2013; Dumitru et al., 2014; Krampera, 2011). Following activa-
tion, the spectrum of MSC immunosuppressive activity in hu-
mans includes secretion of human leukocyte antigen (HLA-G),
transforming growth factor b (TGFb), prostaglandin E2 (PGE2),
tumor necrosis factor alpha-inducible protein 6 (TNFAIP6/
TSG-6), heme oxygenase 1 (HO-1/HMOX1), IL-10, IL-6, indole-
amine 2,3-dioxygenase 1 (IDO1), hepatocyte growth factor
(HGF), and leukemia inhibitory factor (LIF) as well as pro-
grammed death ligand (PD-L1/2) and Fas ligand (FasL) signaling
(Poggi and Giuliani, 2016; Poggi et al., 2014; Spaggiari and Mor-
etta, 2013; Stagg and Galipeau, 2013; Turley et al., 2015; Uccelli
et al., 2006; Le Blanc and Davies, 2015). The immunosuppres-
sive effects of MSCs require proximity to their target cells, which
include T and B lymphocytes as well as natural killer (NK) cells
(Aggarwal and Pittenger, 2005; Uccelli et al., 2008).
As a first line of defense against tumors and pathogens, NK
cells patrol tissues and can exert antitumor immunosurveillance
by secreting cytokines, including IFN-g, TNFa, and IL-10, and
releasing cytotoxic granules whose contents kill tumor cells.
Not surprisingly, NK cell infiltration of tumor tissue correlates
with better prognosis in diverse cancer types, including lung car-
cinomas (Platonova et al., 2011; Villegas et al., 2002), and lowNK
cell activity is associated with increased cancer risk in adults
(Imai et al., 2000). NK cell detection of and response to target
cells are regulated by cell surface activating and inhibitory recep-
tors. Activation of NK cells therefore requires integration of sig-
nals from their target cells that may be subject to modulations 20, 2891–2905, September 19, 2017 ª 2017 The Author(s). 2891
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Clinical Data and MSC Characterization
(A) Clinical data related to the five patients. See also Table S1.
(B–D) Characterization of N- and T-MSCs from one representative patient. (B)
Expression of CD90, CD105, CD73, and lineage (Lin: anti-CD14, -CD20,
2892 Cell Reports 20, 2891–2905, September 19, 2017by diverse cell types, including MSCs (Moretta et al., 2001;
Spaggiari et al., 2008; Vivier et al., 2008).
NK cell function correlates with CD56 expression, where high
(CD56bright) and low (CD56dim) expression are associated with
elevated cytokine production and high degranulation potential,
respectively (Caligiuri, 2008; Cooper et al., 2001; Lanier et al.,
1986). NK cells are found in the stroma of human lung tumors
(Jin et al., 2014), where they primarily display a CD56dim pheno-
type, low expression of multiple activating receptors (Platonova
et al., 2011; Vitale et al., 2014), and reduced function (Cremer
et al., 2012; Gillard-Bocquet et al., 2013; Hodge et al., 2014;
Pross and Lotzova´, 1993).
Bone-marrow-derived MSCs (BM-MSCs) can inhibit NK cell
proliferation, cytotoxicity, and cytokine production by secreting
IDO1, TGFb, HLA-G, and PGE2 (Casado et al., 2013; Krampera
et al., 2006; Rasmusson et al., 2003; Spaggiari et al., 2008). How-
ever, they can also be lysed by activated NK cells, depending on
their expression of activating NK receptor ligands, including
MHC class I polypeptide-related sequence (MICA, B), UL16
binding proteins (ULBPs), CD112, and CD155 (Poggi et al.,
2005; Spaggiari et al., 2006, 2008). Most of our understanding
of the functional MSC-NK cell relationship stems from experi-
ments using normal BM-MSCs, peripheral blood NK cells, and
tumor cell lines. In tumors, however, MSCsmay become constit-
uents of the tumor niche and display distinct features from those
of MSCs derived from healthy tissues or the BM (DelaRosa et al.,
2012; Di Trapani et al., 2013; Gottschling et al., 2013; Johann
et al., 2010; Liu et al., 2014).
Here, we provide insight into the effect of tumor-associated
MSCsonNKcell activitybycomparing the immunomodulatoryac-
tivity toward freshly isolatedNKcells fromhealthydonorsofpaired
samples ofMSCs isolated from tumor tissue (T-MSCs) andnormal
adjacent lung tissue (N-MSCs) of patientswith squamouscell lung
carcinoma. We observed marked differences between T- and
N-MSCs, from their phenotype to their immunosuppressive
function. Despite the ability of MSCs to secrete a variety of medi-
ators with immunosuppressive effects, T-MSCs could mediate
inhibition ofNKcell functionprimarily throughPGE2.Our observa-
tions provide insight into how stromal responses to cancer growth
blunt NK cell activity in human lung SCC.RESULTS
Characterization of MSCs Isolated from Patients with
Lung SCC
Stromal cells were isolated from dissociated primary lung SCC
(Figure 1A) as well as from adjacent non-tumor tissue from five
patients and verified for functional and phenotypic MSC features
as defined by the International Society for Cellular Therapy
(ISCT) (Dominici et al., 2006). Accordingly, both tumor and-CD34, and -CD45 antibody cocktail) markers by flow cytometry is shown. Cell
passage (p) is shown in brackets. Cells stained with isotype-matched anti-
bodies provided the negative control. (C) Adipogenic (Oil red O), osteogenic
(Von Kossa), and chondrogenic (Alcian blue) MSC differentiation potentials are
shown. Cells cultured in standard medium provided the control condition. The
scale bar represents 100 mm. (D) H&E, a-SMA, and vimentin IHC stainings are
shown. The scale bar represents 100 mm.
AB C
F
E
D
G
(legend on next page)
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tumor-free lung-tissue-derived stromal cells, which we selected
for our study, were adherent to plastic under standard culture
conditions; expressed comparable levels of CD105, CD73, and
CD90 and lacked expression of lineage markers (Figure 1B);
and underwent differentiation to osteocytes, adipocytes, and
chondrocytes in vitro in response to appropriate stimulation (Fig-
ure 1C). Because of the uncertainty as to the distinction between
tumor-associated MSCs and myofibroblasts, often termed can-
cer-associated fibroblasts (CAFs) (Kalluri, 2016), we assessed
the expression of the intermediate filament vimentin, a marker
of mesenchymal cells, and a-smooth muscle actin (a-SMA), a
hallmark of myofibroblasts (Desmoulie`re et al., 2004) in our stro-
mal cells. Immunohistochemical (IHC) analysis using specific
anti-vimentin and anti-a-SMA antibodies revealed that, as
expected, the majority of MSCs expressed vimentin but dis-
played undetectable levels of a-SMA (Figure 1D).
Immunophenotype of Tumor-Infiltrating Cells and
Primary Cancer Cell Characterization
Untreated, surgically removed primary lung tumors from five
patients with a smoking history were subjected to histological
analysis and diagnosed as moderately to poorly differentiated,
invasive SCC (TNM pT2-pT3; Figure 1A; Table S1). Immune
cell tumor infiltrates were assessed by immunostaining of tissue
sections from four patients for CD3, CD4, CD8, CD20, CD68
KP1, Granzyme B, CD56, PD-L1, PD1, and FoxP3 (Table S1)
and by flow cytometry of cells from three of the tumors (patients
1, 2, and 5). NK cells constituted less than 1% of the total CD45+
cell infiltrate in all three tumors (0.2% of CD45+ cells for patient 1,
0.59% for patient 2, and 0.55% for patient 5). The relative abun-
dance of T cells (CD4+, CD8+, and FoxP3+CD25+ T reg cells),
B cells, and myeloid cells was variable among the samples,
reflecting IHC staining (Figure S1; Table S1).
Primary cancer cells (PCC) from three of the patients (patients
2, 3, and 4) were obtained by culturing single cells from the tumor
bulk in ultra-low attachment flasks and in knockout (KO) mediumFigure 2. T-MSCs Are More Immunosuppressive Than N-MSCs Towar
(A) Schematic representation of direct and indirect co-culture experiments.
(B, C, D, and F) NK cell activation (percentages of CD107a and intracellular IFN-g
as assessed by flow cytometry. Results were normalized to those of NK cells
(the control condition is represented by the horizontal dashed line). Results show
(B) Direct co-cultures. Graphs plot individual values of 8 independent experimen
licates]; MSC2 [n = 2]; MSC3 [n = 6]; MSC4 [n = 2]; MSC5 [n = 1]) and 3 experime
MSC4 [n = 1]).
(C) Indirect co-cultures. Two experiments were done with K562 cells (two NK cell
PCC (one NK cell donor; MSC1 [n = 1]; MSC3 [n = 1]).
(D) Comparison of the effects of BM-MSCs to those of lung tissueMSCs. Graphs p
(two different NK cell donors; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n = 1]; BM-MSC
[n = 1]; MSC3 [n = 1]; MSC4 [n = 1]; BM-MSC [n = 3]).
(E) IFN-g secretion (pg/mL) by NK cells co-cultured with N- (blue bar) and T-MSCs
right panel). IFN-g secretion by NK cells cultured alone is shown in green. Light co
after activation. Mean values ± SEM for 3 experiments with K562 as target cells (th
one experiment with PCC as target cells (one single NK cell donor; MSC1 [n = 1
(F) Percentages of IFN-g+/CD107a+/ NK cell subpopulations after 4 days of co-
and MSCs from one patient (MSC3; n = 6).
(G) Representative flow density dot plots showing expression of IFN-g and CD107
NK cell donor; MSC3).
Statistical significance was determined by Wilcoxon matched-pairs signed ran
correction (D; * indicates significance at p < 0.05; **p < 0.01; ns, not significant).
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ability to form spheres in culture and tested for tumorigenicity
following injection beneath the kidney capsule of NOD-SCID
common g-chain knock out (NSG) mice. We then addressed
the potential of the PCC to become NK target cells by assessing
their expression of NK activating receptor ligands (Figures S2A
and S2B) and HLA class I molecules (Figure S2C) in comparison
to that of the K562 leukemia cell line, a classical NK target.
Primary cells from lung SCC displayed lower expression of
several NK cell ligands than the K562 cell line, including CD112
(NECTIN2), CD155 (PVR), and ULBP1. In contrast, expression
of the NKG2D ligands MICA and MICB was higher than that of
other ligands in PCC (Figure S2A) and comparable to their
expression in K562 cells (Figure S2B). MICA and MICB are
involved in NK cell activation by interacting with NKG2D (Jamie-
son et al., 2002), on the one hand, and in NK exhaustion upon
extended stimulation on the other (Groh et al., 2002; Chretien
et al., 2014; Oppenheim et al., 2005). HLA class I expression
tended to increase over time in PCC co-cultured with NK cells
(Figures S2Ci and S2Cii), which may provide a mechanism of
resistance to NK cell killing. Although PCC appeared to display
a phenotype that is less prone to induce NK activation than
that of K562 cells, they were nevertheless able to stimulate NK
cell degranulation at different effector:target ratios (Figure S2D).
Thus, primary lung SCC cells are sensitive to NK-mediated
immunosurveillance.
T-MSCs Suppress the NK Cell Response to K562 and
Primary SCC Cells More Strongly Than N-MSCs
The effect of T- and N-MSCs on NK cell function was investi-
gated in direct and indirect (Transwell) co-culture conditions
(Figure 2A). Freshly isolated NK cells were cultured with T- and
N-MSCs for 4 days, following which their activation by tumor
cells was assessed in a 4-hr assay. NK cells from different
donors displayed variable activation in response to K562 cells
and PCC (Figure S3A). Nevertheless, in direct co-culture,d the NK Response to K562 and PCC
-positive cells) by K562 or PCC cells following N-, T-, and BM-MSC co-culture,
cultured without MSCs for the same duration and activated by target cells
the mean ± SEM.
ts with K562 cells (eight different NK cell donors; MSC1 [n = 3 biological rep-
nts with PCC (three NK cell donors; MSC1 [n = 1]; MSC2 [n = 1]; MSC3 [n = 2];
donors; MSC1 [n = 2]; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n = 1]) and one with
lot individual values of two experiments in direct MSC-NK co-culture with K562
[n = 2]) and 2 experiments with PCC (PCC2, 3, and 4; two NK cell donors; MSC2
(red bar) before and after activation by tumor cells (K562, left panel, and PCC,
lor bars, basal NK cell secretion (without tumor cells); dark color bars, secretion
ree NK cell donors; MSC1 [n = 2]; MSC2 [n = 1]; MSC3 [n = 3]; MSC4 [n = 1]) and
] and 3 [n = 1]) are shown.
culture with MSCs in 5 independent experiments using NK cells from 5 donors
a by K562-activated NK cells in direct co-culture with and without MSCs (single
k test (pairing on MSC patient; B, C, and F) or unpaired t test with Welch’s
See also Figure S3.
T-MSCs were consistently and significantly more immunosup-
pressive than N-MSCs toward NK cells exposed to K562 cells,
as assessed by IFN-g production and CD107a (lysosomal-asso-
ciated membrane protein-1) expression, commonly used as a
marker of degranulation (Alter et al., 2004; Figures 2B and
S3Bi). Following activation by PCC, production of IFN-g as well
as degranulation were slightly, but not significantly, more
reduced in the presence of T-MSCs than in that of N-MSCs (Fig-
ures 2B and S3Bi). T-MSCs also exerted stronger suppression of
IFN-g production than of degranulation (Figure 2B).
In indirect co-culture, T-MSCs were less immunosuppres-
sive than in direct co-culture and their inhibition of NK cell
IFN-g production and degranulation was comparable to that
of N-MSCs (Figures 2C and S3Bii). In contrast to direct co-cul-
ture, NK cell production of IFN-g in response to PCC was more
strongly inhibited by N- than by T-MSCs. Thus, the robust
immunosuppressive activity of T-MSCs toward NK cells ap-
peared to be contact dependent and effective in the presence
of both K562 cells and PCC. Because the immunosuppressive
potential of MSCs has thus far been studied mainly using
BM-MSCs, we included one sample isolated from an adult
healthy donor as a reference for MSC-mediated NK inhibition.
Bone marrow MSCs displayed strong inhibitory activity toward
both IFN-g production and degranulation by NK cells (Fig-
ure 2D) that was more closely reminiscent of T- than of
N-MSCs.
Inhibition by MSCs (T-MSC > N-MSC) of intracellular IFN-g
production was reflected at the secretory level (Figure 2E, dark
bars). Moreover, the inhibition was observed even before NK
cell activation by K562 cells and PCC (Figure 2E, light bars).
Similar to IFN-g secretion, TNFa secretion by NK cells after acti-
vation by K562 cells was inhibited in the presence of MSCs and
more strongly so in that of T- than of N-MSCs. Although the inhi-
bition was less marked when K562 cells were substituted by
PCC, the tendency was similar (Figure S3C).
We next interrogated the response to T- and N-MSCs of the
different functional NK cell subpopulations, including IFN-
g+CD107a+ double-positive, IFN-g+CD107a single-positive,
and IFN-gCD107a+ single-positive cells (Figures 2F, 2G, and
S3D). The strongest and most selective inhibition by T-MSCs
was observed in the NK double-positive subpopulation. The
IFN-g+CD107a single-positive subpopulation was equally
inhibited by N- and T-MSCs, whereas the IFN-gCD107a+ sin-
gle-positive NK subpopulation was virtually unaffected (Fig-
ure 2F). Thus, the NK subpopulations that are the most strongly
inhibited by MSCs, particularly in direct co-culture, are those
capable of secreting IFN-g (Figures 2F and 2G).
T-MSCs Downregulate NK-Cell-Activating Receptors
and Induce the CD56dim NK Cell Phenotype
To understand how MSCs downregulate NK cell function, we
interrogated NK receptor modulation in the presence of T- and
N-MSCs. MSCs (T-MSC > N-MSC) inhibited cell surface expres-
sion of the NK receptors NKp44, NKp30, NKG2D, DNAM-I, and
NKG2A (Figure 3Ai). Differences between the inhibitory effects of
N- and T-MSCs were significant for NKG2D, DNAM-I, and
NKG2A receptors. Interestingly, their expression was affected
only in direct contact with MSCs (Figure 3Ai), with the exceptionof NKp44, whose expression was partially inhibited in indirect
co-culture (Figure 3Aii).
Surprisingly, we observed marked changes in the
CD56bright/dim ratios of NK subpopulations in response to
MSCs. In the absence of MSCs and after 4 days of exposure
to IL-2, NK cells were predominantly CD56bright. However, an
inversion in the CD56bright/dim NK cell ratio was observed in direct
co-culture with MSCs (Figures 3Bi and 3C) that was largely
contact dependent (Figures 3B and 3C).
CD56bright and CD56dim NK Subpopulation Function Is
Differentially Modulated by MSCs
In functional assays where NK cells are activated by tumor cells,
the presence of MSCs, particularly T-MSCs, also tipped the
balance toward the CD56dim NK phenotype in a contact-depen-
dent manner (Figure 4A). Functional comparison revealed that
BM-MSCs were more closely related to T-MSCs than to
N-MSCs, as demonstrated by their robust induction of the
CD56dim NK subset after activation by K562 cells (Figure 4Bi)
and PCC (Figure 4Bii).
Interestingly, inhibition of NK cell function exerted by MSCs
differed between the CD56dim/bright subpopulations. In control
conditions (NK cells cultured with K562 cells alone), the
CD56bright NK cell subset (Figure 4C, first line), associated with
elevated cytokine production, was dominant. Upon introduction
of MSCs (Figure 4C, lines 2 and 3), the bulk NK cell population
decreased its cytokine production and degranulation capacity.
However, because the presence ofMSCs increased the CD56dim
subpopulation, which was associated with degranulation, the
change in function of the total NK cell populationmostly reflected
functional inhibition of the CD56dim subset. Thus, MSC-medi-
ated IFN-g inhibition occurred predominantly in the CD56bright
subpopulation, whereas NK degranulation was inhibited by
MSCs in the CD56dim subtype. Inhibition of both functions,
particularly cytokine production, was largely contact dependent
(Figure 4C). The total NK cell population indirectly co-cultured
with MSCs was mainly composed of CD56bright cells, prone to
cytokine secretion and comparable to NK cells activated by
tumor cells without MSCs.
Modulation of NK receptors also differed between the
CD56dim and CD56bright NK subsets. Thus, downregulation of
NKp44, NKp30, NKG2D, and DNAM-I receptor expression
occurred in the CD56dim subpopulation, appeared to be highly
contact dependent, and was more pronounced in the presence
of T-MSCs than in that of N-MSCs (Figure 4D). In indirect co-cul-
ture, only NKp44 receptor expression was mildly inhibited,
whereas NKG2D receptor expression was slightly increased. In
the CD56bright subset, only NKG2D expression was slightly
decreased in direct co-culture with MSCs. With this exception,
receptor expression in CD56bright NK cells remained virtually
unaffected by direct or indirect co-cultures with MSCs.
Inhibition of NK cell activating receptors (NKp44, NKp30,
NKG2D, and DNAM-I) may provide the mechanism that under-
lies MSC-mediated dysfunction of CD56dim NK cells. In contrast,
inhibition of cytokine production in the CD56bright subset was not
associated with major changes in receptor expression, except
for mild NKG2D downregulation in direct co-culture with MSCs
(Figure 4D). We therefore interrogated the mechanisms involvedCell Reports 20, 2891–2905, September 19, 2017 2895
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Figure 3. The NK Cell Phenotype Is Strongly Modulated by Direct
Co-culture with N- and T-MSCs
(A and B) NK phenotype as assessed by flow cytometry after direct (i) and
indirect (ii) co-cultures with N- or T-MSCs, normalized to control conditions
(NK cells alone, horizontal dashed line). Mean values ± SEM are shown.
(A) Expression of NK cell receptors is shown. (i) Data from 4 experiments are
shown (four NK cell donors; MSC1 [n = 2]; MSC2 [n = 2]; MSC3 [n = 2]; MSC4
[n = 1]; MSC5 [n = 1]). (ii) Results from 2 experiments are shown (two NK cell
donors; MSC1 [n = 2]; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n = 1]). Data were
analyzed using Wilcoxon matched-pairs signed rank test. (B) Percentages of
CD56bright and CD56dim NK subpopulations in control conditions (NK cultured
alone, green bar) and in co-culture with N- and T-MSCs are shown. Light tones
depict the CD56dim NK subset, dark tones the CD56bright subset. (i) Results
from 4 experiments are shown (four NK cell donors; MSC1 [n = 6]; MSC2
[n = 2]; MSC3 [n = 8]; MSC4 [n = 2]). (ii) Data from 2 experiments are shown (two
NK cell donors; MSC1 [n = 6]; MSC2 [n = 3]; MSC3 [n = 6]; MSC4 [n = 3]).
(C) Representative flow smooth contour plots (with outliers) showing CD16 and
CD56 expression by NK cells in direct and indirect co-cultures with and
without MSCs (single NK cell donor; MSC3).
2896 Cell Reports 20, 2891–2905, September 19, 2017in MSC-induced suppression of cytokine production in the
CD56bright NK subset.
Expression of Immunosuppressive Mediators in T- and
N-MSCs
First, we addressed the expression of genes implicated in
immune regulation in T-, N-, and BM-MSCs, including IDO1,
IL10, TGFB1, TNFAIP6 (TSG6), HMOX1, HLAG, IL6, and
PTGS2 (COX-2; Figures 5A and S4A). Whereas IDO1, IL10, and
HLAG transcripts were almost undetectable at day 0 in culture
(data not shown), IL6 and PTGS2 were expressed at variable
levels in T- and N-MSCs from different patients (Figures 5A
and S4A). Expression of some of these genes differed between
BM-MSCs and lung tissue MSCs (Figure S4A). Thus, IL6 expres-
sion in BM-MSCs was lower than in most T-MSCs and TNFAIP6
was almost undetectable (Figure S4A). Conversely, TGFB1 and
PTGS2 were more highly expressed in BM-MSCs than in
T-MSCs, with the exception of T-MSC1 (Figure S4A). T-MSCs
from patients 2 and 5 expressed higher levels of IL6 than their
non-tumor-tissue-derived counterparts, whereas PTGS2
expression was comparable in the twoMSC subsets (Figure 5A).
However, T- and N-MSCs displayed distinct secretion levels of
IL-6 and PGE2 after 4 days in culture (even though the statistical
values for the latter were not significant; Figure 5B), which could
explain, at least in part, the differential impairment by the MSC
subsets of NK cell function. Expression of IL6 and PTGS2 by
T-MSCs increased over time in culture and was strongly induced
by the presence of NK cells, whereas expression of TGFB1
remained constant (Figure 5C). In co-culture with tumor-acti-
vated NK cells, MSCs secreted high levels of IL-6, TGFb1, and
HGF, but of the three cytokines, IL-6 was the most differentially
secreted between T- and N-MSCs and more so in the presence
of PCC-activated NK cells (Figure S4B). Comparison between
BM- and lung tissue MSC secretion of IL-6 and PGE2 (Fig-
ure S4C) in direct co-culture with NK cells and following activa-
tion by tumor cells revealed lower secretion of IL-6 by BM-MSCs
than by T-MSCs but comparable secretion of PGE2 by the two
MSC populations. In addition, BM-MSCs bore similarities to
lung tissue MSCs for MICA and TLR3 expression but also a
distinct profile with higher TLR4 and lower CD274, NECTIN2,
DC
A  B
(legend on next page)
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and PVR expression (Figure S4D). MSCs expressed low levels of
NK-activating receptor ligands, except for the DNAM-I ligand
PVR (CD155; Figures S4D and S4E).
IL-6 and PGE2 Are Implicated in T-MSC-Mediated
Inhibition of NK Cell Function
Neutralization of IL-6 with a specific antibody (MAB206) and
inhibition of COX-2 using a specific inhibitor (NS-398) were
each partially effective in restoring NK function that had been
suppressed by MSCs. However, the efficacy of the inhibitors
appeared to be highly individual patient MSC dependent.
COX-2 inhibition was the most effective in restoring NK cell func-
tion, whereas IL-6 had more heterogeneous effects. Analysis of
co-culture supernatants demonstrated the level of inhibition
reached using the inhibitors (Figure S5A). Interestingly, IL-6 inhi-
bition increased PGE2 secretion (Figure S5Aiii).
Three experiments highlighted the heterogeneity of immuno-
modulatory mechanisms used by primary cells. In experiments
using patient 2 MSCs, neutralization of IL-6 with antibody
partially restored NK cell function, asmeasured by IFN-g expres-
sion in response to K562 cells (Figure 6Ai). Similarly, inhibition of
PGE2 synthesis using the COX-2 inhibitor NS-398 resulted in
partial reversion of NK loss of IFN-g expression induced by
MSCs (Figure 6Ai). In contrast, neither inhibitor had a marked
effect on NK cell degranulation (Figure S5Bi). Interestingly,
rescue of NK cell cytokine expression resulting from inhibiting
IL-6 and COX-2 function correlated with restoration of the
CD56bright NK cell phenotype (Figures 6Aii and 6Aiii).
Surprisingly, in experiments with patient 5 MSCs (n = 2), addi-
tion of anti-IL-6 antibody did not restore NK cell function,
whereas COX-2 inhibition partially reversed MSC-mediated
blockade of IFN-g expression and degranulation (Figures 6Bi
and S5Ci). Nevertheless, COX-2 and IL-6 inhibition appeared
to have a synergistic effect. Partial restoration of both NK cell
cytokine production and degranulation by inhibition of MSC-der-
ived immunosuppressive molecules was significantly correlated
with an increase in the CD56bright NK cell phenotype (Figures
6Bii, 6Biii, and S5Cii).
We next investigated the mechanisms involved in the restora-
tion of NK function and CD56 expression and assessed NK
receptor expression. Addition of IL-6 inhibitor partially restored
NKG2D expression in NK cells cultured with T-MSCs from
patient 2 (Figure 6Ci). However, anti-IL-6 enhanced the inhibition
of NKp30 and DNAM-I expression induced by T-MSCs. COX-2Figure 4. MSC Exert Different Effects on CD56dim and CD56bright NK Su
(A and B) Percentages of CD56dim and CD56bright NK cell subpopulations co-cultu
Light tones, CD56dim NK subset; dark tones, CD56bright subset. Tumor-activate
Results show the mean ± SEM. Statistical significance was determined by 2-way
co-cultures with N- and T-MSCs after 4 hr activation by K562 cells are shown. Da
(MSC1-4) and a single NK cell donor. (B) Direct co-cultures with N-MSCs, T-MSCs
representative of two experiments with pooled MSCs from 3 patients (MSC2-4), o
experiments are shown (two NK cell donors; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n
shown (two NK cell donors; MSC2 [n = 1]; MSC3 [n = 1]; MSC4 [n = 1]; BM-MSC
(C) Representative dot plots showing the percentages of IFN-g+ and CD107a+ cell
direct and indirect co-cultures with MSCs from patient 2 and activation by K562
(D) Modulation of NK receptor expression in CD56bright and CD56dim subsets i
(NK cultured alone). Results show the mean ± SEM for a single experiment (si
determined by 2-way ANOVA followed by Dunnett’s multiple comparisons test w
2898 Cell Reports 20, 2891–2905, September 19, 2017inhibition increased NKp30 and NKp44 expression slightly and
NKG2D expression more strongly. Neutralization of IL-6 from
patient 5 MSCs had the same effect on NKG2D and NKp30 as
its neutralization in patient 2 MSCs, increasing and decreasing
their expression, respectively (Figure 6Cii). COX-2 inhibition
partially restored NKp44, NKG2D, and NKp30 expression that
had been downregulated by T-MSCs (Figure 6Cii). Combination
of anti-IL-6 and the COX-2 inhibitor was comparable to the effect
of the COX-2 inhibitor alone. Hence, COX-2 inhibitor administra-
tion to MSCs from both patients was effective in at least partially
restoring IFN-g production and NK receptor (NKG2D, NKp30,
and NKp44) expression, whereas anti-IL-6 effects were patient
MSC dependent.
We also assessed NK cell expression of CD25 (IL-2Ra) in
co-cultures with MSCs, which was expressed by a small per-
centage of NK cells. In the presence of T-MSCs, CD25 was
strongly downregulated, and its expression was partially and
completely restored by anti-IL-6 antibody and COX-2 inhibitor,
respectively (Figure 6D).
NK Stimulation with PGE2Mimics T-MSC-Mediated IFN-
g Immunosuppression
To confirm the importance of MSC-mediated PGE2 secretion in
NK cell inhibition, we stimulated NK cells with PGE2 in the
absence of MSCs (donor 14 NK cells) at doses comparable to
those secreted by T-MSCs in the presence of NK cells. PGE2
inhibited cytokine production by NK cells stimulated by K562
cells to a level comparable to that observed in T-MSC co-cul-
tures (Figure 7A). In contrast, IL-6 stimulation did not affect NK
function nor did it display synergy with PGE2 (Figure 7A). NK
degranulation was unchanged after stimulation by PGE2, IL-6,
or both, suggesting a role for PGE2 predominantly in the inhibi-
tion of cytokine production. Moreover, addition of PGE2 to NK
cells increased the CD56dim subpopulation, as did the presence
of T-MSCs (Figure 7B). Finally, stimulation with PGE2 alone was
sufficient to reproduce the downregulation of NK receptors
induced by T-MSCs (Figure 7C).
DISCUSSION
Using paired samples of primary MSCs isolated from lung SCC
and adjacent tumor-free tissue, we showed that tumor-associ-
ated MSCs are more strongly immunosuppressive toward NK
cells than their tumor-free tissue-derived counterparts, exertingbsets
red with MSCs after 4 hr activation by tumor cells, assessed by flow cytometry.
d NK cells cultured in the absence of MSCs provided a control (green bars).
ANOVA followed by Tukey’s multiple comparisons test. (A) Direct and indirect
ta are representative of a single experiment with pooled MSCs from 4 patients
, and BM-MSCs after 4 hr activation by K562 (i) or PCC cells (ii) are shown. Data
ne donor of BM-MSCs, and two NK cell donors are shown. (i) Results from two
= 1]; BM-MSC [n = 2]). (ii) Data from two experiments with PCC2, 3, and 4 are
[n = 2]).
s in the total NK cell population and in the CD56bright and CD56dim subsets after
cells.
n direct and indirect co-cultures with MSCs compared to control conditions
ngle NK cell donor; MSC1 [n = 1] and 3 [n = 1]). Statistical significance was
ith NK cells alone set as the control.
A  
C
B
Figure 5. Differential Expression of Immune-Modulating Mediators
by T- and N-MSCs
(A) Relative gene expression of IL6 and PTGS2 by N- and T-MSCs in the basal
state (day 0 of co-culture) as assessed by qPCR and shown as a fold change in
expression (N-MSC2 expression set as the control condition). Data are
representative of four experiments (four NK cell donors; MSC2, 3, and 5), and
results show the mean ± SEM.
(B) IL-6 and PGE2 secretion (pg/mL) by MSCs after 4 days in culture alone.
Results show the mean ± SEM: MSC1, 2, 3, and 5 for IL-6 and MSC2 and 5 for
PGE2. Statistical significance was determined by Wilcoxon matched-pairs
signed rank test (* indicates significance at p < 0.05; **p < 0.01).
(C) Relative gene expression of IL6, PTGS2, and TGFB1 by T-MSCs collected
at the indicated time points with and without direct co-culture with NK cells
(four NK cell donors; MSC2, 3, and 5). Results show fold change in gene
expression compared to T-MSCs at day 0. Statistical significance was
determined by 2-way ANOVA with Tukey’s multiple comparisons test.
See also Figure S4.stronger inhibition of NK cell IFN-g secretion and degranulation
in response to K562 and primary cancer cells. Functionally,
T-MSCs were more closely related to BM-MSCs than
N-MSCs. As two key functions of BM-MSCs are to participate
in building a hematopoietic stem cell (HSC) niche and to protect
HSCs from injury bymediators of inflammation and inflammatory
effector cells, they must display potent immunosuppressive
properties (Sotiropoulou et al., 2006; Spaggiari and Moretta,2013; Spaggiari et al., 2008). In quiescent tissues, in the absence
of inflammatory stimuli, MSCsmay decrease or even temporarily
lose their immunosuppressive features. However, in a tumor
microenvironment, which mimics tissue repair and contains a
vast array of cytokines derived from inflammatory, tumor, and
activated stromal cells, MSCs may regain their full immunosup-
pressive potential and resemble their BM counterparts. The
immunosuppressive mechanisms, as illustrated by the type
and quantity of immunosuppressive cytokines produced and
the level of NK cell receptor ligands expressed, may differ be-
tween BM- and T-MSCs, possibly as a function of the type of
stimulatory microenvironment to which the cells are exposed.
MSCs, particularly T-MSCs, displayed markedly different
degrees of inhibition of functional NK cell subpopulations, pre-
dominantly inhibiting NK cell subsets that produce IFN-g.
Because IFN-g plays a prominent role in tumor rejection by
preventing tumor stroma formation and tumor-induced angio-
genesis (Zaidi and Merlino, 2011), as well as by activating the
immune system, inhibition of its production by T-MSCs may
be highly relevant toward facilitating tumor progression. Consis-
tent with this notion, recent observations suggest that the
predominant activity of NK cell subsets recruited to lung cancer
is IFN-g production rather than direct cancer cell killing (Carrega
and Ferlazzo, 2017).
In addition to their production of IFN-g, the activating receptor
expression profile of NK cells was significantly affected by
MSCs, with downregulation of NKp44, NKp30, NKG2D,
DNAM-I, and NKG2A. MSCs also induced an inversion in the
CD56bright/dim NK cell ratio in favor of the CD56dim phenotype.
These effects were more pronounced in response to T-MSCs
than to N-MSCs and, just like inhibition of IFN-g production,
were contact dependent. Consistent with these observations, in-
tratumoral NK cells in human lung cancer display low expression
of NKp30, CD56, NKG2D, and DNAM-I (Platonova et al., 2011;
Esendagli et al., 2008; Levi et al., 2015).
The observed shift toward the CD56dim NK cell phenotype
after exposure to MSCs is consistent with low expression of
CD56 by NK cells in vivo (Esendagli et al., 2008; Platonova
et al., 2011; Levi et al., 2015) and selective inhibition of the
CD56bright subtype rather than expansion of the CD56dim sub-
population (Sotiropoulou et al., 2006). Following IL-2 stimulation,
NK cells acquire a CD56bright phenotype, which correlates with
an activated state of the cells in vitro. The CD56dim phenotype
observed in the presence of MSCs therefore seems to reflect a
decrease in NK cell activation, as suggested by our functional
assays and by the reduced NK cell expression of IL-2Ra
following T-MSC co-culture.
CD56dim and CD56bright NK cell functions were differentially
modulated by MSCs. With the exception of NKG2D, T-MSCs
downregulated activating receptor expression exclusively in
the CD56dim NK cell subset, where they also inhibited degranu-
lation. In contrast, T-MSCs inhibited IFN-g production in
CD56bright NK cells where no obvious receptor expression
changes occurred (except for the mild downregulation of
NKG2D). Distinct mechanisms may therefore underlie T-MSC-
mediated inhibition of cytokine production by CD56bright and
degranulation of CD56dim NK cells, with the possible implication
of NKG2D in both functions of the two NK subsets.Cell Reports 20, 2891–2905, September 19, 2017 2899
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Figure 6. Targeting T-MSC-Derived Immunosuppressive Mediators Rescues NK Cell Activity
Data were analyzed by flow cytometry, and results show mean values ± SEM.
(A) Results are from one rescue experiment with a single NK cell donor and MSCs from patient 2.
(legend continued on next page)
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Marked differences in expression and secretion of IL-6 and
PGE2 by N- and T-MSCs suggested that both mediators may
be implicated in T-MSC-mediated immunosuppression. Inter-
leukin-6 and COX-2 inhibitors revealed that T-MSCs rely on
PGE2 to mediate much of their immunosuppressive effect.
Accordingly, addition of COX-2 inhibitor to MSC-NK cell
co-cultures partially restored NK cell IFN-g expression, the
proportion of CD56bright cells, and NKp30, NKp44, NKG2D,
and IL-2Ra expression. COX-2 inhibition in different experi-
ments and using MSCs from different patients consistently
restored NK function, suggesting that PGE2 secretion provides
an immunosuppressive mechanism common to MSCs, irre-
spective of their origin.
PGE2 Is a Key Mediator of T-MSC-Dependent
Immunosuppression
Bone marrowMSCs have been shown to exert a profound inhib-
itory effect on NK-cell function, outside of the tumor context,
mediated by PGE2, IDO1, and/or TGFb (Sotiropoulou et al.,
2006; Spaggiari and Moretta, 2013; Spaggiari et al., 2008). Our
observations suggest that T-MSCs suppress NK cell function
primarily by PGE2, as neither TGFb nor IDO1 were upregulated
in T-MSCs. Interestingly, plasma PGE2 levels in NSCLC patients
have been found to be elevated compared to healthy subjects
(Hidalgo et al., 2002), and high expression of COX-2 in tumor
sections of NSCLC has been associated with poor prognosis
(Bhooshan et al., 2016; Brown and DuBois, 2004; Khuri et al.,
2001). Stimulation of NK cells with PGE2 alone reproduced all
of the principal effects of T-MSCs, including inhibition of IFN-g
production, the shift toward the CD56dim phenotype, and down-
regulation of NK-cell-activating receptors.
Prostaglandin E2 secretion can occur through an IL-6-depen-
dent mechanism, which has been suggested to provide an anti-
inflammatory mediator in arthritis (Bouffi et al., 2010). Abrogation
of IL-6 increased PGE2 secretion by MSCs, which may consti-
tute a candidate mechanism to explain why the combined inhibi-
tion of both was able to better rescue NK cell function. However,
the implication of IL-6 in MSC-mediated NK cell immunomodu-
lation was variable. Whereas in one patient, IL-6 inhibition
partially restored NK cell function, the same did not hold true
for MSC-inhibited NK cells of another patient. Thus, whereas
PGE2 secretion appeared to be a commonmediator of immuno-
suppression by MSCs from different patients, IL-6 seemed to
provide a more patient-specific immunosuppressive function.
Nevertheless, we identified a novel (possibly context-depen-
dent) role for IL-6 in permitting tumor-subverted MSCs to help(B) Summary of two rescue experiments with MSCs from patient 5 (two NK cell
(A and B) (i) Percentage of IFN-g+ NK cells after activation by K562 cells in the pres
Results are normalized to NK cell activation by K562 cells in the absence of MS
activated CD56bright and CD56dim NK subsets cultured alone or with T-MSCs in
determined by 2-way ANOVA followed by Dunnett’s multiple comparisons test, wi
Correlation between the percentage of CD56bright NK cells and intracellular IFN-g
the Spearman correlation coefficient r, p values are reported, and linear regressi
(C) Percentage of NK receptor expression after 4 days in culture alone (gray ba
inhibitors (light red bar). (i) MSC2 is shown; one NK cell donor. (ii) MSC5 is show
(D) Percentage of IL-2Ra (CD25) expression on NK cells cultured alone (gray bar)
Data are representative of a single experiment with a single NK cell donor and M
See also Figure S5.establish an immunosuppressive microenvironment that impairs
NK cell function.
Taken together, our observations show that, despite the vari-
ability of MSCs (including the patient origin of the cells, the stage
of the tumor from which they were extracted, and the variable
expression of ligands for NK cells) and of donor NK cells (from
14 donors, with variations in the panel of receptors expressed
and response to tumor cells), which may influence NK cell acti-
vation and the degree of inhibition mediated by MSCs,
T-MSCs consistently exert stronger immunosuppression of NK
cells than N-MSCs. They also provide a mechanistic explanation
for differences between the immunomodulatory potential of
T- andN-MSCs and highlight the notion that T-MSCsmay largely
rely on PGE2 and to a lesser extent on IL-6 to exert their immu-
nosuppressive effects. Selection of immunosuppressive media-
tors by T-MSCs may be determined by signals derived from the
tumor cells or from the microenvironment they condition, which
may vary from patient to patient. Efforts to discover drugs that
could affect MSC behavior by blocking their inhibitory effects
may provide promising options to improve anti-tumor NK cell
function.EXPERIMENTAL PROCEDURES
Primary MSC and Tumor Cell Isolation
MSCs
Fresh primary human tumor samples and adjacent macroscopically normal
lung tissue were obtained at surgery from 5 SCC patients at the Centre Hospi-
talier Universitaire Vaudois (CHUV) (Lausanne) with the approval and accord-
ing to the guidelines of the Ethics Committee of the Canton de Vaud (project
authorization no. 131/12). Patients 1–5 were aged 79, 64, 70, 83, and 74,
respectively, at the time of surgery. Patients 1 and 2 were female, and patients
35 were male. Pathologic tumor staging varied among patients from T2a to
T3 and was performed at the CHUV. T-MSCs and N-MSCs were isolated after
tissue disruption (see Supplemental Experimental Procedures) and cultured in
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% fetal
calf serum (FCS) (PAN-Biotech), 1% penicillin/streptomycin (PS) (Gibco), 1%
non-essential amino acids (NEAA) (Gibco), and 10 ng/mL platelet-derived
growth factor (PDGF) (Prospec; MSC medium). Cells were used at early pas-
sages for all experiments (below p 7). MSCs were assessed for differentiation
potential (to osteocytic, chondrocytic, and adipocytic lineages) andmembrane
expression of selected markers (see Supplemental Experimental Procedures).
Fresh human BM-MSCs were obtained from a healthy donor (male donor; 78
years old; project authorization no. 131/12) and harvested as described above.
Tumor Cells
From 3 out of 5 patient samples, PCCs were isolated and cultured as spheres
in low-attachment conditions in IMDM supplemented with 20% knockout
serum (Gibco), 1%PS, and 20 ng/mL epidermal growth factor (EGF), fibroblast
growth factor (FGF), and LIF (Prospec). PCCs were assessed by flowdonors).
ence of T-MSCs with or without anti-IL-6-neutralizing antibody and/or NS-398.
Cs, considered to be 100% (horizontal dashed line). (ii) Percentages of K562-
the presence or absence of inhibitors are shown. Statistical significance was
th K562-activated NK cells co-cultured with T-MSCs set as the control (red). (iii)
production in different culture conditions is shown. The statistical test used was
on line with R square for goodness of fit.
r) or with T-MSCs in the absence (dark red bar) or presence of the indicated
n; two NK cell donors.
or in the presence of T-MSCs (red bars) with or without the indicated inhibitors.
SC5.
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Figure 7. NK Stimulation with PGE2 Mimics MSC-Mediated IFN-g
Immunosuppression
Data were assessed by flow cytometry on NK cells from a single donor.
T-MSCs used for co-culture were from patient 5.
(A) Percentages of IFN-g+ (black bar) and CD107a+ NK cells (gray bar) after
activation by K562 cells in different culture conditions: with IL-6, PGE2, a
combination of both, or co-cultured with T-MSCs for 4 days (set as the control
condition, red). Results are normalized to 100% as the level of IFN-g
production and CD107a expression by NK cells activated by K562 cells
(horizontal dashed line).
(B) (i) Percentages of CD56bright and CD56dim NK subsets after activation by
K562 cells under conditions described in (A). (ii) Correlation between the
percentages of CD56bright and IFN-g+ NK cells is shown. The statistical test
used was the Spearman correlation coefficient r, significance determined at
p < 0.05, and linear regression line and significance determined with R square
value.
(C) Percentage of indicated receptor expression on NK cells alone, stimulated
with IL-6, PGE2, or both or co-cultured with T-MSCs.
2902 Cell Reports 20, 2891–2905, September 19, 2017cytometry for HLA-ABC expression (see Supplemental Experimental Proced-
ures). The K562 human leukemia cell line (ATCC no. CCL-243) was cultured in
RPMI1640 supplemented with 10% FCS and 1% PS.
Tumor-Infiltrating Immune Cell Characterization
Immune cell infiltration in the tumor bulk was assessed by IHC on whole-tissue
sections from SCCs of four patients and by flow cytometry of tumor bulk from
three patients after dissociation (see Supplemental Experimental Procedures).
Microscopy
Images were taken with a Nikon Eclipse E800, digital camera DXM1200, at
203 or 403 magnification and at a resolution of 1,280 3 1,024, and analyzed
with the ACT-1 (v.2) software.
NK Cell Isolation and Culture
NK cells were isolated from peripheral blood mononuclear cells derived from
buffy coats obtained from 14 healthy volunteer donors with donor consent
and approval from the Ethics Committee of the Canton de Vaud (project autho-
rization no. P-108). NK cells were cultured in RPMI1640 (Gibco) supplemented
with 10% heat-inactivated human serum (Sigma and Life Technologies),
1% PS, and IL-2 (10 ng/mL; R&D Systems; NK medium; see Supplemental
Experimental Procedures).
Co-culture Experiments
T-MSCs and N-MSCs were plated in 96-well plates 24 hr before co-culture
(0.53 105 cells/well). MSCs were treated with mitomycin C 50 mg/mL (Sigma),
and freshly isolated NK cells (105 cells) were added at 1:2MSC:NK ratio. Media
were supplemented with IL-2 10 ng/mL (R&D). After 4 days of NK-MSC co-cul-
ture in NKmedium, 105 K562 target cells or PCCwere added andmaintained in
co-culture for 4 hr.
Flow Cytometry
See Supplemental Experimental Procedures for more detailed information.
MSC Characterization
Cells were stained with the « human MSC phenotyping kit » (no. 130-095-198;
Miltenyi Biotec) according to the manufacturer’s protocol.
NK Phenotype
Before and after 4 days of co-culture with MSCs, the NK cell phenotype was
assessed using anti-NKp30 (phycoerythrin [PE]; no. 558407; BD Biosciences;
1:50), -NKG2D (antigen-presenting cell [APC]; no. 562064; BD Biosciences;
1:10), -NKG2A (fluorescein isothiocyanate [FITC]; no. 130-098-817; Miltenyi;
1:20), -NKp44 (PE; no. 558563, BD Biosciences; 1:15), -DNAM-I (PE; no.
130-100-461; Miltenyi; 1:20), and -CD25 (APC; no. 555434; BD Biosciences;
1:10) antibodies among CD45+CD3CD56+CD16+/ cells (anti-CD45 Alexa
Fluor 700, no. 560566, BD Biosciences, 1:20; anti-CD3 PC7, no. 41116015,
Beckman Coulter, 1:20; anti-CD56 ECD, no. 41116015, Beckman Coulter,
1:40; anti-CD16 PerCP-Cy5.5, no. 560717, BD Biosciences, 1:20).
CD107a Degranulation and Intracellular IFN-g
After 4 hr activation by target cells, NK cells were stained with anti-CD107a
(FITC; no. 555800; BD Biosciences; 1:10), -CD3, -CD45, -CD56, and -CD16
antibodies. Intracellular IFN-g expression was assessed with APC-conjugated
anti-IFN-g antibody (no. 130-097-944; Miltenyi; 1:25) after cell fixation (PFA)
and permeabilization (PBS + BSA 0.2% + saponine 0.1% buffer, for 30 min
at room temperature). NK degranulation and IFN-g expression were quantified
within the CD45+CD3CD56+CD16+/ cell population. NK cells without target
tumor cells were used as a control.
Inhibitors/Stimulatory Molecules
Inhibitors
Human anti-IL-6 antibody (MAB206; clone no. 6708; R&D) was added at the
final concentration of 2 mg/mL at the start of co-culture. Inhibition of PGE2
was achieved using NS-398 (no. 70590; Cayman Chemical) at the final con-
centration of 5 mM. Medium + DMSO or + PBS were used as negative controls
for NS-398 and IL-6 treatment, respectively.
NK Stimulation
Human recombinant IL-6 (SRP3096; Sigma) was used at a final concentration
of 25 ng/mL. PGE2 was obtained from Sigma (P0409) and used at 1 mM
(350 ng/mL). Medium + EtOH was used as a negative control. NK cells were
treated for 4 days.
ELISA
IFN-g ELISA (Human IFN-g DuoSet ELISA; no. DY285-05; R&D) was
performed on MSC/NK/K562 and MSC/NK/PCC co-culture supernatants,
according to the manufacturer’s instructions. Controls for baseline IFN-g
secretion were supernatants from NK cells alone and NK cells cultured with
K562 cells. Samples were diluted 2-fold and analyzed in duplicates.
Quantification of IL-6 secretion by MSCs was performed by ELISA (Human
IL-6 DuoSet ELISA; no. DY206-05; R&D) in culture supernatants, according to
the manufacturer’s instructions. Samples were diluted 4- to 8-fold.
PGE2 was quantified using the Prostaglandin E2 Parameter Assay Kit
(no. KGE004B; R&D) according to the manufacturer’s protocol. Samples
were diluted 3- to 7-fold.
IFN-g, TNFa, HGF, IL-6, and TGFb1 were assessed in the co-culture super-
natants by Luminex assay (Bio-Plex Pro Human Cytokine/TGFb; Bio-Rad).
RNA Extraction, cDNA Synthesis, and qRT-PCR
Total RNA was extracted from MSCs using the RNeasy mini Kit (QIAGEN),
following standard procedures. cDNA was synthesized by reverse transcrip-
tion using M-MLV Reverse Transcriptase (Promega) according to the manu-
facturer’s instructions. qRT-PCR amplification was performed using TaqMan
Universal PCR mastermix or SYBR Green mix (Applied Biosystems). Samples
were analyzed in triplicates (37.5 ng of cDNA/reaction). Data were analyzed by
the 2DDCt method, normalizing threshold cycles first to housekeeping gene
expression (PPIA [protein phosphatase 1; TaqMan probe; Hs99999904_m1],
GAPDH [SYBR Green], or TBP [SYBR Green]) and then to controls. Primers
were purchased from Microsynth AG (see Supplemental Experimental
Procedures).
Statistics
Wilcoxon matched-pairs signed rank test was used for nonparametric data
and for comparing twomatched groups (N- and T-MSCs). Multiple group anal-
ysis was performed by 2-way ANOVA test followed by Tukey’s multiple
comparisons test or Dunnett’s multiple comparisons test for nonparametric
data. Statistical significance (adjusted p value) of the comparison between
BM-MSCs and lung tissue MSCs was determined by an unpaired t test with
Welch’s correction. For qRT-PCR data, multiple t tests corrected for multiple
comparisons using the Holm-Sidak method were used to compare mean
expression levels between N- and T-MSCs for each patient. For correlation
analysis, the Spearman test was used with the correlation coefficient r. Figures
also showed linear regression line with R2 for the goodness of fit. Calculations
were performed in Prism 7 (GraphPad Software). p values < 0.05 were consid-
ered statistically significant and are denoted by asterisks: *p < 0.05; **p < 0.01;
***p < 0.001; ns, not significant. Error bars represent the SEM, unless stated
otherwise.
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Table S1
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Others Partially bullous emphysema in non tumoral lung tissue
Diffuse emphysema in lung 
parenchyma
IHC
CD3 > CD20 CD3+++ (tumor and stroma 
totally infiltrated) >CD20
CD20 > CD3 CD3 > CD20
CD4 > CD8 (5:1) CD8 > CD4
CD4 > CD8 (intratumor+periphery) CD4  >CD8, diffuse (B cells more 
organized)
very few CD56, GrzB
CD20 in the periphery CD20 in follicules (GC-like), CD4 
also  lot of T cells, diffuse, 
septa+invasive marginLymphoid follicules very few CD56 (everywhere)
lot of B cells, more organizedno CD56, GrzB+++(CD8) FoxP3: ++, in the stroma and in 
 the tumor very few CD56, not in contact with 
tumor cells
FoxP3: small amount, in the 
periphery
lot of FoxP3 at the interface tumor-
stroma
PDL1 status tumor PDL1- tumor PDL1+++ tumor PDL1+ and PDL1- (two 
areas)
tumor PDL1+
FACS
CD11b+HLA-DR- 77.49% CD11b+HLA-DR- 3.38%
4.42% CD3+ within CD45+ cells 44.74% CD3+ within CD45+ cells
42.11% CD8+ within CD3+ cells 62.05% CD8+ within CD3+ cells
49.08% CD4+ within CD3+ cells 32.29% CD4+ within CD3+ cells
23.11% of Treg within CD3+ cells 2.96% Treg within CD3+ cells
0.2% of NK cells within CD45+ 
cells
0.59% of NK cells within CD45+ 
cells
not available
not available
Histology
Abundant stroma, necrosis and 
desmoplasia; Smaller intratumoral 
immune infiltrate compared to 
others tumors
Tumor with very scant stroma;  
Large lymphocytic infiltrate, 
organized in clusters
Highly invasive tumor; necrotic 
areas, desmoplastic stroma 
(similar to patient 1); Less 
immune infltrate compared to all 
others tumors
Tumor with scant stroma
(comparable to patient 2); 
Abundant lymphocytic infiltrate
not availablenot available
CD11b+HLA-DR- 24.61%
17.26% CD3+ within CD45+ cells
24.87% CD8+ within CD3+ cells
73.46% CD4+ within CD3+ cells
25.54% of Treg within CD3+ cells
0.55% of NK cells within CD45+ 
cells
+, ++, +++: relative abundance of immune infiltrate; GC-like: germinal center-like
92.9% of CD45+ cells 
in total living cells
95.7% of CD45+ cells 
in total living cells
80.2% of CD45+ cells 
in total living cells
Supplemental Table Legends 
 
Table S1. Related to Figure 1. Tumor histology.  Description of tumor histology for patients 1 to 4. Immune cell 
infiltrate in the tumor bulk was assessed by immunohistochemistry for patients 1, 2, 3 and 4 and by flow cytometry 
for patients 1, 2 and 5. PDL1 expression in tumor cells is also indicated. 
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Figure S1. Related to Figure 1. Tumor-infiltrating immune cells. Characterization of tumor-infiltrating immune 
cells from patients 1, 2 and 5 by flow cytometry. Percentages of different immune cell populations were calculated 
in the tumor bulk within CD45+ cells: CD4+ T cells, CD8+ T cells, FoxP3+CD25+ Treg, CD19+ B cells, CD3-CD56+ 
NK cells, CD14+ cells, CD11b+HLA-DR- myeloid cells.  
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Figure S2. Primary cancer cell profile. (A) (B) Relative gene expression of NECTIN2, PVR, ULBP1, MICA and 
MICB NK receptor ligands by PCC from patients 2, 3, and 4 and K562 as assessed by qPCR and analyzed as a fold 
change in expression. Results show the mean ± SD of triplicates, normalized to GAPDH expression. (A) For each 
tumor cell type, NECTIN2 expression was set as the control condition. (B) For each NK cell receptor ligand, PCC2 
expression set as the control condition. (C) HLA class I expression by PCC2, 3 and 4 and K562 cells in the basal 
condition and after 4 hours of co-culture with NK cells, analyzed by flow cytometry (i) Representative histograms 
(count of cells); (ii) HLA class I expression level expressed as mean fluorescence intensity (MFI). (D) Percentage of 
NK cell degranulation (CD107a expression) after 4 hours of activation by PCC from patients 2, 3 and 4 at different 
effector:target (E:T) ratios (2:1; 1:1; 1:2) (NK from one donor). Results were assessed by flow cytometry and 
analyzed with FlowJo software.  
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Figure S3. Related to Figure 2. Heterogeneity of different donor NK cells. Comparison of NK cell activation 
levels between the different donors. (A) Percentages of IFN-γ+ and CD107a+ NK cells assessed by flow cytometry. 
NK cells were stimulated for 4 days with IL-2 (black bars) and activated by K562 cells (left panels) or PCC (right 
panels) for 4 hours (gray bars). (B) and (C): Percentages of IFN-γ+ and CD107a+ NK cells co-cultured with N-MSCs 
(blue) or T-MSCs (red) and activated by K562 cells (left panels) or PCC (right panels). Data were obtained by flow 
cytometry and normalized to those of NK cells cultured alone for the same duration and activated by K562 cells or 
PCC considered as 100 percent (horizontal dashed lines). (B) Graphs show the mean ± SEM of (i) eight experiments 
in direct MSC-NK co-culture with K562 (eight different NK cell donors, MSC1 (n=3 biological replicates); MSC2 
(n=2); MSC3 (n=6); MSC4 (n=2); MSC5 (n=1)); and 3 experiments with PCC (three NK cell donors, MSC1 (n=1); 
MSC2 (n=1); MSC3 (n=2); MSC4) (ii) two experiments in indirect MSC-NK co-culture with K562 (two NK cell 
donors, MSC1 (n=2); MSC2 (n=1); MSC3 (n=2); MSC4 (n=1); one experiment with PCC (one NK cell donor, 
MSC1 (n=1); MSC3 (n=1)). (C) IFN-γ and TNFα secretion (pg/ml) by IL-2 stimulated NK cells cultured alone 
(green bars) or co-cultured with N- (blue bars) or T-MSCs (red bars), after activation by K562 or PCC target cells 
(one NK cell donor, MSC3 and MSC4). (D) Percentages of functional NK subpopulations from each donor: IFN-
γ+CD107a+, IFN-γ+CD107a-, IFN-γ-CD107a+ and IFN-γ-CD107a- NK cells, stimulated for 4 days with IL-2 and 
activated by K562 cells. Data were assessed by flow cytometry. 
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Figure S4. Related to Figure 5. MSC profile. (A), (D) and (E) Relative gene expression by N- (blue bars), T-
MSCs (red bars) and BM-MSCs (purple bars) assessed by qPCR and analyzed as a fold change in expression. 
Graphs show the mean of triplicates ± SD. TBP (A and D) or GAPDH (E) were used as housekeeping genes. 
Statistical significance was determined by a multiple T-test, corrected for multiple comparisons using the Holm-
Sidak method and the p-value for significance (* indicates significance at P < 0.05; **, P < 0.01; ns, not significant). 
Paired N- and T-MSCs were compared for each patient. (A) Relative expression of IL6, PTGS2, TGFB1, TNFAIP6 
and HMOX1 in MSCs from patients 1 to 5 and from the bone-marrow of one donor. N-MSC1 expression was set as 
the control condition. (B) Graph shows the concentration of IL-6, TGFβ1, and HGF secreted by MSCs (1, 3, and 4) 
in direct co-culture with one NK cell donor for 4 days and activated for 4 hours by K562 cells or PCC. (C) IL-6 and 
PGE2 secretion (pg/ml) by MSCs (N-MSCs (blue bar), T-MSCs (red bar) and BM-MSCs (purple bar)) co-cultured 
with NK cells at a 1:2 MSC:NK ratio (IL-6) and 1:4 ratio (PGE2), after activation by K562 cells. Secretion by NK 
cells cultured alone and activated by tumor cells is shown in green. Data are displayed as the mean ± SEM of 2 
experiments (two NK cell donors, MSC1 (n=2); MSC2 (n=1); MSC3 (n=1) and BM-MSCs (n=2)) (D) Relative gene 
expression of NK receptor ligands, ULBP1, MICA, MICB, NECTIN2, PVR, CD274, TLR3 and TLR4 by MSCs from 
patients 1 to 5, and BM-MSCs. N-MSC1 expression was set as the control condition. (E) Relative gene expression 
of the same genes as in (D) by MSCs from patient 3. TLR3 expression level was set as the control condition. 
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Figure S5. Related to Figure 6. Targeting T-MSC immunosuppressive activity. (A) Graphs show the 
concentrations of IL-6 and PGE2 (pg/ml) secreted by T-MSCs alone or T-MSCs with the indicated inhibitors (anti-
IL-6 neutralizing antibody and NS-398) in the supernatant of a 4 days MSC-NK co-culture and after NK activation 
by K562 target cells. (i) Level of IL-6 secretion inhibition obtained with the indicated inhibitors and MSC2 in one 
experiment (one NK donor, in duplicate), and MSC5 in two experiments (two NK donors). (ii) Level of PGE2 
secretion obtained with NS-398 and (iii) anti-IL-6 antibody. Results are representative of one experiment with 
MSC5 and one with MSC2. (B) and (C) (i) Percentage of CD107a+ NK cells co-cultured with T-MSCs alone or T-
MSCs with the indicated inhibitors and activated by K562 cells. Data were analyzed by flow cytometry and 
normalized to the control condition (NK cells alone activated by K562 cells, horizontal dashed line). (ii) Correlation 
between the percentage of CD56bright NK cells and of CD107a+ NK cells in different culture conditions. The 
statistical test used was the Spearman correlation coefficient r; significance determined at P < 0.05 *; P < 0.01 **; 
ns, not significant, p-values are reported; linear regression line with R square for goodness of fit. (B) Results are 
shown for one rescue experiment (single NK cell donor, MSC2). (C) Results obtained from two experiments (two 
NK cell donors, MSC5 (n=2)).  
  
Supplemental Experimental Procedures 
Primary MSC isolation 
T-MSCs and N-MSCs were isolated after mechanical and enzymatic disruption of the fresh primary human tumor 
samples and adjacent macroscopically normal lung tissue (project authorization n°131/12), in IMDM (GIBCO) 
supplemented with collagenase II and IV (0.5 mg/ml, GIBCO) and DNAse I (0.1 mg/ml, Roche) for 2h at 37°C. 
Multilineage differentiation potential of MSCs 
MSC differentiation potential along osteocytic, chondrocytic and adipocytic lineages was assessed in culture using 
three different conditioned media. For induction of osteocytic and adipocytic differentiation, MSCs were seeded at 
0.1 M cells/well in 12-well plates, in 1 ml medium/well. When MSCs reached 80% confluence, cells for osteocytic 
induction were treated with DMEM (GIBCO), supplemented with PS 1%, FCS 10%, NEAA 1%, APP (Ascorbic 
Acid P; 50 µg/ml, Sigma), Dexamethasone (10-7 M, Sigma) and βGP (betaGlycerophospate; 5 mM, Sigma). For 
adipocytic differentiation, MSCs were treated with IMDM, supplemented with 1% PS, 10% FCS and 1% NEAA, 
ITSS (Insulin Transferin Sodium Selenite; 10 µg/ml, Roche), Dexamethasone (10-6 M), Indometacine (100 µM, 
Fluka) and IBMX (3 Isobutyl 1 Methylxanthine, 100 µM, Sigma). Control conditions for both inductions are MSCs 
cultured in MSC medium. For chondrocytic induction, MSCs were cultured as a pellet at 0.5 M cells/pellet, in 1ml 
medium. Induction medium was composed of DMEM (high glucose), 1% PS, ITSS (10 µg/ml) and linoleic acid (1 
mg/ml, Sigma), with AAP (50 µg/ml), Dexamethasone (10-7 M), and TGFβ (10 ng/ml, Miltenyi Biotec). Control 
medium consisted of DMEM, 1% PS, ITSS (10 µg/ml) and linoleic acid (1 mg/ml). Following the treatments, cells 
were fixed and stained with oil red O (adipocytes), silver nitrate for von Kossa staining (osteocytes), and Alcian blue 
(chondrocytes).  
Immunohistochemistry (IHC) 
T- and N-MSCs grown in 24-well plates (40,000 cells/well) for 24 hours were washed twice in PBS, then were fixed 
at room temperature in 4% PFA, and were stained with anti-vimentin (#M0725, Dako) and anti-α-SMA (#ab5694, 
Abcam) antibodies.  
Characterization of tumor-infiltrating immune cells by IHC 
Whole-tissue sections from the SCC were formalin-fixed and paraffin-embedded (FFPE) and stained with antibodies 
to assess immune cell infiltration. Haematoxylin/eosin staining (J.T. Baker; Merk) and staining with anti-CD3 
(2GV6, #790-4341, Roche), -CD20 (#CD20-L26-L-CE, Novocastra), -CD68 KP1 (#GA60961-2, DAKO), -PD-L1 
(#SP263, Roche Ventana), -Granzyme B (GrB-7, #MON7029-1, MONOSAN), -CD56 (#NCL-L-CD56-1B6, 
Novocastra), -CD8 (C8/144B, #MA5-13473, DAKO), -PD1 (#AF1086, R&D), -CD4 (SP35, #790-4423, Ventana), -
FoxP3 (236A/E7, #ab20034, Abcam) antibodies were performed. 
 
Flow Cytometry 
For all experiments, cells were first incubated 15 minutes with FcR Blocking Reagent (Miltenyi), and then stained 
for 30 min with conjugated antibodies at 4°C. Before acquisition, cells were washed in PBS and fixed in 1% PFA. 
All samples were acquired with a Gallios Cytometer (Beckman Coulter) and data analyzed using FlowJo version10 
software. The initial gating strategy included cell size selection, cell doublet and dead cell exclusion (with fixable 
viability dye (LIVE/DEAD®, #L-34963, Life Technology) or DAPI). Beads were used to set compensation for 
multicolor flow cytometry experiments (VersaComp Antibody Capture Bead kit, #22804, Beckman Coulter). 
Figures and graphs were made with GraphPad Prism7 software.  
 
Characterization of tumor-infiltrating immune cells. Immune infiltrates in the tumor bulk of Patient 1, 2 and 5 were 
assessed using anti-CD45 (Alexa700, #560566, BD, 1:20), -CD4 (PE, #555347, BD, 1:40), -CD8 (Pacific Blue, 
#558207, BD, 1:20), -CD3 (PC7, #41116015, BC, 1:20), -CD19 (FITC, #11-0199-41, eBioscience, 1:40), -CD56 
(ECD, #41116015, BC, 1:40), -HLA-DR (APC, #559866, BD, 1:20), -CD14 (PE, #557154, BD, 1:10), -CD16 
(PerCP-Cy5.5, #560717, BD, 1:20), -CD11b (APC-eFluor780, #47-0118-41, eBioscience, 1:20) antibodies. 
Regulatory T cells (Tregs) were stained with anti-human FoxP3 Staining Set FITC from eBioscience (#71-5776-40), 
according to the manufacturer’s protocol. CD4+ T cells were defined as CD45+CD3+CD4+, CD8+ T cells as 
CD45+CD3+CD8+, regulatory T cells as CD45+CD3+CD4+CD25+FoxP3+, B cells as CD45+CD3-CD19+CD14-CD16-
CD56-, NK cells as CD45+CD3-HLA-DR-CD56+CD16+/-, myeloid cells as CD45+CD3-CD11b+HLA-DR+/-, and 
CD14+ cells as CD45+CD3-CD16+/-CD56-HLA-DR+CD14+cells. 
 
Characterization of tumor cells. K562 cells and primary lung carcinoma cells (PCC) were thawed, blocked with FcR 
Blocking Reagent and stained with anti-HLA-ABC (VioGreen, #130-101-449, Miltenyi) antibodies. DAPI was used 
to mark living cells. Signal-to-noise ratio was calculated as the MFI (mean fluorescence intensity) of the positive 
cells divided by the MFI of the negative cells. 
 
NK cell isolation and culture 
Buffy coats (project authorization n° P-108) were diluted 1:4 in PBS and NK cells isolated from PBMC 
(Lymphoprep, StemCell Technologies) using a negative sorting kit (NK Isolation Kit, #130-092-657, Miltenyi), with 
95% purity. 
  
Primers used in this work 
 
Genes Primers Amplicon size (bp) 
PTGS2 FW 5’ – CTG GCG CTC AGC CAT ACA G – 3’ 94 
 RV 5’ – CGC ACT TAT  ACT GGT CAA ATC CC – 3’  
TGFB1 FW 5’ – CAG ATC CTG TCC AAG CTG – 3’ 270 
 RV 5’ – TCG GAG CTC TGA TGT GTT – 3’  
IL6 FW 5’ – CAG TTG CCT TCT CCC TGG G – 3’ 111 
 RV 5’ – TGA GTG GCT GTC TGT GTG GG – 3’  
IL2RA  FW 5’ – CGC AGA ATA AAA AGC GGG TCA – 3’ 116 
 RV 5’ – ACT TGT TTC GTT GTG TTC CGA – 3’  
MICA  FW 5’ – CTT CAG AGT CAT TGG CAG ACA T – 3’ 172 
 RV 5’ – TGT GGT CAC TCG TCC CAA CT – 3’  
MICB FW 5’ – TCT TCG TTA CAA CCT CAT GGT G – 3’ 168 
 RV 5’ – TCC CAG GTC TTA GCT CCC AG – 3’  
NECTIN2(CD112) FW 5’- GGA TGT GCG AGT TCA AGT GCT – 3‘ 179 
 RV 5’ – TGG GAC CCA TCT TAG GGT GG – 3’  
PVR (CD155)  FW 5’ – TGG AGG TGA CGC ATG TGT C – 3’ 105 
 RV 5’ – GTT TGG ACT CCG AAT AGC TGG – 3’  
ULBP1 FW 5’ – TAA GTC CAG ACC TGA ACC ACA – 3’ 174 
 RV 5’ – TCC ACC ACG TCT CTT AGT GTT – 3’  
TLR3 FW 5’ – TTA AAG AGT TTT CTC CAG GGT GTT TT – 3’ 125 
 RV 5’ – AAT GCT TGT GTT TGC TAA TTC CAA – 3’  
TLR4 FW 5’ – CCC CTT CTC AAC CAA GAA CCT – 3’ 123 
 RV 5’ – ATT GTC TGG ATT TCA CAC CTG GAT – 3’  
CD274 (PDL1) FW 5’ - TGGCATTTGCTGAACGCATTT – 3’ 120 
 RV 5’ – TGCAGCCAGGTCTAATTGTTTT – 3’  
HMOX1 FW 5’ – AAGACTGCGTTCCTGCTCAAC – 3’ 247 
 RV 5’ – AAAGCCCTACAGCAACTGTCG – 3’  
TNFAIP6 FW 5’ – TCTGGCAAATACAAGCTCACC – 3’ 143 
 RV 5’ – CTGCCCTTAGCCATCCATCC – 3’  
GAPDH FW 5’ – GGC TCT CCA GAA CAT CAT CC – 3’  
 RV 5’ – CCT GCT TCA CCA CCT TCT TG – 3’  
PPIA FW 5’ – ACC GTG TTC TTC GAC ATT GC – 3’  
 RV 5’ – TTA TGC CGT GTG AAG TCA CC – 3’  
TBP FW 5’ – CGG CTG TTT AAC TTC GCT TC – 3’  
 RV 5’ – CAC ACG CCA AGA AAC AGT GA – 3’  
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3. PART II: COMPLEMENTARY UNPUBLISHED DATA  
3.1 Results 
In view of the large amount of data collected during this thesis, some of them were not included 
in the peer-reviewed manuscript but are presented here as complements to specific sections of 
the article, or as preliminary data. We start by giving more detailed descriptions and discussions 
of some figures of the paper in sections 3.1.1 to 3.1.3. Then, in sections 3.1.4 to 3.1.6, we present 
supplemental data which directly complement the manuscript and reveal additional details of the 
MSC-NK interaction. Finally, section 3.1.7 presents preliminary data on the role of the tumor 
cells in T-MSC specific profile induction. 
 
3.1.1 Tumor-Infiltrating Immune Cells. Related to Table S1 and Figure S1. 
Surgically-removed primary tumors from the five studied patients were subjected to a 
histological analysis and immunostaining was performed on tissue sections for CD3, CD4, CD8, 
CD20, CD68 KP1, Granzyme B, CD56, PD-L1, PD1, and FoxP3 (Table S1). The immune cell 
infiltrate of tumors from three patients (patients 1, 2 and 5) was assessed by flow cytometry for 
the expression of lineage-specific markers, using specific gating strategies (Fig. S6 A-D). 
Myeloid cells, defined as CD45+CD11b+HLA-DR-, constituted the major (77.49%) infiltrating 
sub-population in the tumor bulk of patient 1, with only 4.42% of cells corresponding to T 
lymphocytes, defined as CD45+CD3+ cells. In contrast, T lymphocytes were the dominant sub-
population in the infiltrate of the tumor bulk of patient 2 (44.74%), with only 3.38% of cells 
displaying a myeloid phenotype. The infiltrate of the tumor bulk from patient 5 fell between 
those of the other two patients, with 24.61% of myeloid cells and 17.26% of T lymphocytes. 
Among the CD3+ cells in the tumor infiltrate of patient 2, 62.05% were CD8+ and 32.29% were 
CD4+. The CD45+CD3+ infiltrate in the tumor from patient 1 was composed of 49.08% CD4+ 
ungated size single cells
CD45living cells
CD3- CD3- CD3-
P1 P3 P4
P2 P5
Figure S6
A
Figure S6. Gating procedure for characterization of tumor-infiltrating immune cells. 
Gating strategy used for flow cytometry data on tumor bulk sample from one representative 
patient (patient 5) to determine the frequencies of (A) NK, T, B and CD14+ cells; (B) Myeloid 
cells; (C) CD8+ T cells; (D) FoxP3+CD25+ Treg starting from CD45+ gated cells.  
CD45+ CD3- HLA-DR- CD11bCD33
CD45+ CD3+
B
C
D CD45+ CD3+ CD3+CD4+
Figure S6 bis
45 
 
and 42.11% CD8+ cells. Patient 5 tumor infiltrating CD3+ cells were composed of 73.46% CD4+ 
and 24.87% CD8+ cells. Interestingly, regulatory (FoxP3+) T cells represented a substantial 
fraction of CD3+ cells (23.11%), in patient 1 and 5 (25.54%) but only 2.96% in patient 2. NK 
cells constituted less than 1% of the total CD45+ tumor infiltrate in all three patients (0.2% of 
CD45+ cells for patient 1, 0.59% for patient 2 and 0.55% for patient 5). These data were 
consistent with IHC staining (Fig. S1).  
 
The percentage of T-MSCs in the tumor bulks was also assessed by flow cytometry and was 
higher than the percentage of N-MSCs in normal tissues, but represented less than 1% of the 
total bulk population for all patients (data not shown). An analysis from other human cancers 
also showed that MSCs represented about 1% of total cells present in the tumor (Brennen et al., 
2012). 
3.1.2 Ligands for NK receptors expressed by tumor cells. Related to figures S1, S2 and 
Table S1 
K562 cell line is known to be a NK preferential target due to the lack of HLA class I expression 
and the expression of different ligands for NK activating receptors. We confirmed that the K562 
cell line transcriptionally expressed high levels of CD112, CD155, ULBP1, MICA, and MICB. In 
contrast, PCC from lung carcinoma did not express CD112 and showed only low levels of 
CD155 and ULBP1, whereas they expressed the NKG2D ligands MICA and MICB (Fig. S2 A 
and B). Expression also differed between patients. PCC isolated from patient 2 were the less 
immunogenic according to their lower levels of expression of all tested ligands (Fig. S2 B). It is 
interesting to note that, for this patient, expression of NK ligands by tumor cells and immune 
infiltrate of the tumor bulk differed from others patients. Flow cytometry and IHC revealed a 
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higher content of CD8+ T cells in the tumor, compared to CD4+ cells (Fig. S1 and Table S1). 
CD8+ T cells, in contrast to NK cells, required HLA-I expression to be activated and to kill 
tumor cells. PCC from all patients expressed HLA-I, and this surface expression was induced by 
the presence of NK cells in co-culture (Fig. S2 C). Compared to other patients, Treg infiltration 
was very low in patient 2 tumor bulk. Patient 2 tumor was also highly positive for PD-L1 and 
more immune-infiltrated compared to all other tumors (Table S1).  
3.1.3 Ligands for NK receptors expressed by MSCs. Related to figure S4 
Lung MSCs expressed several ligands for NK activating receptors (Fig. S4 D) that have been 
studied in NK-mediated MSC killing (Spaggiari et al., 2006b). However, these ligands also 
contribute to NK cell exhaustion and subsequent down-regulation of NK receptors, similarly to 
prolonged contact with tumor cells inducing NK cell anergy. In this work, we showed that lung 
MSCs highly expressed Nectin-2 and PVR even more, which are ligands for DNAM-1. Besides, 
compared to DNAM-1 ligands, MICA/B (ligands for NKG2D) were expressed at a lower level. 
 
MSCs can bear ligands for surface molecules involved either in the activation or inhibition of 
lymphocyte functions (Poggi and Zocchi, 2015; Turley et al., 2015). Indeed, DNAM-1 can react 
with MSC-expressing PVR and Nectin-2 (Bottino et al., 2003). This recognition generally leads 
to the killing of the DNAM-1L-bearing cell. However, it is also possible that DNAM-1L can 
bind TIGIT or CD96 inhibitory molecules on lymphocytes, leading to the impairment of an 
immune response (Blake et al., 2016). Moreover, NKG2DL and DNAM-1L are widely expressed 
in several carcinomas and leukemic disorders, suggesting that MSCs, rather than tumor cells, can 
be a suitable alternative target in TME.  
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Other groups have shown that BM-MSCs can secrete Matrix Metalloproteinases (MMPs) and 
other proteases able to shed ligands from their surface (Giuliani et al., 2014; Nausch and 
Cerwenka, 2008) and to induce NK cell exhaustion. NKG2D ligand (NKG2DL) expressed on 
MSCs can be shed in the extracellular milieu (sMICA e.g.), thus interfering with NKG2D-
mediated recognition of tumor target cells (Poggi et al., 2014). Indeed, ADAMs can function as 
sheddases of NKG2DL (Zocchi et al., 2015), contributing to the immune cell escape of 
neoplastic cells. Recently, a soluble form of PVR (sCD155) was detected in patients with various 
tumors (Iguchi-Manaka et al., 2016). Soluble CD155 levels were significantly higher in the sera 
of patients with lung, gastrointestinal, breast, and gynecologic cancers than in sera from healthy 
donors (Iguchi-Manaka et al., 2016).  
 
Future investigations of the mechanisms controlling the regulation of NKG2D and DNAM-1 
ligands should offer a better understanding of the MSC-NK interaction and a better assessment 
of NK ligands as potential targets for therapy. The idea would be to avoid overexposure of NK 
cells to a continuous positive signal leading to their exhaustion and their inability to respond to 
later stimulations by tumor cells. Interestingly, MSCs (T-MSCs more than N-MSCs) also 
expressed PD-L1 (Fig. S4 D), that can directly inhibit NK cells and we would like to test this 
interaction in future co-culture experiments.  
 
3.1.4 MSC: NK ratios in co-culture. Related to the set-up of co-culture experiments 
Before choosing the 1:2 ratio for subsequent functional co-culture experiments, different 
MSC:NK ratios were tested (from 1:1 to 1:16) (Fig. S7). At 1:2 MSC:NK ratio, a recurrent 
immunosuppressive effect of MSCs was observed, with large differences between N- and T-
MSCs (Fig. S7). Comparable results were observed with 1:4 MSC:NK ratio. 
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Figure S7. NK:MSC ratios. NK cell activation (percentages of CD107a and intracellular IFN-γ 
positive cells) by K562 following N- and T-MSC co-culture at different NK: MSC ratio (1:1 to 
1:16), as assessed by flow cytometry. Results were normalized to those of NK cells cultured 
without MSCs for the same duration and activated by target cells (the control condition is 
represented by the horizontal dashed line). Results show the mean ± SEM. For 1:1 MSC:NK 
ratio: two experiments with MSC1 (n=1), 2 (n=1), 3 (n=1) and 4 (n=1)); 1:2 ratio (nine 
experiments, MSC1 (n=4), 2 (n=3), 3 (n=8), 4 (n=2), 5 (n=2)); 1:4 ratio (five experiments, 
MSC1 (n=4), 2 (n=2), 3 (n=6), 4 (n=2)); 1:8 ratio (3 experiments, MSC1 (n=2), 2 (n=1), 3 (n=4), 
4 (n=1)); 1:16 ratio (2 experiments, MSC1 (n=1), 2 (n=1), 3 (n=3)).  
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3.1.5 Inhibition of NK cell proliferation by MSCs. Related to MSC effect on NK function 
BM-MSCs have been largely studied for their ability to decrease T and NK cell proliferation 
(Krampera et al., 2006; Spaggiari et al., 2008), through PGE2 and IDO secreted factors. Lung 
MSCs reduced NK proliferation when co-cultured at 1:4 MSC:NK ratio (Fig. S8 A). 
Interestingly, at 1:2 MSC:NK ratio, at which a decreased NK function and a reduced expression 
of NK activating receptors were observed, NK proliferation was less affected and even preserved 
for some MSC patients (Fig. S8 A). Whereas the modulation of lung MSCs on NK cells was 
dependent on MSC:NK ratios, BM-MSCs exerted their inhibition in all tested conditions. 
Furthermore, MSC modulation of NK proliferation occurred similarly in both CD56 NK subsets 
(Fig. S8 B), and did not explain the enrichment in the CD56dim subset through a selective 
inhibition of the CD56bright population. 
3.1.6 ICAM-1 expressed by T-MSCs modulates NK degranulation but not cytokine 
secretion. Related to the investigation of molecules potentially involved in NK function 
modulation. 
MSCs express high levels of several molecules, namely IL-6, COX-2/PGE2 and ICAM-1. IL-6 
and COX-2 have been deeply investigated in this work and presented in the article, but ICAM-1 
also seemed to play a role in NK function modulation by MSCs. At the basal level, before co-
culture, T-MSCs from Patients 2 and 5 expressed higher levels of ICAM1 than their non-tumor 
tissue-derived counterparts (Fig. S9 A), and ICAM1 was highly induced over time in co-culture 
with NK cells (Fig. S9 A). The antibody blockade of ICAM-1 (MAB720) in MSCs from Patient 
5 (Fig. S9 B) failed to restore IFN-γ production by NK cells in response to K562. In contrast, NK 
degranulation was restored at a similar level to the one reached by COX-2 inhibition. Thus, 
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Figure S8. NK proliferation. (A) and (B): Histograms showing the distinct generations of 
proliferating NK cells, stained with CFSE beforehand and cultured alone or in the presence of 
MSCs (N-, T- or BM-MSCs) for 4 days. NK cells are defined as CD45+CD3-CD56+CD16+/- cells 
and histograms are normalized to mode. (A) (i) one experiment with a single NK cell donor and 
MSCs from patient 1 and BM-MSCs, at different MSC: NK ratios (1:1 to 1:8); (ii) one 
experiment with a single NK cell donor and MSCs from patient 2 and BM-MSCs, at 1:2 and 1:4 
MSC:NK ratios. (B) Histograms showing the proliferative peaks of the total NK cell population 
and of the CD56bright and CD56dim subsets, after co-culture with MSCs from patient 2, at 1:4 
MSC:NK ratio. 
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Figure S9: ICAM-1 is highly expressed by T-MSCs. (A) Relative gene expression of ICAM1 
by N- and T-MSCs as assessed by qPCR and shown as a fold change in expression (N-MSC2 
expression set as the control condition). Data are representative of four experiments (four NK 
cell donors, MSC2, 3, 5 (n=2)) and results show the mean ± SEM. (i) in the basal state (day 0 of 
co-culture); (ii) relative gene expression of ICAM1 by T-MSCs collected at the indicated time 
points with and without direct co-culture with NK cells (four NK cell donors, MSC2, 3, 5(n=2)). 
Results show fold change in gene expression compared to T-MSCs at day 0. Statistical 
significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (* 
indicates significance at P < 0.05; **, P < 0.01; ns, not significant). (B) and (C) Data were 
analyzed by flow cytometry and results show mean values ± SEM. (B) Results are from two 
rescue experiments with two NK cell donor and MSCs from patients 3 and 5. Percentage of IFN-
γ+ (i) and CD107a+ (ii) NK cells after activation by K562 cells in the presence of T-MSCs with 
or without anti-IL-6 neutralizing antibody and/or NS-398 and/or anti-ICAM-1 antibody. Results 
are normalized to NK cell activation by K562 cells in the absence of MSCs, considered to be 100 
percent (horizontal dashed line). (iii) Percentage of K562-activated CD56bright and CD56dim NK 
subsets cultured alone or with T-MSCs in the presence or absence of inhibitors. Statistical 
significance was determined by 2-way ANOVA followed by Dunnett’s multiple comparisons 
test, with K562-activated NK cells co-cultured with T-MSCs set as the control (red). (iv) 
Correlation between the percentage of CD56bright NK cells and intracellular IFN-γ 
production/CD107a surface expression in different culture conditions. The statistical test used 
was the Spearman correlation coefficient r; p-values are reported; linear regression line with R 
square for goodness of fit. (C) Percentage of NK receptor expression after 4 days in culture alone 
(gray bar) or with T-MSCs in the absence (dark red bar) or presence of anti-ICAM-1 neutralizing 
antibody (light red bar). MSC5 (n=2), two NK cell donors.  
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ICAM-1 expressed by T-MSCs appeared to be more closely correlated with the regulation of NK 
cytotoxicity than with the cytokine production. In addition, NK cell brightness was almost not 
affected (Fig. S9 B (iii) and (iv)), in line with the inability of ICAM-1 blockade to restore NK 
cytokine production. Surprisingly, ICAM-1 inhibition slightly exacerbated NK receptor 
downregulation induced by Patient 5 T-MSCs, with the exception of DNAM-1 (Fig. S9 C). 
Exploration of the role of ICAM-1 in MSC-mediated immunosuppression underscores the 
complexity of MSC-NK crosstalk, also highlighted by others (Casado et al., 2013) and the 
plasticity of MSCs in terms of their immunomodulatory functions. It is known that IFN-γ 
induces MSC expression of the enzymes IDO and COX-2 (Le Blanc and Davies, 2015), which 
generate immunosuppressive mediators, and of the adhesion receptor ICAM-1 (Ren et al., 2010). 
Ren et al. found that ICAM-1 and VCAM-1 were critical for MSC-mediated immunosuppression 
(Ren et al., 2010). Furthermore, ICAM-1 and VCAM-1 were found to be inducible by the 
concomitant presence of IFN-γ and inflammatory cytokines (TNFα or IL-1). ICAM-1 and 
VCAM-1 were required for lymphocyte–MSC adhesion and, when the function of the adhesion 
molecules was inhibited by blocking Abs or gene knockout, MSC-mediated immunosuppression 
was significantly reversed in vitro and in vivo. However, we did not confirm their observations in 
our human model, where only the cytotoxic function of NK cells was restored by adhesion 
blockade. In addition, NK activating receptors, that are commonly associated with NK 
cytotoxicity, were even more down-regulated in the concomitant presence of MSCs and anti-
ICAM-1, than in the presence of T-MSCs alone.  
 
As previously described, we observed a major role of PGE2 in MSC-mediated NK cytokine 
inhibition. We hypothesize that PGE2 was still secreted, even in the presence of anti-ICAM-1 
antibody, due to the experimental setup of the co-culture that allowed close proximity between 
50 
 
cells. Blocking MSC-NK adhesion disturbed the balance that favored MSC immunosuppression, 
but the mechanisms are not fully understood and require more investigations.  
 
3.1.7 MSC-tumor cell co-cultures. Preliminary results on the modulation of MSC 
phenotype by tumor cells 
We have shown that N- and T-MSCs differed in their gene expression profile and their 
immunosuppressive potential toward NK cells, but how does the tumor – or the tumor 
microenvironment – contribute to the T-MSC specific characteristics? MSCs in tumors have 
been described as originating from various sources: either from recruited BM-MSCs, or from 
adipose tissue-derived stem cells, or from perivascular MSCs, or even from resident N-MSCs 
that, in contact with tumor cells and other components of the tumor microenvironment, could 
switch to a T-MSC phenotype (Karnoub et al., 2007; Kidd et al., 2012; Kucerova et al., 2010; 
Prantl et al., 2010; de Souza et al., 2016; Suzuki et al., 2011). Therefore, we co-cultured N-MSCs 
from patients 2, 3 and 4 for seven days with growing amounts of paired PCC or K562 at 1:2 and 
1:5 MSC:tumor cell ratios and assessed their gene expression (Fig. S10 A) and secretory profiles 
(Fig. S10 B). IL6 and PTGS2 were significantly induced in N-MSCs in indirect co-culture and 
this phenomenon followed the increasing MSC:PCC ratios (Fig. S10 A). For patient 2 and 4, the 
presence of K562 also increased IL6 gene expression (Fig. S10 A) and secretion (Fig. S10 B) by 
N-MSCs. Interestingly, PCC from patient 3 expressed IL6 (data not shown), unlike other PCCs, 
suggesting that the tumor of patient 3 was enriched in IL-6 cytokine coming from at least these 
two sources: MSCs and PCC. PTGS2 expression was induced in the presence of K562 cells in 
MSCs from all patients (Fig. S10 A). In contrast, TGFB1 expression remained unchanged, 
except in patient 3 MSCs co-cultured with K562 at the highest MSC:tumor cell ratio, where its 
expression increased (Fig. S10 A). 
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Figure S10: MSC-PCC co-culture. (A) (B) MSCs and K562 or PCC (patient 2, 3 and 4) were 
co-cultured for 7 days at different MSC:tumor cells ratios (1:2, 1:5) in indirect conditions and 
analyzed for IL6, PTGS2 and TGFB1 expression modulation and IL-6 secretion. (A) Relative 
gene expression of IL6, PTGS2 and TGFB1 by N-MSCs co-cultured for 7 days with tumor cells, 
assessed by qPCR and shown as a fold change in expression (N-MSC expression set as the 
control condition, in black bar). Gene expression by T-MSCs is reported as a control (red bar). 
Results show the mean ± SD of triplicates, normalized to GAPDH expression. Statistical 
significance was determined by a multiple T-test, corrected for multiple comparisons using the 
Holm-Sidak method and the adjusted p-value for significance (* indicates significance at P < 
0.05; **, P < 0.01; ns, not significant). (B) IL-6 secretion (pg/ml) by MSCs from patients 2, 3 
and 4 after 7 days in culture with or without K562 and PCC. (C) Relative gene expression of IL6, 
PTGS2 and TGFB1 by N-MSCs from patient 2 after 7 days of treatment with TGFβ1 (1 and 
10ng/ml) and/or IL-6 (10ng/ml) and in control medium. Results show fold change in gene 
expression compared to N-MSCs. Statistical significance was determined by a multiple T-test, 
corrected for multiple comparisons using the Holm-Sidak method and the adjusted p-value for 
significance (* indicates significance at P < 0.05; **, P < 0.01; ns, not significant). 
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On one hand, the tumor is able to prime MSCs, on the other hand, MSCs themselves – as a part 
of the TME – contribute to create a niche that favors tumor growth (Karnoub et al., 2007; 
Kucerova et al., 2010; Prantl et al., 2010; Suzuki et al., 2011). T-MSCs expressed and secreted 
IL-6, TGFβ1 and PGE2 (Fig. S4. A and B, Fig. 5 A). To test the potential role of some of these 
cytokines likely to be present in the tumor microenvironment, we treated N-MSCs with IL-6 or 
TGFβ1 alone or in combination for 7 days. IL-6 treatment alone did not bring any significant 
modulation of TGFB1, PTGS2 or IL6 gene expression (Fig. S10 D). By contrast, TGFβ1 
treatment, both alone and in combination with IL-6, was able to enhance the expression of 
TGFB1 (feedback amplification loop) and IL6 (Fig. S10 D). Although TGFβ1 is produced by 
MSCs and seemed involved in the production of IL-6, this cytokine failed to fully explain the N-
MSC change into an immunosuppressive phenotype, as PTGS2 expression is not modulated by 
its presence. 
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3.2 Complementary Material and Methods 
CFSE staining 
Freshly isolated NK cells were washed with 10 ml PBS+5%FCS and stained at room 
temperature with CellTrace™ CSFE (ThermoFisher, C34570) at the final concentration of 5µM 
(1:1000 dilution from stock solution) for 5 minutes, protected from light. After staining, cells 
were washed 3 times in PBS+ 5% FCS, and then co-cultured with MSCs in NK medium+IL-2 
for 4 days (as described in the section “co-culture experiments”). NK cells treated with 
Mitomycine C after having been stained with CSFE were used as control sample for non 
proliferative cells.  
After 4 days, cells were harvested for flow cytometry analysis. More precise technical 
information about antibody staining, sample acquisition and analysis can be found in 
Supplemental Experimental Procedures. 
Inhibitors/ stimulatory molecules 
Inhibitors. Human anti-ICAM-1 antibody (MAB720, R&D) was added at the final concentration 
of 10 µg/ml at the start of co-culture. Medium + PBS was used as negative control.  
N-MSC expression analysis after tumor cell co-culture and cytokine treatment 
Co-culture. N-MSCs from patients 2, 3 and 4 were co-cultured with K562 cells and with primary 
cancer cells from the same patient for 7 days in transwell culture conditions at different 
MSC:tumor cell ratios (1:2 and 1:5). MSCs (20.000 cells/well) were seeded onto six-well plates 
(Costar, Corning incorporated). PCC or K562 cells were seeded into 1,0 µm-pore insert of PET-
membrane (Corning, Falcon) at different amounts according to the two different ratios. Controls 
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were T-MSCs and N-MSCs cultured alone. Cells were cultured in MSC medium, half of which 
was refreshed at day 3 and 5 and frozen at -20°C for subsequent analysis of the supernatant. At 
day 7, cells (tumor cells and MSCs) were harvested, washed twice in ice-cold PBS, snap frozen 
and stored at -80°C until RNA extraction. Supernatant of the co-culture at day 7 was also frozen 
for later analysis.  
TGFβ1 and IL-6 treatment. N-MSCs from patients 2 were seeded at 20.000 cells per well in six-
well plates and treated for 7 days with IL-6 (10ng/ml, ref. SRP3096, Sigma), TGFβ1 (1ng/ml or 
10ng/ml, ref. 130-095-066 Miltenyi Biotec) or a combination of both in MSC medium. Controls 
were N-MSCs cultured in MSC medium. Medium was changed at day 3 and 5. At day 7, N-
MSCs were harvested, washed twice in ice-cold PBS, snap frozen and stored at -80°C until RNA 
extraction. 
For both culture experiments, N-MSC expression was assessed by qRT-PCR as described in the 
previous “RNA extraction, cDNA synthesis and qRT-PCR” section. 
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4. PERSPECTIVES 
In this work, we provided insights into the effects of tumor-associated MSCs on NK cell activity. 
Indeed, we compared the immunomodulatory activity toward freshly isolated IL-2-activated NK 
cells from healthy donors of paired samples of MSCs isolated from tumor tissue (T-MSCs) and 
normal adjacent lung tissue (N-MSCs) of patients with squamous cell lung carcinoma. 
Interestingly, we observed marked differences between T- and N-MSCs in their phenotype and 
immunosuppressive function. Despite the ability of MSCs to secrete a variety of mediators with 
immunosuppressive effects, T-MSCs seemed to mediate inhibition of NK cell function primarily 
through PGE2. Our observations provide insight into how stromal responses to cancer growth 
blunt NK cell activity in human lung SCC.  
 
In the future, we would like to follow two major axes in the investigation of MSC-NK 
interactions. Firstly, we would like to better understand how tumor cells induce stromal cells to 
produce high levels of IL-6, PGE2 and other mediators, and to become immunosuppressive. Our 
preliminary studies indicate that TGFβ1 could participate in this process. Additional candidates 
would be interesting to test, such as IL-1β, which could be involved in MSC conditioning. In a 
study on the influence of inflammatory microenvironment on human MSCs in the context of 
polytrauma, it has been shown that COX2, PTGES (which catalyzes the conversion of PGH2 to 
PGE2) and TSG-6 were upregulated in MSCs upon stimulation with IL-1β (Hengartner et al., 
2015). Thus, IL-1β seems to be a promising targetable candidate for future experiments, in order 
to reverse T-MSC immunosuppressive priming.  
Secondly, we would like to address the mechanisms leading to NK receptor downregulation and 
hyporesponsiveness by looking more precisely at the immunological synapse formation. The role 
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of PD-L1 and PD1, as well as the role of ICAM-1-LFA1 and other adhesion molecules will be 
addressed in more detail. We already know, from lung MSC gene expression profile analysis, 
that PD-L1 (CD274) is much more highly expressed by T-MSCs than by N-MSCs. For the study 
of PD-L1/PD1 interaction, it would be interesting to characterize their expression on both MSCs 
and NK cells, and test an anti-PD1 receptor-blocking monoclonal antibody (BMS-936558, 
Nivolumab) (Wang et al., 2014a) in co-culture experiments. ICAM-1 and LFA1 binding could be 
analyzed using Real-time fluorescent microscopy, ICAM-1 bead binding assay or study of LFA-
1–mediated NK spreading, e.g. (Sanborn et al., 2010).  
Having examined direct cell-to-cell interactions, we would like to address the potential shedding 
of NKG2D and DNAM-1 ligands expressed by MSCs, and the role of MSC proteases in this 
mechanism. For this purpose, we would like to detect the potential presence of sMICA and/or 
sCD155 in the supernatant of NK:MSC co-cultures. Moreover, data from another project in our 
laboratory on the secretory and gene expression profile of MSCs indicate that they 
express/secrete specific proteolytic enzymes, like MMP2. Thus, one interesting experiment 
would be to target these proteases and analyze the effect on NK receptor expression in co-culture 
with MSCs.  
Interestingly, the secretory profile analysis of lung MSCs from patient 1 (not shown) indicates 
that T-MSCs have a marked immunosuppressive profile, with significantly higher secretion of 
TSG-6, PTGD2 (which synthesizes PGH2) and CD81 and CD9 (two exosome-related proteins) 
compared to N-MSCs. We also found various molecules from the complement system secreted 
in larger amount by T-MSCs compared to N-MSCs (C4a, CFD, C1r, CFB, C1s). Thus, it would 
be interesting to explore the role of these molecules in the immunomodulatory potential of T-
MSCs. 
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Regarding the immunomodulatory molecules secreted by MSCs, we largely discussed IL-6 
cytokine in previous sections. Its receptor is composed of two subunits: IL-6Rα (CD126) and 
gp130 (CD130). The latest is ubiquitously expressed, while IL-6Rα is cell specific, but the two 
subunits are required to allow IL-6 signaling. However, for the cells that do not express the 
CD126 subunit, it also exists as a soluble form of IL-6Rα, which binds to IL-6, increasing its 
half-life time and allowing trans-signaling when binding to gp130 on target cells (Hunter and 
Jones, 2015). Other groups have shown that MSCs secrete IL-6 but also soluble IL-6Rα (Luu et 
al., 2013). Curiously, we did not detect any IL-6/IL-6 Rα complexes in the supernatant of MSC-
NK co-cultures, although this could be due to the detection limit of the kit (78.10 pg/ml; Human 
IL-6/IL-6 Rα Complex DuoSet ELISA, R&D).  
All these data underline how intriguing, complicated and heterogeneous, the profile of T-MSCs 
and their role in immunosuppression in lung tumors are, and they call for further investigations. 
Finally, in parallel to the directions proposed above, it would be of great interest to transpose our 
observations and investigations to an in vivo model. A patient-derived tumor graft model with 
infused NK cells preconditioned or not with T- or N-MSCs or BM-MSCs would allow us to 
explore the role of the MSC-NK axis in promoting tumorigenesis.  
This work reveals the potential for MSC targeting or reprogramming as an additional anti-tumor 
therapeutic strategy, considering their immunosuppressive and pro-inflammatory phenotype, 
particularly through the release of PGE2. To conclude, it is important to add a few general 
comments regarding the role of TME-targeting therapies, their place in the anti-tumor treatment 
arsenal, but also their limitations. The TME is a complex ecosystem that supports tumor growth 
and metastatic dissemination, and that constitutes an integral part of cancer. Accordingly, novel 
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candidate targets within the TME are constantly being proposed to improve the actions of 
various anti-cancer therapies, notably immunotherapy, that work by potentiating host anti-tumor 
immune responses (Pitt et al., 2016). However, the major limitation of TME targeting is the 
redundancy of its anti-immune and pro-tumor mechanisms, which can occur concurrently within 
the tumor microenvironment. The complexity of their interplay results in multiple levels of 
immune suppression, reducing the effectiveness of immunotherapy. As an example, many 
different cells can be the sources of TGFβ release in the TME, which induces both tumor 
progression and immunosuppression. To effectively counteract or neutralize tumor-promoting 
inflammation, simultaneous reprogramming or the repression of multiple immune-response 
programs activated in cancers will be needed (Coussens et al., 2013). As previously described in 
this work, the tumor microenvironment, including the MSCs can impede the immune response. 
Besides, approaches to specifically reduce immune suppression within the tumor 
microenvironment tend to become part of the immunotherapy strategy. 
In the above paragraph, we only briefly discussed therapies targeting the immune responses 
within the TME, but anti-TME therapies represent a broader spectrum of strategies, including the 
use of drugs targeting cancer-associated inflammation (e.g. MSCs, TGFβ, COX-2, IL-6 and 
TNFα), and also targeting the tumor vasculature, the interplay between tumor cells and TME, 
and hypoxia (Fang and DeClerck, 2013). 
We also have to take into consideration the side effects of targeting the TME. First, many agents 
targeting the TME alter the homeostatic balance in normal organs and tissues and can be toxic. 
Then, agents targeting the TME often affect cells or pathways that are not necessarily the enemy 
of cancer cells. In addition, targeting the TME does not prevent resistance and requires optimal 
biological dosage that may be difficult to determine (Fang and DeClerck, 2013).  
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Lastly, it is important to remember that there are several questions regarding the activity and 
place of agents targeting the TME in our therapeutic arsenal against cancer that remain to be 
answered. Are these agents most effective when used alone or in combination with conventional 
therapies, such as chemotherapy? When taking into account the dynamic changes in the pro- or 
anti-tumorigenic functions of the TME during cancer progression (Fang and DeClerck, 2013), 
which agents are more likely to be effective at early stages of cancer progression and which are 
the ones more likely to have an impact at later stages (e.g. TGFβ inhibitors)? Most importantly, it 
is necessary to stratify patients according to the likelihood that they may respond to a specific 
singular treatment or to combinatorial therapy. This emphasizes the importance of identifying 
reliable biomarkers that allow determination of the TME properties at different stages of 
evolution of different tumor types (Fridman et al., 2012; Sun, 2015). 
 
 
 
 
  
59 
 
5. REFERENCES 
Aggarwal, S., and Pittenger, M.F. (2005). Human mesenchymal stem cells modulate allogeneic 
immune cell responses. Blood 105, 1815–1822. 
Alshaker, H.A., and Matalka, K.Z. (2011). IFN-γ, IL-17 and TGF-β involvement in shaping the 
tumor microenvironment: The significance of modulating such cytokines in treating malignant 
solid tumors. Cancer Cell Int. 11, 33. 
Alter, G., Malenfant, J.M., and Altfeld, M. (2004). CD107a as a functional marker for the 
identification of natural killer cell activity. J. Immunol. Methods 294, 15–22. 
Beckermann, B.M., Kallifatidis, G., Groth, A., Frommhold, D., Apel, A., Mattern, J., Salnikov, 
A.V., Moldenhauer, G., Wagner, W., Diehlmann, A., et al. (2008). VEGF expression by 
mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 99, 
622–631. 
Berger, L., Shamai, Y., Skorecki, K.L., and Tzukerman, M. (2016). Tumor Specific Recruitment 
and Reprogramming of Mesenchymal Stem Cells in Tumorigenesis. Stem Cells Dayt. Ohio 34, 
1011–1026. 
Bergfeld, S.A., and DeClerck, Y.A. (2010). Bone marrow-derived mesenchymal stem cells and 
the tumor microenvironment. Cancer Metastasis Rev. 29, 249–261. 
Bernardo, M.E., and Fibbe, W.E. (2013). Mesenchymal Stromal Cells: Sensors and Switchers of 
Inflammation. Cell Stem Cell 13, 392–402. 
Bhooshan, N., Staats, P.N., Fulton, A.M., Feliciano, J.L., and Edelman, M.J. (2016). 
Prostaglandin E Receptor EP4 expression, survival and pattern of recurrence in locally advanced 
NSCLC. Lung Cancer 101, 88–91. 
Blake, S.J., Dougall, W.C., Miles, J.J., Teng, M.W.L., and Smyth, M.J. (2016). Molecular 
Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin. Cancer Res. Off. J. Am. 
Assoc. Cancer Res. 22, 5183–5188. 
Blankenstein, T. (2005). The role of tumor stroma in the interaction between tumor and immune 
system. Curr. Opin. Immunol. 17, 180–186. 
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, 
J., Marcenaro, S., Reymond, N., et al. (2003). Identification of PVR (CD155) and Nectin-2 
(CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule. J. 
Exp. Med. 198, 557–567. 
Bouffi, C., Bony, C., Courties, G., Jorgensen, C., and Noël, D. (2010). IL-6-Dependent PGE2 
Secretion by Mesenchymal Stem Cells Inhibits Local Inflammation in Experimental Arthritis. 
PLoS ONE 5. 
60 
 
Brandt, C.S., Baratin, M., Yi, E.C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, 
C.D., Kaifu, T., Chabannon, C., et al. (2009). The B7 family member B7-H6 is a tumor cell 
ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495–
1503. 
Bremnes, R.M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., Stenvold, H., 
Camps, C., and Busund, L.-T. (2011). The role of tumor-infiltrating immune cells and chronic 
inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on 
non-small cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 6, 824–
833. 
Brennen, W.N., Chen, S., Denmeade, S.R., and Isaacs, J.T. (2012). Quantification of 
Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer. Oncotarget 4, 106–117. 
Brown, J.R., and DuBois, R.N. (2004). Cyclooxygenase as a Target in Lung Cancer. Clin. 
Cancer Res. 10, 4266s–4269s. 
Brune, J.C., Tormin, A., Johansson, M.C., Rissler, P., Brosjö, O., Löfvenberg, R., von Steyern, 
F.V., Mertens, F., Rydholm, A., and Scheding, S. (2011). Mesenchymal stromal cells from 
primary osteosarcoma are non-malignant and strikingly similar to their bone marrow 
counterparts. Int. J. Cancer 129, 319–330. 
Bryceson, Y.T., March, M.E., Ljunggren, H.-G., and Long, E.O. (2006). Activation, co–
activation, and co–stimulation of resting human NK cells. Immunol. Rev. 214. 
Burrello, J., Monticone, S., Gai, C., Gomez, Y., Kholia, S., and Camussi, G. (2016). Stem Cell-
Derived Extracellular Vesicles and Immune-Modulation. Front. Cell Dev. Biol. 4. 
Bussard, K.M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., and Marini, F.C. (2016). Tumor-
associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 
BCR 18. 
Caligiuri, M.A. (2008). Human natural killer cells. Blood 112, 461–469. 
Caligiuri, M.A., Murray, C., Robertson, M.J., Wang, E., Cochran, K., Cameron, C., Schow, P., 
Ross, M.E., Klumpp, T.R., and Soiffer, R.J. (1993). Selective modulation of human natural killer 
cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91, 
123–132. 
Carrega, P., and Ferlazzo, G. (2017). Natural Killers Are Made Not Born: How to Exploit NK 
Cells in Lung Malignancies. Front. Immunol. 8. 
Carrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., Ratto, G.B., Mingari, 
M.C., Moretta, L., and Ferlazzo, G. (2008). Natural killer cells infiltrating human nonsmall-cell 
lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill 
tumor cells. Cancer 112, 863–875. 
61 
 
Carrega, P., Bonaccorsi, I., Di Carlo, E., Morandi, B., Paul, P., Rizzello, V., Cipollone, G., 
Navarra, G., Mingari, M.C., Moretta, L., et al. (2014). CD56(bright)perforin(low) noncytotoxic 
human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to 
secondary lymphoid organs via afferent lymph. J. Immunol. Baltim. Md 1950 192, 3805–3815. 
Casado, J.G., Tarazona, R., and Sanchez-Margallo, F.M. (2013). NK and MSCs crosstalk: the 
sense of immunomodulation and their sensitivity. Stem Cell Rev. 9, 184–189. 
Castriconi, R., Cantoni, C., Chiesa, M.D., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., 
Bottino, C., Moretta, L., and Moretta, A. (2003). Transforming growth factor β1 inhibits 
expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of 
dendritic cells. Proc. Natl. Acad. Sci. 100, 4120–4125. 
Chan, A., Hong, D.-L., Atzberger, A., Kollnberger, S., Filer, A.D., Buckley, C.D., McMichael, 
A., Enver, T., and Bowness, P. (2007). CD56bright Human NK Cells Differentiate into 
CD56dim Cells: Role of Contact with Peripheral Fibroblasts. J. Immunol. 179, 89–94. 
Chan, C.J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M.T., Town, L., 
Ritchie, D.S., Colonna, M., Andrews, D.M., and Smyth, M.J. (2014). The receptors CD96 and 
CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 
431–438. 
Chang, Y.-J., Holtzman, M.J., and Chen, C.-C. (2002). Interferon-gamma-induced epithelial 
ICAM-1 expression and monocyte adhesion. Involvement of protein kinase C-dependent c-Src 
tyrosine kinase activation pathway. J. Biol. Chem. 277, 7118–7126. 
Chatterjee, D., Marquardt, N., Tufa, D.M., Beauclair, G., Low, H.Z., Hatlapatka, T., Hass, R., 
Kasper, C., Kaisenberg, C. von, Schmidt, R.E., et al. (2014). Role of gamma-secretase in human 
umbilical-cord derived mesenchymal stem cell mediated suppression of NK cell cytotoxicity. 
Cell Commun. Signal. 12, 63. 
Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., and Wong, K.-K. (2014). Non-small-
cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14, 535–546. 
Chester, C., Fritsch, K., and Kohrt, H.E. (2015). Natural Killer Cell Immunomodulation: 
Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer 
Immunotherapy. NK Cell Biol. 601. 
Cho, J.A., Park, H., Lim, E.H., and Lee, K.W. (2012). Exosomes from breast cancer cells can 
convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int. J. 
Oncol. 40, 130–138. 
Chretien, A.-S., Le Roy, A., Vey, N., Prebet, T., Blaise, D., Fauriat, C., and Olive, D. (2014). 
Cancer-induced alterations of NK-mediated target recognition: current and investigational 
pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. NK Cell Biol. 5, 
122. 
62 
 
Cooper, M.A., Fehniger, T.A., Turner, S.C., Chen, K.S., Ghaheri, B.A., Ghayur, T., Carson, 
W.E., and Caligiuri, M.A. (2001b). Human natural killer cells: a unique innate 
immunoregulatory role for the CD56bright subset. Blood 97, 3146–3151. 
Cooper, M.A., Fehniger, T.A., and Caligiuri, M.A. (2001a). The biology of human natural killer-
cell subsets. Trends Immunol. 22, 633–640. 
Coussens, L.M., Zitvogel, L., and Palucka, A.K. (2013). Neutralizing Tumor-Promoting Chronic 
Inflammation: A Magic Bullet? Science 339, 286–291. 
Cremer, I., Fridman, W.H., and Sautès-Fridman, C. (2012). Tumor microenvironment in NSCLC 
suppresses NK cells function. Oncoimmunology 1, 244–246. 
Davis, D.M., Chiu, I., Fassett, M., Cohen, G.B., Mandelboim, O., and Strominger, J.L. (1999). 
The human natural killer cell immune synapse. Proc. Natl. Acad. Sci. U. S. A. 96, 15062–15067. 
De Maria, A., and Moretta, L. (2011). Revisited function of human NK cell subsets. Cell Cycle 
Georget. Tex 10, 1178–1179. 
Delahaye, N.F., Rusakiewicz, S., Martins, I., Ménard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, 
M., Chaput, N., Semeraro, M., et al. (2011). Alternatively spliced NKp30 isoforms affect the 
prognosis of gastrointestinal stromal tumors. Nat. Med. 17, 700–707. 
DelaRosa, O., Sánchez-Correa, B., Morgado, S., Ramírez, C., del Río, B., Menta, R., Lombardo, 
E., Tarazona, R., and Casado, J.G. (2012). Human adipose-derived stem cells impair natural 
killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev. 
21, 1333–1343. 
Desmoulière, A., Guyot, C., and Gabbiani, G. (2004). The stroma reaction myofibroblast: a key 
player in the control of tumor cell behavior. Int. J. Dev. Biol. 48, 509–517. 
Di Trapani, M., Bassi, G., Ricciardi, M., Fontana, E., Bifari, F., Pacelli, L., Giacomello, L., 
Pozzobon, M., Féron, F., De Coppi, P., et al. (2013). Comparative Study of Immune Regulatory 
Properties of Stem Cells Derived from Different Tissues. Stem Cells Dev. 22, 2990–3002. 
Di Trapani, M., Bassi, G., Midolo, M., Gatti, A., Kamga, P.T., Cassaro, A., Carusone, R., 
Adamo, A., and Krampera, M. (2016). Differential and transferable modulatory effects of 
mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci. Rep. 
6. 
Ding, G., Shao, J., Ding, Q., Fang, Z., Wu, Z., Xu, J., and Gao, P. (2012). Comparison of the 
characteristics of mesenchymal stem cells obtained from prostate tumors and from bone marrow 
cultured in conditioned medium. Exp. Ther. Med. 4, 711–715. 
Djouad, F., Charbonnier, L.-M., Bouffi, C., Louis-Plence, P., Bony, C., Apparailly, F., Cantos, 
C., Jorgensen, C., and Noël, D. (2007). Mesenchymal stem cells inhibit the differentiation of 
dendritic cells through an interleukin-6-dependent mechanism. Stem Cells Dayt. Ohio 25, 2025–
2032. 
63 
 
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., 
Keating, A., Prockop, D., and Horwitz, E. (2006). Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for Cellular Therapy position statement. 
Cytotherapy 8, 315–317. 
Dostert, G., Mesure, B., Menu, P., and Velot, É. (2017). How Do Mesenchymal Stem Cells 
Influence or Are Influenced by Microenvironment through Extracellular Vesicles 
Communication? Front. Cell Dev. Biol. 5. 
Dumitru, C.A., Hemeda, H., Jakob, M., Lang, S., and Brandau, S. (2014). Stimulation of 
mesenchymal stromal cells (MSCs) via TLR3 reveals a novel mechanism of autocrine priming. 
FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 28, 3856–3866. 
Dvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma 
generation and wound healing. N. Engl. J. Med. 315, 1650–1659. 
Elboim, M., Gazit, R., Gur, C., Ghadially, H., Betser-Cohen, G., and Mandelboim, O. (2010). 
Tumor Immunoediting by NKp46. J. Immunol. 184, 5637–5644. 
Enqvist, M., Ask, E.H., Forslund, E., Carlsten, M., Abrahamsen, G., Béziat, V., Andersson, S., 
Schaffer, M., Spurkland, A., Bryceson, Y., et al. (2015). Coordinated expression of DNAM-1 
and LFA-1 in educated NK cells. J. Immunol. Baltim. Md 1950 194, 4518–4527. 
Esendagli, G., Bruderek, K., Goldmann, T., Busche, A., Branscheid, D., Vollmer, E., and 
Brandau, S. (2008). Malignant and non-malignant lung tissue areas are differentially populated 
by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer Amst. 
Neth. 59, 32–40. 
Fang, H., and DeClerck, Y.A. (2013). Targeting the Tumor Microenvironment: From 
Understanding Pathways to Effective Clinical Trials. Cancer Res. 73, 4965–4977. 
Fauci, A.S., Mavilio, D., and Kottilil, S. (2005). NK cells in HIV infection: paradigm for 
protection or targets for ambush. Nat. Rev. Immunol. 5, 835–843. 
Fauriat, C., Long, E.O., Ljunggren, H.-G., and Bryceson, Y.T. (2010). Regulation of human NK-
cell cytokine and chemokine production by target cell recognition. Blood 115, 2167–2176. 
Fawcett, J., Holness, C.L., Needham, L.A., Turley, H., Gatter, K.C., Mason, D.Y., and Simmons, 
D.L. (1992). Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on 
resting leukocytes. Nature 360, 481–484. 
Fibbe, W.E., and Noort, W.A. (2003). Mesenchymal Stem Cells and Hematopoietic Stem Cell 
Transplantation. Ann. N. Y. Acad. Sci. 996, 235–244. 
Fridman, W.H., Pagès, F., Sautès-Fridman, C., and Galon, J. (2012). The immune contexture in 
human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306. 
64 
 
Gilfillan, S., Chan, C.J., Cella, M., Haynes, N.M., Rapaport, A.S., Boles, K.S., Andrews, D.M., 
Smyth, M.J., and Colonna, M. (2008). DNAM-1 promotes activation of cytotoxic lymphocytes 
by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965–2973. 
Gillard-Bocquet, M., Caer, C., Cagnard, N., Crozet, L., Perez, M., Fridman, W.H., Sautès-
Fridman, C., and Cremer, I. (2013). Lung tumor microenvironment induces specific gene 
expression signature in intratumoral NK cells. Front. Immunol. 4, 19. 
Giuliani, M., Bennaceur-Griscelli, A., Nanbakhsh, A., Oudrhiri, N., Chouaib, S., Azzarone, B., 
Durrbach, A., and Lataillade, J.-J. (2014). TLR Ligands Stimulation Protects MSC from NK 
Killing. STEM CELLS 32, 290–300. 
Glenn, J.D., and Whartenby, K.A. (2014). Mesenchymal stem cells: Emerging mechanisms of 
immunomodulation and therapy. World J. Stem Cells 6, 526–539. 
Gottschling, S., Granzow, M., Kuner, R., Jauch, A., Herpel, E., Xu, E.C., Muley, T., Schnabel, 
P.A., Herth, F.J.F., and Meister, M. (2013). Mesenchymal stem cells in non-small cell lung 
cancer—Different from others? Insights from comparative molecular and functional analyses. 
Lung Cancer 80, 19–29. 
Grakoui, A., Bromley, S.K., Sumen, C., Davis, M.M., Shaw, A.S., Allen, P.M., and Dustin, M.L. 
(1999). The immunological synapse: a molecular machine controlling T cell activation. Science 
285, 221–227. 
Grégoire, C., Chasson, L., Luci, C., Tomasello, E., Geissmann, F., Vivier, E., and Walzer, T. 
(2007). The trafficking of natural killer cells. Immunol. Rev. 220, 169–182. 
Groh, V., Wu, J., Yee, C., and Spies, T. (2002). Tumour-derived soluble MIC ligands impair 
expression of NKG2D and T-cell activation. Nature 419, 734–738. 
Handgretinger, R., Lang, P., and André, M.C. (2016). Exploitation of natural killer cells for the 
treatment of acute leukemia. Blood 127, 3341–3349. 
Hengartner, N.-E., Fiedler, J., Schrezenmeier, H., Huber-Lang, M., and Brenner, R.E. (2015). 
Crucial Role of IL1beta and C3a in the In Vitro-Response of Multipotent Mesenchymal Stromal 
Cells to Inflammatory Mediators of Polytrauma. PLOS ONE 10, e0116772. 
Henney, C.S., Kuribayashi, K., Kern, D.E., and Gillis, S. (1981). Interleukin-2 augments natural 
killer cell activity. Nature 291, 335–338. 
Herbst, R.S., Heymach, J.V., and Lippman, S.M. (2008). Lung cancer. N. Engl. J. Med. 359, 
1367–1380. 
Hernanda, P.Y., Pedroza-Gonzalez, A., van der Laan, L.J.W., Bröker, M.E.E., Hoogduijn, M.J., 
Ijzermans, J.N.M., Bruno, M.J., Janssen, H.L.A., Peppelenbosch, M.P., and Pan, Q. (2013). 
Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular 
carcinoma. Carcinogenesis 34, 2330–2340. 
65 
 
Hershkovitz, O., Jivov, S., Bloushtain, N., Zilka, A., Landau, G., Bar-Ilan, A., Lichtenstein, 
R.G., Campbell, K.S., van Kuppevelt, T.H., and Porgador, A. (2007). Characterization of the 
Recognition of Tumor Cells by the Natural Cytotoxicity Receptor, NKp44. Biochemistry 
(Mosc.) 46, 7426–7436. 
Hidalgo, G.E., Zhong, L., Doherty, D.E., and Hirschowitz, E.A. (2002). Plasma PGE-2 levels 
and altered cytokine profiles in adherent peripheral blood mononuclear cells in non-small cell 
lung cancer (NSCLC). Mol. Cancer 1, 5. 
Hodge, G., Barnawi, J., Jurisevic, C., Moffat, D., Holmes, M., Reynolds, P.N., Jersmann, H., and 
Hodge, S. (2014). Lung cancer is associated with decreased expression of perforin, granzyme B 
and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. 
Clin. Exp. Immunol. 178, 79–85. 
Hong, I.-S., Lee, H.-Y., and Kang, K.-S. (2014). Mesenchymal stem cells and cancer: Friends or 
enemies? Mutat. Res. Mol. Mech. Mutagen. 768, 98–106. 
Hunter, C.A., and Jones, S.A. (2015). IL-6 as a keystone cytokine in health and disease. Nat. 
Immunol. 16, 448–457. 
Iguchi-Manaka, A., Okumura, G., Kojima, H., Cho, Y., Hirochika, R., Bando, H., Sato, T., 
Yoshikawa, H., Hara, H., Shibuya, A., et al. (2016). Increased Soluble CD155 in the Serum of 
Cancer Patients. PLOS ONE 11, e0152982. 
Imai, K., Matsuyama, S., Miyake, S., Suga, K., and Nakachi, K. (2000). Natural cytotoxic 
activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a 
general population. The Lancet 356, 1795–1799. 
Jamieson, A.M., Diefenbach, A., McMahon, C.W., Xiong, N., Carlyle, J.R., and Raulet, D.H. 
(2002). The Role of the NKG2D Immunoreceptor in Immune Cell Activation and Natural 
Killing. Immunity 17, 19–29. 
Jin, S., Deng, Y., Hao, J.-W., Li, Y., Liu, B., Yu, Y., Shi, F.-D., and Zhou, Q.-H. (2014a). NK 
Cell Phenotypic Modulation in Lung Cancer Environment. PLoS ONE 9. 
Jin, S., Deng, Y., Hao, J.-W., Li, Y., Liu, B., Yu, Y., Shi, F.-D., and Zhou, Q.-H. (2014b). NK 
Cell Phenotypic Modulation in Lung Cancer Environment. PLoS ONE 9. 
Jing, Y., Han, Z., Liu, Y., Sun, K., Zhang, S., Jiang, G., Li, R., Gao, L., Zhao, X., Wu, D., et al. 
(2012). Mesenchymal Stem Cells in Inflammation Microenvironment Accelerates Hepatocellular 
Carcinoma Metastasis by Inducing Epithelial-Mesenchymal Transition. PLoS ONE 7. 
Johann, P.-D., Vaegler, M., Gieseke, F., Mang, P., Armeanu-Ebinger, S., Kluba, T., 
Handgretinger, R., and Müller, I. (2010). Tumour stromal cells derived from paediatric 
malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer 10, 
501. 
66 
 
Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–
598. 
Kansy, B.A., Dißmann, P.A., Hemeda, H., Bruderek, K., Westerkamp, A.M., Jagalski, V., 
Schuler, P., Kansy, K., Lang, S., Dumitru, C.A., et al. (2014). The bidirectional tumor--
mesenchymal stromal cell interaction promotes the progression of head and neck cancer. Stem 
Cell Res. Ther. 5, 95. 
Karnoub, A.E., Dash, A.B., Vo, A.P., Sullivan, A., Brooks, M.W., Bell, G.W., Richardson, A.L., 
Polyak, K., Tubo, R., and Weinberg, R.A. (2007). Mesenchymal stem cells within tumour stroma 
promote breast cancer metastasis. Nature 449, 557–563. 
Khakoo, A.Y., Pati, S., Anderson, S.A., Reid, W., Elshal, M.F., Rovira, I.I., Nguyen, A.T., 
Malide, D., Combs, C.A., Hall, G., et al. (2006). Human mesenchymal stem cells exert potent 
antitumorigenic effects in a model of Kaposi’s sarcoma. J. Exp. Med. 203, 1235–1247. 
Khuri, F.R., Wu, H., Lee, J.J., Kemp, B.L., Lotan, R., Lippman, S.M., Feng, L., Hong, W.K., and 
Xu, X.-C. (2001). Cyclooxygenase-2 Overexpression Is a Marker of Poor Prognosis in Stage I 
Non-Small Cell Lung Cancer. Clin. Cancer Res. 7, 861–867. 
Kidd, S., Spaeth, E., Dembinski, J.L., Dietrich, M., Watson, K., Klopp, A., Battula, V.L., Weil, 
M., Andreeff, M., and Marini, F.C. (2009). Direct evidence of mesenchymal stem cell tropism 
for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 
Dayt. Ohio 27, 2614–2623. 
Kidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M., and Marini, F.C. 
(2012). Origins of the tumor microenvironment: quantitative assessment of adipose-derived and 
bone marrow-derived stroma. PloS One 7, e30563. 
Kim, R., Emi, M., and Tanabe, K. (2007). Cancer immunoediting from immune surveillance to 
immune escape. Immunology 121, 1–14. 
Kornstein, M.J., Stewart, R., and Elder, D.E. (1987). Natural killer cells in the host response to 
melanoma. Cancer Res. 47, 1411–1412. 
Krampera, M. (2011). Mesenchymal stromal cell “licensing”: a multistep process. Leukemia 25, 
1408–1414. 
Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., Santarlasci, V., 
Mazzinghi, B., Pizzolo, G., Vinante, F., et al. (2006). Role for interferon-gamma in the 
immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells Dayt. 
Ohio 24, 386–398. 
Krampera, M., Galipeau, J., Shi, Y., Tarte, K., and Sensebe, L. (2013). Immunological 
characterization of multipotent mesenchymal stromal cells—The International Society for 
Cellular Therapy (ISCT) working proposal. Cytotherapy 15, 1054–1061. 
67 
 
Kucerova, L., Matuskova, M., Hlubinova, K., Altanerova, V., and Altaner, C. (2010). Tumor cell 
behaviour modulation by mesenchymal stromal cells. Mol. Cancer 9, 129. 
Lanier, L.L., Le, A.M., Civin, C.I., Loken, M.R., and Phillips, J.H. (1986). The relationship of 
CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells 
and cytotoxic T lymphocytes. J. Immunol. Baltim. Md 1950 136, 4480–4486. 
Lanier, L.L., Testi, R., Bindl, J., and Phillips, J.H. (1989). Identity of Leu-19 (CD56) leukocyte 
differentiation antigen and neural cell adhesion molecule. J. Exp. Med. 169, 2233–2238. 
Lazennec, G., and Jorgensen, C. (2008). Concise review: adult multipotent stromal cells and 
cancer: risk or benefit? Stem Cells Dayt. Ohio 26, 1387–1394. 
Le Blanc, K., and Davies, L.C. (2015). Mesenchymal stromal cells and the innate immune 
response. Immunol. Lett. 168, 140–146. 
Le Blanc, K., and Mougiakakos, D. (2012). Multipotent mesenchymal stromal cells and the 
innate immune system. Nat. Rev. Immunol. 12, 383–396. 
Lee, J.W., Fang, X., Krasnodembskaya, A., Howard, J.P., and Matthay, M.A. (2011). Concise 
review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem 
Cells Dayt. Ohio 29, 913–919. 
Levi, I., Amsalem, H., Nissan, A., Darash-Yahana, M., Peretz, T., Mandelboim, O., and 
Rachmilewitz, J. (2015). Characterization of tumor infiltrating Natural Killer cell subset. 
Oncotarget 6, 13835–13843. 
Li, W., Ren, G., Huang, Y., Su, J., Han, Y., Li, J., Chen, X., Cao, K., Chen, Q., Shou, P., et al. 
(2012). Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell 
Death Differ. 19, 1505–1513. 
Li, Y., Qu, Y.H., Wu, Y.F., Liu, L., Lin, X.H., Huang, K., and Wei, J. (2014). Bone marrow 
mesenchymal stem cells suppressing activation of allogeneic cytokine-induced killer/natural 
killer cells either by direct or indirect interaction. Cell Biol. Int. 
Lieberman, J. (2003). The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. 
Nat. Rev. Immunol. 3, 361–370. 
Liu, R., Wei, S., Chen, J., and Xu, S. (2014). Mesenchymal stem cells in lung cancer tumor 
microenvironment: their biological properties, influence on tumor growth and therapeutic 
implications. Cancer Lett. 353, 145–152. 
Liu, Y., Han, Z., Zhang, S., Jing, Y., Bu, X., Wang, C., Sun, K., Jiang, G., Zhao, X., Li, R., et al. 
(2011). Effects of inflammatory factors on mesenchymal stem cells and their role in the 
promotion of tumor angiogenesis in colon cancer. J. Biol. Chem. 286, 25007–25015. 
68 
 
Loebinger, M.R., Kyrtatos, P.G., Turmaine, M., Price, A.N., Pankhurst, Q., Lythgoe, M.F., and 
Janes, S.M. (2009). Magnetic resonance imaging of mesenchymal stem cells homing to 
pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res. 69, 8862–8867. 
Long, E.O., Kim, H.S., Liu, D., Peterson, M.E., and Rajagopalan, S. (2013). Controlling Natural 
Killer Cell Responses: Integration of Signals for Activation and Inhibition. Annu. Rev. Immunol. 
31, 227–258. 
Lu, Y., Liu, J., Liu, Y., Qin, Y., Luo, Q., Wang, Q., and Duan, H. (2015a). TLR4 plays a crucial 
role in MSC-induced inhibition of NK cell function. Biochem. Biophys. Res. Commun. 464, 
541–547. 
Lu, Y., Liu, J., Liu, Y., Qin, Y., Luo, Q., Wang, Q., and Duan, H. (2015b). TLR4 plays a crucial 
role in MSC-induced inhibition of NK cell function. Biochem. Biophys. Res. Commun. 464, 
541–547. 
Luo, J., Ok Lee, S., Liang, L., Huang, C.-K., Li, L., Wen, S., and Chang, C. (2014). Infiltrating 
bone marrow mesenchymal stem cells increase prostate cancer stem cell population and 
metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 33, 
2768–2778. 
Luu, N.T., McGettrick, H.M., Buckley, C.D., Newsome, P.N., Rainger, G.E., Frampton, J., and 
Nash, G.B. (2013). Crosstalk between mesenchymal stem cells and endothelial cells leads to 
downregulation of cytokine-induced leukocyte recruitment. Stem Cells Dayt. Ohio 31, 2690–
2702. 
Ma, S., Xie, N., Li, W., Yuan, B., Shi, Y., and Wang, Y. (2014a). Immunobiology of 
mesenchymal stem cells. Cell Death Differ. 21, 216–225. 
Ma, S., Xie, N., Li, W., Yuan, B., Shi, Y., and Wang, Y. (2014b). Immunobiology of 
mesenchymal stem cells. Cell Death Differ. 21, 216–225. 
Mandelboim, O., Malik, P., Davis, D.M., Jo, C.H., Boyson, J.E., and Strominger, J.L. (1999). 
Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. 
Acad. Sci. 96, 5640–5644. 
Marquardt, N., Kekäläinen, E., Chen, P., Kvedaraite, E., Wilson, J.N., Ivarsson, M.A., Mjösberg, 
J., Berglin, L., Säfholm, J., Manson, M.L., et al. (2017a). Human lung natural killer cells are 
predominantly comprised of highly differentiated hypofunctional CD69(-)CD56(dim) cells. J. 
Allergy Clin. Immunol. 139, 1321–1330.e4. 
Marquardt, N., Kekäläinen, E., Chen, P., Kvedaraite, E., Wilson, J.N., Ivarsson, M.A., Mjösberg, 
J., Berglin, L., Säfholm, J., Manson, M.L., et al. (2017b). Human lung natural killer cells are 
predominantly comprised of highly differentiated hypofunctional CD69(-)CD56(dim) cells. J. 
Allergy Clin. Immunol. 139, 1321–1330.e4. 
Martinet, L., and Smyth, M.J. (2015). Balancing natural killer cell activation through paired 
receptors. Nat. Rev. Immunol. 15, 243–254. 
69 
 
Maumus, M., Guérit, D., Toupet, K., Jorgensen, C., and Noël, D. (2011). Mesenchymal stem 
cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res. 
Ther. 2, 14. 
McCann, F.E., Vanherberghen, B., Eleme, K., Carlin, L.M., Newsam, R.J., Goulding, D., and 
Davis, D.M. (2003). The size of the synaptic cleft and distinct distributions of filamentous actin, 
ezrin, CD43, and CD45 at activating and inhibitory human NK cell immune synapses. J. 
Immunol. Baltim. Md 1950 170, 2862–2870. 
McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, 
L., Cho, K.R., et al. (2011). Human ovarian carcinoma–associated mesenchymal stem cells 
regulate cancer stem cells and tumorigenesis via altered BMP production. J. Clin. Invest. 121, 
3206–3219. 
Monks, C.R., Freiberg, B.A., Kupfer, H., Sciaky, N., and Kupfer, A. (1998). Three-dimensional 
segregation of supramolecular activation clusters in T cells. Nature 395, 82–86. 
Moretta, L., Biassoni, R., Bottino, C., Mingari, M.C., and Moretta, A. (2001). Immunobiology of 
human NK cells. Transplant. Proc. 33, 60–61. 
Morgado, S., Sanchez-Correa, B., Casado, J.G., Duran, E., Gayoso, I., Labella, F., Solana, R., 
and Tarazona, R. (2011). NK cell recognition and killing of melanoma cells is controlled by 
multiple activating receptor-ligand interactions. J. Innate Immun. 3, 365–373. 
Nagler, A., Lanier, L.L., Cwirla, S., and Phillips, J.H. (1989). Comparative studies of human 
FcRIII-positive and negative natural killer cells. J. Immunol. 143, 3183–3191. 
Nausch, N., and Cerwenka, A. (2008). NKG2D ligands in tumor immunity. Oncogene 27, 5944–
5958. 
Nomoto-Kojima, N., Aoki, S., Uchihashi, K., Matsunobu, A., Koike, E., Ootani, A., Yonemitsu, 
N., Fujimoto, K., and Toda, S. (2011). Interaction between adipose tissue stromal cells and 
gastric cancer cells in vitro. Cell Tissue Res. 344, 287–298. 
Opitz, C.A., Litzenburger, U.M., Lutz, C., Lanz, T.V., Tritschler, I., Köppel, A., Tolosa, E., 
Hoberg, M., Anderl, J., Aicher, W.K., et al. (2009). Toll-like receptor engagement enhances the 
immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by 
inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 
Dayt. Ohio 27, 909–919. 
Oppenheim, D.E., Roberts, S.J., Clarke, S.L., Filler, R., Lewis, J.M., Tigelaar, R.E., Girardi, M., 
and Hayday, A.C. (2005). Sustained localized expression of ligand for the activating NKG2D 
receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. 
Immunol. 6, 928–937. 
Orange, J.S. (2008). Formation and function of the lytic NK-cell immunological synapse. Nat. 
Rev. Immunol. 8, 713–725. 
70 
 
Pesce, S., Tabellini, G., Cantoni, C., Patrizi, O., Coltrini, D., Rampinelli, F., Matta, J., Vivier, E., 
Moretta, A., Parolini, S., et al. (2015). B7-H6-mediated downregulation of NKp30 in NK cells 
contributes to ovarian carcinoma immune escape. Oncoimmunology 4, e1001224. 
Peters, S., Camidge, D.R., Shaw, A.T., Gadgeel, S., Ahn, J.S., Kim, D.-W., Ou, S.-H.I., Pérol, 
M., Dziadziuszko, R., Rosell, R., et al. (2017). Alectinib versus Crizotinib in Untreated ALK-
Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 0, null. 
Pitt, J.M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., and Zitvogel, L. (2016). 
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses 
and immunotherapy. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27, 1482–1492. 
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, 
M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. (1999). Multilineage potential of adult 
human mesenchymal stem cells. Science 284, 143–147. 
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., 
Dieu-Nosjean, M.-C., Alifano, M., Régnard, J.-F., et al. (2011a). Profound Coordinated 
Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. Cancer Res. 
71, 5412–5422. 
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., 
Dieu-Nosjean, M.-C., Alifano, M., Régnard, J.-F., et al. (2011b). Profound Coordinated 
Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. Cancer Res. 
71, 5412–5422. 
Poggi, A., and Giuliani, M. (2016). Mesenchymal Stromal Cells Can Regulate the Immune 
Response in the Tumor Microenvironment. Vaccines 4. 
Poggi, A., and Zocchi, M.R. (2015). Mesenchymal stromal cells as regulators of anti-tumour 
immune response. Indian J. Med. Res. 141, 139–142. 
Poggi, A., Prevosto, C., Massaro, A.-M., Negrini, S., Urbani, S., Pierri, I., Saccardi, R., Gobbi, 
M., and Zocchi, M.R. (2005). Interaction between human NK cells and bone marrow stromal 
cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J. Immunol. Baltim. Md 
1950 175, 6352–6360. 
Poggi, A., Musso, A., Dapino, I., and Zocchi, M.R. (2014). Mechanisms of tumor escape from 
immune system: Role of mesenchymal stromal cells. Immunol. Lett. 159, 55–72. 
Pradier, A., Passweg, J., Villard, J., and Kindler, V. (2011). Human bone marrow stromal cells 
and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity. Cell Transplant. 
20, 681–691. 
Prantl, L., Muehlberg, F., Navone, N.M., Song, Y.-H., Vykoukal, J., Logothetis, C.J., and Alt, 
E.U. (2010). Adipose tissue-derived stem cells promote prostate tumor growth. The Prostate 70, 
1709–1715. 
71 
 
Pross, H.F., and Lotzová, E. (1993). Role of natural killer cells in cancer. Nat. Immun. 12, 279–
292. 
Puré, E., and Lo, A. (2016). Can Targeting Stroma Pave the Way to Enhanced Antitumor 
Immunity and Immunotherapy of Solid Tumors? Cancer Immunol. Res. 4, 269–278. 
Raffaghello, L., and Dazzi, F. (2015). Classification and biology of tumour associated stromal 
cells. Immunol. Lett. 168, 175–182. 
Rasmusson, I., Ringdén, O., Sundberg, B., and Le Blanc, K. (2003). Mesenchymal stem cells 
inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or 
natural killer cells. Transplantation 76, 1208–1213. 
Razmkhah, M., Jaberipour, M., Erfani, N., Habibagahi, M., Talei, A., and Ghaderi, A. (2011). 
Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and 
TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast 
cancer cells from the immune response? Cell. Immunol. 266, 116–122. 
Ren, G., Zhao, X., Zhang, L., Zhang, J., L’Huillier, A., Ling, W., Roberts, A.I., Le, A.D., Shi, S., 
Shao, C., et al. (2010). Inflammatory cytokine-induced intercellular adhesion molecule-1 and 
vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for 
immunosuppression. J. Immunol. Baltim. Md 1950 184, 2321–2328. 
Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z., Roberts, A.I., Zhang, L., 
Zheng, B., et al. (2012). CCR2-dependent recruitment of macrophages by tumor-educated 
mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem 
Cell 11, 812–824. 
Ridge, S.M., Sullivan, F.J., and Glynn, S.A. (2017). Mesenchymal stem cells: key players in 
cancer progression. Mol. Cancer 16, 31. 
Robbins, P.D., and Morelli, A.E. (2014). Regulation of immune responses by extracellular 
vesicles. Nat. Rev. Immunol. 14, 195–208. 
Romieu-Mourez, R., François, M., Boivin, M.-N., Bouchentouf, M., Spaner, D.E., and Galipeau, 
J. (2009). Cytokine modulation of TLR expression and activation in mesenchymal stromal cells 
leads to a proinflammatory phenotype. J. Immunol. Baltim. Md 1950 182, 7963–7973. 
Rosental, B., Brusilovsky, M., Hadad, U., Oz, D., Appel, M.Y., Afergan, F., Yossef, R., 
Rosenberg, L.A., Aharoni, A., Cerwenka, A., et al. (2011). Proliferating cell nuclear antigen is a 
novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J. Immunol. Baltim. Md 
1950 187, 5693–5702. 
Ruggeri, L., Mancusi, A., Burchielli, E., Aversa, F., Martelli, M.F., and Velardi, A. (2006). 
Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy 
8, 554–558. 
72 
 
Sanborn, K.B., Rak, G.D., Mentlik, A.N., Banerjee, P.P., and Orange, J.S. (2010). Analysis of 
the NK cell immunological synapse. Methods Mol. Biol. Clifton NJ 612, 127–148. 
Schleypen, J.S., von Geldern, M., Weiß, E.H., Kotzias, N., Rohrmann, K., Schendel, D.J., Falk, 
C.S., and Pohla, H. (2003). Renal cell carcinoma-infiltrating natural killer cells express 
differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA 
class I allotypes. Int. J. Cancer 106, 905–912. 
Schoenborn, J.R., and Wilson, C.B. (2007). Regulation of Interferon‐γ During Innate and 
Adaptive Immune Responses. B.-A. in Immunology, ed. (Academic Press), pp. 41–101. 
Seo, S.H., Kim, K.S., Park, S.H., Suh, Y.S., Kim, S.J., Jeun, S.-S., and Sung, Y.C. (2011). The 
effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated 
antitumor activity. Gene Ther. 18, 488–495. 
Shi, Y., Su, J., Roberts, A.I., Shou, P., Rabson, A.B., and Ren, G. (2012a). How mesenchymal 
stem cells interact with tissue immune responses. Trends Immunol. 33, 136–143. 
Shi, Y., Su, J., Roberts, A.I., Shou, P., Rabson, A.B., and Ren, G. (2012b). How mesenchymal 
stem cells interact with tissue immune responses. Trends Immunol. 33, 136–143. 
Shi, Y., Du, L., Lin, L., and Wang, Y. (2017). Tumour-associated mesenchymal stem/stromal 
cells: emerging therapeutic targets. Nat. Rev. Drug Discov. 16, 35–52. 
Shibuya, K., Lanier, L.L., Phillips, J.H., Ochs, H.D., Shimizu, K., Nakayama, E., Nakauchi, H., 
and Shibuya, A. (1999). Physical and Functional Association of LFA-1 with DNAM-1 Adhesion 
Molecule. Immunity 11, 615–623. 
Siegel, R.L., Miller, K.D., and Jemal, A. (2015). Cancer statistics, 2015. CA. Cancer J. Clin. 65, 
5–29. 
Sotiropoulou, P.A., Perez, S.A., Gritzapis, A.D., Baxevanis, C.N., and Papamichail, M. (2006a). 
Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells. STEM CELLS 
24, 74–85. 
Sotiropoulou, P.A., Perez, S.A., Gritzapis, A.D., Baxevanis, C.N., and Papamichail, M. (2006b). 
Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells Dayt. 
Ohio 24, 74–85. 
de Souza, L.E.B., Malta, T.M., Kashima Haddad, S., and Covas, D.T. (2016). Mesenchymal 
Stem Cells and Pericytes: To What Extent Are They Related? Stem Cells Dev. 25, 1843–1852. 
Spaggiari, G.M., and Moretta, L. (2013). Cellular and molecular interactions of mesenchymal 
stem cells in innate immunity. Immunol. Cell Biol. 91, 27–31. 
Spaggiari, G.M., Capobianco, A., Becchetti, S., Mingari, M.C., and Moretta, L. (2006a). 
Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are 
73 
 
capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 
107, 1484–1490. 
Spaggiari, G.M., Capobianco, A., Becchetti, S., Mingari, M.C., and Moretta, L. (2006b). 
Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are 
capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 
107, 1484–1490. 
Spaggiari, G.M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M.C., and Moretta, L. 
(2008). Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and 
cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111, 
1327–1333. 
Stagg, J., and Galipeau, J. (2013). Mechanisms of immune modulation by mesenchymal stromal 
cells and clinical translation. Curr. Mol. Med. 13, 856–867. 
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, 
M., Dassa, L., Achdout, H., et al. (2009). The interaction of TIGIT with PVR and PVRL2 
inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 106, 17858–17863. 
Staunton, D.E., Dustin, M.L., and Springer, T.A. (1989). Functional cloning of ICAM-2, a cell 
adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339, 61–64. 
Sun, Y. (2015). Translational Horizons in the Tumor Microenvironment: Harnessing 
Breakthroughs and Targeting Cures. Med. Res. Rev. 35, n/a-n/a. 
Sun, J.C., and Lanier, L.L. (2009). Natural killer cells remember: An evolutionary bridge 
between innate and adaptive immunity? Eur. J. Immunol. 39, 2059. 
Sun, Z., Wang, S., and Zhao, R.C. (2014). The roles of mesenchymal stem cells in tumor 
inflammatory microenvironment. J. Hematol. Oncol.J Hematol Oncol 7, 14. 
Suzuki, K., Sun, R., Origuchi, M., Kanehira, M., Takahata, T., Itoh, J., Umezawa, A., Kijima, H., 
Fukuda, S., and Saijo, Y. (2011). Mesenchymal stromal cells promote tumor growth through the 
enhancement of neovascularization. Mol. Med. Camb. Mass 17, 579–587. 
Trotta, R., Parihar, R., Yu, J., Becknell, B., Allard, J., Wen, J., Ding, W., Mao, H., Tridandapani, 
S., Carson, W.E., et al. (2005). Differential expression of SHIP1 in CD56bright and CD56dim 
NK cells provides a molecular basis for distinct functional responses to monokine costimulation. 
Blood 105, 3011–3018. 
Tseng, H.-C., Bui, V., Man, Y.-G., Cacalano, N., and Jewett, A. (2014). Induction of Split 
Anergy Conditions Natural Killer Cells to Promote Differentiation of Stem Cells through Cell-
Cell Contact and Secreted Factors. Front. Immunol. 5, 269. 
Turley, S.J., Cremasco, V., and Astarita, J.L. (2015). Immunological hallmarks of stromal cells 
in the tumour microenvironment. Nat. Rev. Immunol. 15, 669–682. 
74 
 
Uccelli, A., Moretta, L., and Pistoia, V. (2006). Immunoregulatory function of mesenchymal 
stem cells. Eur. J. Immunol. 36, 2566–2573. 
Uccelli, A., Moretta, L., and Pistoia, V. (2008). Mesenchymal stem cells in health and disease. 
Nat. Rev. Immunol. 8, 726–736. 
Velardi, A. (2008). Role of KIRs and KIR ligands in hematopoietic transplantation. Curr. Opin. 
Immunol. 20, 581–587. 
Velardi, A., Ruggeri, L., Mancusi, A., Aversa, F., and Christiansen, F.T. (2009). Natural killer 
cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for 
immunotherapy of leukemia. Curr. Opin. Immunol. 21, 525–530. 
Vilches, C., and Parham, P. (2002). KIR: Diverse, Rapidly Evolving Receptors of Innate and 
Adaptive Immunity. Annu. Rev. Immunol. 20, 217–251. 
Villegas, F.R., Coca, S., Villarrubia, V.G., Jiménez, R., Chillón, M.J., Jareño, J., Zuil, M., and 
Callol, L. (2002). Prognostic significance of tumor infiltrating natural killer cells subset CD57 in 
patients with squamous cell lung cancer. Lung Cancer 35, 23–28. 
Vitale, M., Cantoni, C., Pietra, G., Mingari, M.C., and Moretta, L. (2014). Effect of tumor cells 
and tumor microenvironment on NK-cell function. Eur. J. Immunol. 44, 1582–1592. 
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., and Ugolini, S. (2008). Functions of natural 
killer cells. Nat. Immunol. 9, 503–510. 
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., and Brossay, L. (2012). Targeting natural 
killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239–252. 
Vivier, E., Ugolini, S., and Nunès, J.A. (2013). ADAPted secretion of cytokines in NK cells. 
Nat. Immunol. 14, 1108–1110. 
Vyas, Y.M., Mehta, K.M., Morgan, M., Maniar, H., Butros, L., Jung, S., Burkhardt, J.K., and 
Dupont, B. (2001). Spatial organization of signal transduction molecules in the NK cell immune 
synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J. Immunol. 
Baltim. Md 1950 167, 4358–4367. 
Wang, C., Thudium, K.B., Han, M., Wang, X.-T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., 
Kuhne, M., Srinivasan, M., et al. (2014a). In vitro characterization of the anti-PD-1 antibody 
nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 
2, 846–856. 
Wang, M., Cao, J.-X., Pan, J.-H., Liu, Y.-S., Xu, B.-L., Li, D., Zhang, X.-Y., Li, J.-L., Liu, J.-L., 
Wang, H.-B., et al. (2014b). Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy 
in the Treatment of Non-Small Cell Lung Cancer. PloS One 9, e112662. 
75 
 
Waterman, R.S., Tomchuck, S.L., Henkle, S.L., and Betancourt, A.M. (2010). A New 
Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an 
Immunosuppressive MSC2 Phenotype. PLoS ONE 5. 
Waterman, R.S., Henkle, S.L., and Betancourt, A.M. (2012). Mesenchymal Stem Cell 1 (MSC1)-
Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth 
and Metastasis. PLoS ONE 7. 
Wei, X., Yang, X., Han, Z., Qu, F., Shao, L., and Shi, Y. (2013). Mesenchymal stem cells: a new 
trend for cell therapy. Acta Pharmacol. Sin. 34, 747–754. 
Williams, A.R., and Hare, J.M. (2011). Mesenchymal stem cells: Biology, patho-physiology, 
translational findings, and therapeutic implications for cardiac disease. Circ. Res. 109, 923–940. 
Wittnebel, S., Da Rocha, S., Giron-Michel, J., Jalil, A., Opolon, P., Escudier, B., Validire, P., 
Khawam, K., Chouaib, S., Azzarone, B., et al. (2007). Membrane-bound interleukin (IL)-15 on 
renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res. 
67, 5594–5599. 
Wood, S.L., Pernemalm, M., Crosbie, P.A., and Whetton, A.D. (2014). The role of the tumor-
microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. 
Cancer Treat. Rev. 40, 558–566. 
Xu, X., Zhang, X., Wang, S., Qian, H., Zhu, W., Cao, H., Wang, M., Chen, Y., and Xu, W. 
(2011). Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and 
adjacent non-cancerous tissues. J. Cancer Res. Clin. Oncol. 137, 495–504. 
Yáñez-Mó, M., Siljander, P.R.-M., Andreu, Z., Zavec, A.B., Borràs, F.E., Buzas, E.I., Buzas, K., 
Casal, E., Cappello, F., Carvalho, J., et al. (2015). Biological properties of extracellular vesicles 
and their physiological functions. J. Extracell. Vesicles 4. 
Zaidi, M.R., and Merlino, G. (2011). The two faces of interferon-γ in cancer. Clin. Cancer Res. 
Off. J. Am. Assoc. Cancer Res. 17, 6118–6124. 
Zocchi, M.R., Camodeca, C., Nuti, E., Rossello, A., Venè, R., Tosetti, F., Dapino, I., Costa, D., 
Musso, A., and Poggi, A. (2015). ADAM10 new selective inhibitors reduce NKG2D ligand 
release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology 5. 
 
